Child Protection and Rehabilitation Trust Charity
MedExcell Interview Skills & Acute Medicine Update & Critical Appraisal Courses
ABCD The National organisation of Diabetes specialists
YDF The trainee and young consultants wing of Diabetes UK
Diabetes UK the leading charity that cares for, connects with and campaigns on behalf of every person affected by or at risk of diabetes
Society for Endocrinology is the major British Endocrine society
4-T
2011. Jenkins N., Hallowell N., Farmer A. J., Holman R. R. and Lawton J. Participants’ experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study.Diabetic Medicine. 28. 543-548.
http://dx.doi.org/10.1111/j.1464-5491.2010.03200.x
4S
1994. Pedersen TR, Kjekshus J., Berg K., Haghfelt T., Faergeman O. and Thorgeirsson G. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet. 344. 1383-1389.
http://fisher.nhri.org.tw/~Chinfu/course/2007spr/reference/084S.pdf
4S
1994. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).The Lancet. 344. 1383-1389.
http://www.sciencedirect.com/science/article/pii/S0140673694905665
4S
1998. Pedersen Terje R., Olsson Anders G., Færgeman Ole, Kjekshus John, Wedel Hans, Berg Kare, Wilhelmsen Lars, Haghfelt Torben, Thorgeirsson Gudmundur, Pyorala Kalevi, Miettinen Tatu, Christophersen Bjorn, Tobert Jonathan A., Musliner Thomas A. and Cook Thomas J. Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S).Circulation. 97. 1453-1460.
http://circ.ahajournals.org/content/97/15/1453.abstract
The A1chieve study
2011. Shah Siddharth, Zilov Alexey, Malek Rachid, Soewondo Pradana, Bech Ole and Litwak Leon. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A1chieve observational study.Diabetes research and clinical practice. 94. 364-370.
http://www.sciencedirect.com/science/article/pii/S0168822711005626
The A1chieve study
2011. Home Philip, Naggar Nabil El, Khamseh Mohammed, Gonzalez-Galvez Guillermo, Shen Chunduo, Chakkarwar Praful and Wenying Yang. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study.Diabetes research and clinical practice. 94. 352-363.
http://www.sciencedirect.com/science/article/pii/S0168822711005638
ABACUS Trial
2013. Ziegler Ralph, Cavan David A., Cranston Iain, Barnard Katharine, Ryder Jacqueline, Vogel Claudia, Parkin Christopher G., Koehler Walter, Vesper Iris, Petersen Bettina, Schweitzer Matthias A. and Wagner Robin S. Use of an Insulin Bolus Advisor Improves Glycemic Control in Multiple Daily Insulin Injection (MDI) Therapy Patients With Suboptimal Glycemic Control: First results from the ABACUS trial.Diabetes Care. 36. 3613-3619.
http://care.diabetesjournals.org/content/36/11/3613.abstract
ACCORD
2007. Goff Jr David C., Gerstein Hertzel C., Ginsberg Henry N., Cushman William C., Margolis Karen L., Byington Robert P., Buse John B., Genuth Saul, Probstfield Jeffrey L. and Simons-Morton Denise G. Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.The American Journal of Cardiology. 99. S4-S20.
http://www.sciencedirect.com/science/article/pii/S0002914907004377
ACCORD
2008. Dluhy Robert G. and McMahon Graham T. Intensive Glycemic Control in the ACCORD and ADVANCE Trials.New England Journal of Medicine. 358. 2630-2633.
http://www.nejm.org/doi/full/10.1056/NEJMe0804182
ACCORD
2008. Group The Action to Control Cardiovascular Risk in Diabetes Study. Effects of Intensive Glucose Lowering in Type 2 Diabetes.New England Journal of Medicine. 358. 2545-2559.
http://www.nejm.org/doi/full/10.1056/NEJMoa0802743
ACCORD
2009. Skyler Jay S., Bergenstal Richard, Bonow Robert O., Buse John, Deedwania Prakash, Gale Edwin A.M., Howard Barbara V., Kirkman M. Sue, Kosiborod Mikhail, Reaven Peter and Sherwin Robert S. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials.Circulation. 119. 351-357.
http://circ.ahajournals.org/content/119/2/351.short
ACCORD
2010. Pop-Busui Rodica, Evans Gregory W., Gerstein Hertzel C., Fonseca Vivian, Fleg Jerome L., Hoogwerf Byron J., Genuth Saul, Grimm Richard H., Corson Marshall A., Prineas Ronald and Group the ACCORD Study. Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.Diabetes Care. 33. 1578-1584.
http://care.diabetesjournals.org/content/33/7/1578.abstract
ACCORD
2010. Ismail-Beigi Faramarz, Craven Timothy, Banerji Mary Ann, Basile Jan, Calles Jorge, Cohen Robert M., Cuddihy Robert, Cushman William C., Genuth Saul, Grimm Jr Richard H., Hamilton Bruce P., Hoogwerf Byron, Karl Diane, Katz Lois, Krikorian Armand, O'Connor Patrick, Pop-Busui Rodica, Schubart Ulrich, Simmons Debra, Taylor Harris, Thomas Abraham, Weiss Daniel and Hramiak Irene. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.The Lancet. 376. 419-430.
http://www.sciencedirect.com/science/article/pii/S0140673610605764
ACCORD
2010. Bonds Denise E, Miller Michael E, Bergenstal Richard M, Buse John B, Byington Robert P, Cutler Jeff A, Dudl R James, Ismail-Beigi Faramarz, Kimel Angela R, Hoogwerf Byron, Horowitz Karen R, Savage Peter J, Seaquist Elizabeth R, Simmons Debra L, Sivitz William I, Speril-Hillen Joann M and Sweeney Mary Ellen. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.British Medical Journal. 340.
http://www.bmj.com/content/340/bmj.b4909.abstract
ACCORD
2011. Anderson Roger T., Narayan K.M. Venkat, Feeney Patricia, Goff David, Ali Mohammed K., Simmons Debra L., Sperl-Hillen Jo-Ann, Bigger Thomas, Cuddihy Robert, O'Conner Patrick J., Sood Ajay, Zhang Ping, Sullivan Mark D. and Investigators for the Action to Control Cardiovascular Risk in Diabetes. Effect of Intensive Glycemic Lowering on Health-Related Quality of Life in Type 2 Diabetes.Diabetes Care. 34. 807-812.
http://care.diabetesjournals.org/content/34/4/807.abstract
ACCORD
2012. Bonds D., Craven T., Buse J., Crouse J., Cuddihy R., Elam M., Ginsberg H., Kirchner K., Marcovina S., Mychaleckyj J., O’Connor P. and Sperl-Hillen J. A. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.Diabetologia. 55. 1641-1650.
http://dx.doi.org/10.1007/s00125-012-2524-2
ACCORD
2012. Barzilay Joshua I., Howard Annie G., Evans Gregory W., Fleg Jerome L., Cohen Robert M., Booth Gillian L., Kimel Angela R., Pedley Carolyn F. and Cushman William C. Intensive Blood Pressure Treatment Does Not Improve Cardiovascular Outcomes in Centrally Obese Hypertensive Individuals With Diabetes.Diabetes Care. 35. 1401-1405.
http://care.diabetesjournals.org/content/35/7/1401.abstract
ACCORD
2012. Mychaleckyj Josyf C., Craven Timothy, Nayak Uma, Buse John, Crouse John R., Elam Marshall, Kirchner Kent, Lorber Daniel, Marcovina Santica, Sivitz William, Sperl-Hillen JoAnn, Bonds Denise E. and Ginsberg Henry N. Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants.Diabetes Care. 35. 1008-1014.
http://care.diabetesjournals.org/content/35/5/1008.abstract
ACCORD
2012. Genuth S. and Ismail-Beigi F. Clinical Implications of the ACCORD Trial.Journal of Clinical Endocrinology & Metabolism. 97. 41-48.
http://jcem.endojournals.org/content/97/1/41.abstract
ACCORD
2012. O’Connor Patrick J., Narayan K.M. Venkat, Anderson Roger, Feeney Patricia, Fine Larry, Ali Mohammed K., Simmons Debra L., Hire Don G., Sperl-Hillen JoAnn M., Katz Lois Anne, Margolis Karen L. and Sullivan Mark D. Effect of Intensive Versus Standard Blood Pressure Control on Depression and Health-Related Quality of Life in Type 2 Diabetes.Diabetes Care. 35. 1479-1481.
http://care.diabetesjournals.org/content/35/7/1479.abstract
ACCORD
2012. Seaquist Elizabeth R., Miller Michael E., Bonds Denise E., Feinglos Mark, Goff David C., Peterson Kevin, Senior Peter and Investigators for the ACCORD. The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD Study.Diabetes Care. 35. 409-414.
http://care.diabetesjournals.org/content/35/2/409.abstract
ACCORD
2012. Riddle Matthew C. and Karl Diane M. Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes.Diabetes Care. 35. 2100-2107.
http://care.diabetesjournals.org/content/35/10/2100.short
ACCORD
2013. Gerstein Hertzel C., Ambrosius Walter T., Danis Ronald, Ismail-Beigi Faramarz, Cushman William, Calles Jorge, Banerji MaryAnn, Schubart Ulrich, Chew Emily Y. and Group for the ACCORD Study. Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial.Diabetes Care. 36. 1266-1271.
http://care.diabetesjournals.org/content/36/5/1266.abstract
ACCORD
2013. Reyes-Soffer Gissette, Ngai Colleen I., Lovato Laura, Karmally Wahida, Ramakrishnan Rajasekhar, Holleran Stephen and Ginsberg Henry N. Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial.Diabetes Care. 36. 422-428.
http://care.diabetesjournals.org/content/36/2/422.abstract
ACCORD
2014. Punthakee Zubin, Miller MichaelE, Simmons DebraL, Riddle MatthewC, Ismail-Beigi Faramarz, Brillon DavidJ, Bergenstal RichardM, Savage PeterJ, Hramiak Irene, Largay JosephF, Sood Ajay and Gerstein HertzelC. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.Diabetologia. 57. 2030-2037.
http://dx.doi.org/10.1007/s00125-014-3318-5
ACE
1993. Lewis Edmund J., Hunsicker Lawrence G., Bain Raymond P. and Rohde Richard D. The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy.New England Journal of Medicine. 329. 1456-1462.
http://www.nejm.org/doi/full/10.1056/NEJM199311113292004
ACE
1996. Ravid Mordchai, Lang Ruth, Rachmani Rita and Lishner Michael. Long-term Renoprotective Effect of Angiotensin-converting Enzyme Inhibition in Non--insulin-dependent Diabetes Mellitus: A 7-Year Follow-up Study.Archives of internal medicine. 156. 286-289.
http://archinte.ama-assn.org/cgi/content/abstract/156/3/286
ACE
2002. Jacobsen Peter, Andersen Steen, Rossing Kasper, Hansen Birgitte V. and Parving Hans-Henrik. Dual blockade of the renin angiotensin system in type 1 patients with diabetic nephropathy.Nephrology Dialysis Transplantation. 17. 1019-1024.
http://ndt.oxfordjournals.org/content/17/6/1019.abstract
ACE
2003. Jacobsen Peter, Andersen Steen, Jensen Berit R. and Parving Hans-Henrik. Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy.Journal of the American Society of Nephrology. 14. 992-999.
http://jasn.asnjournals.org/content/14/4/992.abstract
ACE
2003. Jacobsen Peter, Andersen Steen, Rossing Kasper, Jensen Berit R. and Parving Hans-Henrik. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.Kidney Int. 63. 1874-1880.
http://dx.doi.org/10.1046/j.1523-1755.2003.00940.x
ACE
2004. Azizi Michel and Menard Joel. Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists.Circulation. 109. 2492-2499.
http://circ.ahajournals.org/content/109/21/2492.short
ACE
2004. Barnett Anthony H., Bain Stephen C., Bouter Paul, Karlberg Bengt, Madsbad Sten, Jervell Jak and Mustonen Jukka. Angiotensin-Receptor Blockade versus Converting Enzyme Inhibition in Type 2 Diabetes and Nephropathy.New England Journal of Medicine. 351. 1952-1961.
http://www.nejm.org/doi/full/10.1056/NEJMoa042274
ACE
2004. Strippoli Giovanni F M, Craig Maria, Deeks Jonathan J, Schena Francesco Paolo and Craig Jonathan C. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.British Medical Journal. 329. 828.
http://www.bmj.com/content/329/7470/828.abstract
ACE
2005. Doulton Timothy W.R., He Feng J. and MacGregor Graham A. Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension.Hypertension. 45. 880-886.
http://hyper.ahajournals.org/content/45/5/880.abstract
ACR
2011. Hsu Chih-Cheng, Chang Hsing-Yi, Huang Meng-Chuan, Hwang Shang-Jyh, Yang Yi-Ching, Tai Tong-Yuan, Yang Hung-Jen, Chang Chwen-Tzuei, Chang Chih-Jen, Li Yu-Sheng, Shin Shyi-Jang and Kuo Ken N. Association Between Insulin Resistance and Development of Microalbuminuria in Type 2 Diabetes.Diabetes Care. 34. 982-987.
http://care.diabetesjournals.org/content/34/4/982.abstract
ACT NOW
2013. Bray G. A., Smith S. R., Banerji M. A., Tripathy D., Clement S. C., Buchanan T. A., Henry R. R., Kitabchi A. E., Mudaliar S., Musi N., Ratner R. E., Schwenke D. C., Stentz F. B., Reaven P. D. and DeFronzo R. A. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.Diabetes, Obesity and Metabolism. 15. 931-937.
http://dx.doi.org/10.1111/dom.12099
ACT NOW
2013. DeFronzo Ralph A., Tripathy Devjit, Schwenke Dawn C., Banerji MaryAnn, Bray George A., Buchanan Thomas A., Clement Stephen C., Gastaldelli Amalia, Henry Robert R., Kitabchi Abbas E., Mudaliar Sunder, Ratner Robert E., Stentz Frankie B., Musi Nicolas, Reaven Peter D. and Study for the ACT NOW. Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates.Diabetes. 62. 3920-3926.
http://diabetes.diabetesjournals.org/content/62/11/3920.abstract
Action LADA 7
2013. Hawa Mohammed I., Kolb Hubert, Schloot Nanette, Beyan Huriya, Paschou Stavroula A., Buzzetti Raffaella, Mauricio Didac, De Leiva Alberto, Yderstraede Knud, Beck-Neilsen Henning, Tuomilehto Jaakko, Sarti Cinzia, Thivolet Charles, Hadden David, Hunter Steven, Schernthaner Guntram, Scherbaum Werner A., Williams Rhys, Brophy Sinead, Pozzilli Paolo, Leslie Richard David and consortium on behalf of the Action LADA. Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype: Action LADA 7.Diabetes Care. 36. 908-913.
http://care.diabetesjournals.org/content/36/4/908.abstract
Acute Diabetes Care
2011. McNaughton Candace D., Self Wesley H. and Slovis Corey. Diabetes in the Emergency Department: Acute Care of Diabetes Patients.Clinical Diabetes. 29. 51-59.
http://clinical.diabetesjournals.org/content/29/2/51.abstract
ADDITION
2011. Lauritzen T., Sandbaek A., Skriver M. and Borch-Johnsen K. HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark Diabetologia. 54. 1318-1326.
http://dx.doi.org/10.1007/s00125-011-2077-9
ADDITION
2011. Webb D., Gray L., Khunti K., Srinivasan B., Taub N., Campbell S., Barnett J., Farooqi A., Echouffo-Tcheugui J., Griffin S., Wareham N. and Davies M. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study.Diabetologia. 54. 2237-2246.
http://dx.doi.org/10.1007/s00125-011-2189-2
ADDITION
2013. Barakat A., Williams K. M., Prevost A. T., Kinmonth A. L., Wareham N. J., Griffin S. J. and Simmons R. K. Changes in physical activity and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the ADDITION-Cambridge trial cohort.Diabetic Medicine. 30. 233-238.
http://dx.doi.org/10.1111/j.1464-5491.2012.03765.x
ADDITION-PRO study
2013. Hansen Anne-Louise S., Carstensen Bendix, Helge Jørn W., Johansen Nanna B., Gram Bibi, Christiansen Jens S., Brage Søren, Lauritzen Torsten, Jørgensen Marit E., Aadahl Mette, Witte Daniel R. and Committee ADDITION-Denmark Steering. Combined Heart Rate– and Accelerometer-Assessed Physical Activity Energy Expenditure and Associations With Glucose Homeostasis Markers in a Population at High Risk of Developing Diabetes: The ADDITION-PRO study.Diabetes Care. 36. 3062-3069.
http://care.diabetesjournals.org/content/36/10/3062.abstract
Adiponectin
2012. Turer A. and Scherer P. Adiponectin: mechanistic insights and clinical implications.Diabetologia. 55. 2319-2326.
http://dx.doi.org/10.1007/s00125-012-2598-x
ADOPT
2002. Viberti Giancarlo, Kahn Steven E., Greene Douglas A., Herman William H., Zinman Bernard, Holman Rury R., Haffner Steven M., Levy Daniel, Lachin John M., Berry Rhona A., Heise Mark A., Jones Nigel P. and Freed Martin I. A Diabetes Outcome Progression Trial (ADOPT).Diabetes Care. 25. 1737-1743.
http://care.diabetesjournals.org/content/25/10/1737.abstract
ADOPT
2006. Kahn Steven E., Haffner Steven M., Heise Mark A., Herman William H., Holman Rury R., Jones Nigel P., Kravitz Barbara G., Lachin John M., O'Neill M. Colleen, Zinman Bernard and Viberti Giancarlo. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy.New England Journal of Medicine. 355. 2427-2443.
http://www.nejm.org/doi/full/10.1056/NEJMoa066224
ADOPT
2010. Kahn Steven E., Haffner Steven M., Viberti Giancarlo, Herman William H., Lachin John M., Kravitz Barbara G., Yu Dahong, Paul Gitanjali, Holman Rury R., Zinman Bernard and Group for A Diabetes Outcome Progression Trial Study. Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain.Diabetes Care. 33. 177-183.
http://care.diabetesjournals.org/content/33/1/177.abstract
ADOPT
2011. Kahn Steven E., Lachin John M., Zinman Bernard, Haffner Steven M., Aftring R. Paul, Paul Gitanjali, Kravitz Barbara G., Herman William H., Viberti Giancarlo, Holman Rury R. and Group and the ADOPT Study. Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT.Diabetes. 60. 1552-1560.
http://diabetes.diabetesjournals.org/content/60/5/1552.abstract
ADOPT
2011. Lachin John M., Viberti Giancarlo, Zinman Bernard, Haffner Steven M., Aftring R. Paul, Paul Gitanjali, Kravitz Barbara G., Herman William H., Holman Rury R., Kahn Steven E. and Group the ADOPT Study. Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy.Clinical Journal of the American Society of Nephrology. 6. 1032-1040.
http://cjasn.asnjournals.org/content/6/5/1032.abstract
ADVANCE
2008. Group The ADVANCE Collaborative. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes.New England Journal of Medicine. 358. 2560-2572.
http://www.nejm.org/doi/full/10.1056/NEJMoa0802987
ADVANCE
2012. Zoungas S., Chalmers J., Ninomiya T., Li Q., Cooper M., Colagiuri S., Fulcher G., de Galan B., Harrap S., Hamet P., Heller S., MacMahon S., Marre M., Poulter N., Travert F., Patel A., Neal B., Woodward M. and Group for the Advance Collaborative. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.Diabetologia. 55. 636-643.
http://dx.doi.org/10.1007/s00125-011-2404-1
ADVANCE
2012. van Dieren S., Czernichow S., Chalmers J., Kengne A. P., de Galan B. E., Poulter N., Woodward M., Beulens J. W. J., Grobbee D. E., van der Schouw Y. T. and Zoungas S. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial.Diabetes, Obesity and Metabolism. 14. 464-469.
http://dx.doi.org/10.1111/j.1463-1326.2012.01556.x
ADVANCE-ON
2012. Hamet P. What matters in ADVANCE and ADVANCE-ON.Diabetes, Obesity and Metabolism. 14. 20-29.
http://dx.doi.org/10.1111/j.1463-1326.2011.01509.x
ADVANCE Trial
2014. Hirakawa Yoichiro, Arima Hisatomi, Zoungas Sophia, Ninomiya Toshiharu, Cooper Mark, Hamet Pavel, Mancia Giuseppe, Poulter Neil, Harrap Stephen, Woodward Mark and Chalmers John. Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial.Diabetes Care. 37. 2359-2365.
http://care.diabetesjournals.org/content/37/8/2359.abstract
AFFORD
2009. Holman R., Paul S., Farmer A., Tucker L., Stratton I. and Neil H. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.Diabetologia. 52. 50-59.
http://dx.doi.org/10.1007/s00125-008-1179-5
AGES-R
2012. Gunnlaugsdottir E., Halldorsdottir S., Klein R., Eiriksdottir G., Klein B., Benediktsson R., Harris T., Launer L., Aspelund T., Gudnason V., Cotch M. and Jonasson F. Retinopathy in old persons with and without diabetes mellitus: the Age, Gene/Environment Susceptibility—Reykjavik Study (AGES-R).Diabetologia. 55. 671-680.
http://dx.doi.org/10.1007/s00125-011-2395-y
Alcohol
2012. Cullmann M., Hilding A. and Östenson C. G. Alcohol consumption and risk of pre-diabetes and type 2 diabetes development in a Swedish population.Diabetic Medicine. 29. 441-452.
http://dx.doi.org/10.1111/j.1464-5491.2011.03450.x
AMD-QUASAR
2011. Rossi Maria C.E., Lucisano Giuseppe, Comaschi Marco, Coscelli Carlo, Cucinotta Domenico, Di Blasi Patrizia, Bader Giovanni, Pellegrini Fabio, Valentini Umberto, Vespasiani Giacomo, Nicolucci Antonio and Group on behalf of the AMD-QUASAR Study. Quality of Diabetes Care Predicts the Development of Cardiovascular Events: Results of the AMD-QUASAR Study.Diabetes Care. 34. 347-352.
http://care.diabetesjournals.org/content/34/2/347.abstract
APHO
2011. Holman N., Forouhi N. G., Goyder E. and Wild S. H. The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010–2030.Diabetic Medicine. 28. 575-582.
http://dx.doi.org/10.1111/j.1464-5491.2010.03216.x
APHO
2012. Hayes L., Hawthorne G. and Unwin N. Undiagnosed diabetes in the over-60s: performance of the Association of Public Health Observatories (APHO) Diabetes Prevalence Model in a general practice.Diabetic Medicine. 29. 115-120.
http://dx.doi.org/10.1111/j.1464-5491.2011.03389.x
APOLLO
2008. Bretzel Reinhard G., Nuber Ulrike, Landgraf Wolfgang, Owens David R., Bradley Clare and Linn Thomas. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.The Lancet. 371. 1073-1084.
http://www.sciencedirect.com/science/article/pii/S0140673608604857
ARB
2001. Parving Hans-Henrik, Lehnert Hendrik, Bröchner-Mortensen Jens, Gomis Ramon, Andersen Steen and Arner Peter. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes.New England Journal of Medicine. 345. 870-878.
http://www.nejm.org/doi/full/10.1056/NEJMoa011489
ARB
2001. Brenner Barry M., Cooper Mark E., de Zeeuw Dick, Keane William F., Mitch William E., Parving Hans-Henrik, Remuzzi Giuseppe, Snapinn Steven M., Zhang Zhonxin and Shahinfar Shahnaz. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy.New England Journal of Medicine. 345. 861-869.
http://www.nejm.org/doi/full/10.1056/NEJMoa011161
ARB
2001. Lewis Edmund J., Hunsicker Lawrence G., Clarke William R., Berl Tomas, Pohl Marc A., Lewis Julia B., Ritz Eberhard, Atkins Robert C., Rohde Richard and Raz Itamar. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes.New England Journal of Medicine. 345. 851-860.
http://www.nejm.org/doi/full/10.1056/NEJMoa011303
Arginine
2012. Monti L. D., Setola E., Lucotti P. C. G., Marrocco-Trischitta M. M., Comola M., Galluccio E., Poggi A., Mammì S., Catapano A. L., Comi G., Chiesa R., Bosi E. and Piatti P. M. Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial.Diabetes, Obesity and Metabolism. 14. 893-900.
http://dx.doi.org/10.1111/j.1463-1326.2012.01615.x
ARIC
2000. Saito Isao, Folsom Aaron R., Brancati Frederick L., Duncan Bruce B., Chambless Lloyd E. and McGovern Paul G. Nontraditional Risk Factors for Coronary Heart Disease Incidence among Persons with Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study.Annals of Internal Medicine. 133. 81-91.
http://www.annals.org/content/133/2/81.1.abstract
Artifical Pancreas
2013. Kovatchev Boris P., Renard Eric, Cobelli Claudio, Zisser Howard C., Keith-Hynes Patrick, Anderson Stacey M., Brown Sue A., Chernavvsky Daniel R., Breton Marc D., Farret Anne, Pelletier Marie-Josée, Place Jérôme, Bruttomesso Daniela, Del Favero Simone, Visentin Roberto, Filippi Alessio, Scotton Rachele, Avogaro Angelo and Doyle Francis J. Feasibility of Outpatient Fully Integrated Closed-Loop Control: First studies of wearable artificial pancreas.Diabetes Care. 36. 1851-1858.
http://care.diabetesjournals.org/content/36/7/1851.abstract
ASCOT
2010. Gupta Ajay K., Dahlof Bjorn, Sever Peter S., Poulter Neil R. and investigators for the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm. Metabolic Syndrome, Independent of Its Components, Is a Risk Factor for Stroke and Death But Not for Coronary Heart Disease Among Hypertensive Patients in the ASCOT-BPLA.Diabetes Care. 33. 1647-1651.
http://care.diabetesjournals.org/content/33/7/1647.abstract
ASCOT
2011. Gupta A. K., Prieto-Merino D., Dahlöf B., Sever P. S., Poulter N. R. and on behalf of the Ascot Investigators. Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach.Diabetic Medicine. 28. 941-947.
http://dx.doi.org/10.1111/j.1464-5491.2011.03330.x
Assessment
2012. Peyrot M., Harshaw Q., Shillington A. C., Xu Y. and Rubin R. R. Validation of a tool to assess medication treatment satisfaction in patients with Type 2 diabetes: the Diabetes Medication System Rating Questionnaire (DMSRQ).Diabetic Medicine. 29. 1060-1066.
http://dx.doi.org/10.1111/j.1464-5491.2011.03538.x
AUSDIAB
2012. Gagnon Claudia, Lu Zhong X., Magliano Dianna J., Dunstan David W., Shaw Jonathan E., Zimmet Paul Z., Sikaris Ken, Ebeling Peter R. and Daly Robin M. Low Serum 25-Hydroxyvitamin D Is Associated with Increased Risk of the Development of the Metabolic Syndrome at Five Years: Results from a National, Population-Based Prospective Study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab).Journal of Clinical Endocrinology & Metabolism. 97. 1953-1961.
http://jcem.endojournals.org/content/97/6/1953.abstract
AUSDIAB
2012. Hansen A. L. S., Wijndaele K., Owen N., Magliano D. J., Thorp A. A., Shaw J. E. and Dunstan D. W. Adverse associations of increases in television viewing time with 5-year changes in glucose homoeostasis markers: the AusDiab study.Diabetic Medicine. 29. 918-925.
http://dx.doi.org/10.1111/j.1464-5491.2012.03656.x
AUSDIAB
2013. Grantham N. M., Magliano D. J., Tanamas S. K., Söderberg S., Schlaich M. P. and Shaw J. E. Higher heart rate increases risk of diabetes among men: The Australian Diabetes Obesity and Lifestyle (AusDiab) Study.Diabetic Medicine. 30. 421-427.
http://dx.doi.org/10.1111/dme.12045
AUSTRALIA
2011. Hayes A. J., Leal J., Kelman C. W. and Clarke P. M. Risk equations to predict life expectancy of people with Type 2 diabetes mellitus following major complications: a study from Western Australia.Diabetic Medicine. 28. 428-435.
http://dx.doi.org/10.1111/j.1464-5491.2010.03189.x
AVANCE Study
2012. Halimi S., Aubert J. P., Fontbonne A., Guillausseau P. J., Nachit F., Bouée S. and Detournay B. A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: The AVANCE study.Diabetes & Metabolism. 38. 343-351.
http://www.sciencedirect.com/science/article/pii/S1262363612000481
AWARD-1
2014. Wysham Carol, Blevins Thomas, Arakaki Richard, Colon Gildred, Garcia Pedro, Atisso Charles, Kuhstoss Debra and Lakshmanan Mark. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1).Diabetes Care. 37. 2159-2167.
http://care.diabetesjournals.org/content/37/8/2159.abstract
AWARD-3
2014. Umpierrez Guillermo, Tofé Povedano Santiago, Pérez Manghi Federico, Shurzinske Linda and Pechtner Valeria. Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3).Diabetes Care. 37. 2168-2176.
http://care.diabetesjournals.org/content/37/8/2168.abstract
AWARD-5
2014. Nauck Michael, Weinstock Ruth S., Umpierrez Guillermo E., Guerci Bruno, Skrivanek Zachary and Milicevic Zvonko. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5).Diabetes Care. 37. 2149-2158.
http://care.diabetesjournals.org/content/37/8/2149.abstract
AWARD-6
2014. Dungan Kathleen M., Povedano Santiago Tofé, Forst Thomas, González José G. González, Atisso Charles, Sealls Whitney and Fahrbach Jessie L. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.The Lancet. 384. 1349-1357.
http://linkinghub.elsevier.com/retrieve/pii/S0140673614609764
Back to Top
BAPAD-1
2012. Brazeau A. S., Mircescu H., Desjardins K., Dubé M. C., Weisnagel S. J., Lavoie C. and Rabasa-Lhoret R. The Barriers to Physical Activity in Type 1 Diabetes (BAPAD-1) scale: Predictive validity and reliability.Diabetes & Metabolism. 38. 164-170.
http://www.sciencedirect.com/science/article/pii/S1262363611002059
Bariatric
2011. Pignone M. Bariatric Surgery Reduces the Need for Glycemic Control Medications and Related Health Care Costs.Clinical Diabetes. 29. 34.
http://clinical.diabetesjournals.org/content/29/1/34.extract
Bariatric
2012. Admiraal Wanda M., Celik Funda, Gerdes Victor E., Dallal Ramsey M., Hoekstra Joost B. and Holleman Frits. Ethnic Differences in Weight Loss and Diabetes Remission After Bariatric Surgery.Diabetes Care. 35. 1951-1958.
http://care.diabetesjournals.org/content/35/9/1951.abstract
Bariatric
2012. Dirksen C., Jørgensen N., Bojsen-Møller K., Jacobsen S., Hansen D., Worm D., Holst J. and Madsbad S. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.Diabetologia. 55. 1890-1901.
http://dx.doi.org/10.1007/s00125-012-2556-7
Bariatric
2012. Romeo Stefano, Maglio Cristina, Burza Maria Antonella, Pirazzi Carlo, Sjöholm Kajsa, Jacobson Peter, Svensson Per-Arne, Peltonen Markku, Sjöström Lars and Carlsson Lena M.S. Cardiovascular Events After Bariatric Surgery in Obese Subjects With Type 2 Diabetes.Diabetes Care. 35. 2613-2617.
http://care.diabetesjournals.org/content/35/12/2613.abstract
Bariatric
2012. Cohen Ricardo V., Pinheiro Jose C., Schiavon Carlos A., Salles João E., Wajchenberg Bernardo L. and Cummings David E. Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity.Diabetes Care. 35. 1420-1428.
http://care.diabetesjournals.org/content/35/7/1420.abstract
Bariatric
2013. Dixon John B., Chuang Lee-Ming, Chong Keong, Chen Shu-Chun, Lambert Gavin W., Straznicky Nora E., Lambert Elisabeth A. and Lee Wei-Jei. Predicting the Glycemic Response to Gastric Bypass Surgery in Patients With Type 2 Diabetes.Diabetes Care. 36. 20-26.
http://care.diabetesjournals.org/content/36/1/20.abstract
Bariatric
2013. Pollock R. F., Muduma G. and Valentine W. J. Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK.Diabetes, Obesity and Metabolism. 15. 121-129.
http://dx.doi.org/10.1111/j.1463-1326.2012.01692.x
Bariatric
2013. Dixon J. B., Hur K. Y., Lee W. J., Kim M. J., Chong K., Chen S. C., E. Straznicky N. and Zimmet P. Gastric bypass in Type 2 diabetes with BMI < 30: weight and weight loss have a major influence on outcomes.Diabetic Medicine. 30. e127-e134.
http://dx.doi.org/10.1111/dme.12107
Bariatric
2013. Lingvay Ildiko, Guth Eve, Islam Arsalla and Livingston Edward. Rapid Improvement in Diabetes After Gastric Bypass Surgery: Is it the diet or surgery?Diabetes Care. 36. 2741-2747.
http://care.diabetesjournals.org/content/36/9/2741.abstract
Bariatric
2013. Camastra Stefania, Muscelli Elza, Gastaldelli Amalia, Holst Jens J., Astiarraga Brenno, Baldi Simona, Nannipieri Monica, Ciociaro Demetrio, Anselmino Marco, Mari Andrea and Ferrannini Ele. Long-Term Effects of Bariatric Surgery on Meal Disposal and β-Cell Function in Diabetic and Nondiabetic Patients.Diabetes. 62. 3709-3717.
http://diabetes.diabetesjournals.org/content/62/11/3709.abstract
BEGIN
2013. Battise Dawn. A New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes.Clinical Diabetes. 31. 166-170.
http://clinical.diabetesjournals.org/content/31/4/166.short
BIOMArCS 2 glucose trial
2011. de Mulder M., Umans V. A., Stam F., Cornel J. H., Oemrawsingh R. M. and Boersma E. Intensive management of hyperglycaemia in acute coronary syndromes. Study design and rationale of the BIOMArCS 2 glucose trial.Diabetic Medicine. 28. 1168-1175.
http://dx.doi.org/10.1111/j.1464-5491.2011.03307.x
Biomarkers
2012. Samaropoulos Xanthia F., Light Laney, Ambrosius Walter T., Marcovina Santica M., Probstfield Jeffrey and Jr David C. Goff. The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers.Diabetes research and clinical practice. 95. 389-398.
http://www.sciencedirect.com/science/article/pii/S0168822711005298
BP
2011. Simpson Scot H., Majumdar Sumit R., Tsuyuki Ross T., Lewanczuk Richard Z., Spooner Richard and Johnson Jeffrey A. Effect of Adding Pharmacists to Primary Care Teams on Blood Pressure Control in Patients With Type 2 Diabetes.Diabetes Care. 34. 20-26.
http://care.diabetesjournals.org/content/34/1/20.abstract
BP
2012. van Dieren Susan, Kengne Andre P., Chalmers John, Beulens Joline W. J., Cooper Mark E., Grobbee Diederick E., Harrap Stephen, Mancia Giuseppe, Neal Bruce, Patel Anushka, Poulter Neil, van der Schouw Yvonne T., Woodward Mark and Zoungas Sophia. Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes.Diabetes research and clinical practice. 98. 83-90.
http://linkinghub.elsevier.com/retrieve/pii/S0168822712001635?showall=true
Back to Top
CALM
2000. Mogensen Carl Erik, Neldam Steen, Tikkanen Ilkka, Oren Shmuel, Viskoper Reuven, Watts Richard W and Cooper Mark E. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.British Medical Journal. 321. 1440-1444.
http://www.bmj.com/content/321/7274/1440.abstract
Cancer
2011. Stefansdottir G., Zoungas S., Chalmers J., Kengne A., Knol M., Leufkens H., Patel A., Woodward M., Grobbee D. and De Bruin M. Intensive glucose control and risk of cancer in patients with type 2 diabetes.Diabetologia. 54. 1608-1614.
http://dx.doi.org/10.1007/s00125-011-2104-x
Cancer
2011. van Staa T., Patel D., Gallagher A. and de Bruin M. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.Diabetologia. 1-12.
http://dx.doi.org/10.1007/s00125-011-2390-3
Cancer
2011. Carstensen B., Witte D. and Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects.Diabetologia. 1-11.
http://dx.doi.org/10.1007/s00125-011-2381-4
Cancer
2012. Neumann A., Weill A., Ricordeau P., Fagot J., Alla F. and Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.Diabetologia. 55. 1953-1962.
http://dx.doi.org/10.1007/s00125-012-2538-9
CAPPP
1999. Hansson Lennart, Lindholm Lars H., Niskanen Leo, Lanke Jan, Hedner Thomas, Niklason Anders, Luomanmäki Kimmo, Dahlöf Björn, de Faire Ulf, Mörlin Claes, Karlberg Bengt E., Wester P. O. and Björck Jan-Erik. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.The Lancet. 353. 611-616.
http://www.sciencedirect.com/science/article/pii/S0140673698050120
CARDIA study
2012. Chatterjee R., Colangelo L., Yeh H., Anderson C., Daviglus M., Liu K. and Brancati F. Potassium intake and risk of incident type 2 diabetes mellitus: the Coronary Artery Risk Development in Young Adults (CARDIA) Study.Diabetologia. 55. 1295-1303.
http://dx.doi.org/10.1007/s00125-012-2487-3
Cardiovascular
1994. Kuusisto J, Mykanen L, Pyorala K and Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects.Diabetes. 43. 960-967.
http://diabetes.diabetesjournals.org/content/43/8/960.abstract
Cardiovascular
2001. Fisman Enriqe Z., Tenenbaum Alexander, Adler Yehuda, Motro Michael, Boyko Valentina, Benderly Michal, Friedensohn Aharon, Kohanovski Mira, Rotzak Rene, Schneider Hanan and Behar Solomon. Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.Clinical Cardiology. 24. 151-158.
http://dx.doi.org/10.1002/clc.4960240210
Cardiovascular
2010. Bruce David G., Van Minnen Kylie, Davis Wendy A., Mudhar Jaspreet, Perret Michael, Subawickrama Dayani P., Venkitachalam Stephanie, Ravine David and Davis Timothy M.E. Maternal Family History of Diabetes Is Associated With a Reduced Risk of Cardiovascular Disease in Women With Type 2 Diabetes.Diabetes Care. 33. 1477-1483.
http://care.diabetesjournals.org/content/33/7/1477.abstract
Cardiovascular
2012. Sone Hirohito, Tanaka Sachiko, Tanaka Shiro, Iimuro Satoshi, Ishibashi Shun, Oikawa Shinichi, Shimano Hitoshi, Katayama Shigehiro, Ohashi Yasuo, Akanuma Yasuo, Yamada Nobuhiro and Group on behalf of the Japan Diabetes Complications Study. Comparison of Various Lipid Variables as Predictors of Coronary Heart Disease in Japanese Men and Women With Type 2 Diabetes.Diabetes Care. 35. 1150-1157.
http://care.diabetesjournals.org/content/35/5/1150.abstract
Cardiovascular
2012. Giunti Sara, Gruden Gabriella, Fornengo Paolo, Barutta Federica, Amione Cristina, Ghezzo Giuseppe, Cavallo-Perin Paolo and Bruno Graziella. Increased QT Interval Dispersion Predicts 15-Year Cardiovascular Mortality in Type 2 Diabetic Subjects.Diabetes Care. 35. 581-583.
http://care.diabetesjournals.org/content/35/3/581.abstract
Cardiovascular
2012. Vamos Eszter P., Millett Christopher, Parsons Camille, Aylin Paul, Majeed Azeem and Bottle Alex. Nationwide Study on Trends in Hospital Admissions for Major Cardiovascular Events and Procedures Among People With and Without Diabetes in England, 2004–2009.Diabetes Care. 35. 265-272.
http://care.diabetesjournals.org/content/35/2/265.abstract
Cardiovascular
2012. Rana Jamal S., Dunning Allison, Achenbach Stephan, Al-Mallah Mouaz, Budoff Matthew J., Cademartiri Filippo, Callister Tracy Q., Chang Hyuk-Jae, Cheng Victor Y., Chinnaiyan Kavitha, Chow Benjamin J.W., Cury Ricardo, Delago Augustin, Feuchtner Gudrun, Hadamitzky Martin, Hausleiter Jörg, Kaufmann Philipp, Karlsberg Ronald P., Kim Yong-Jin, Leipsic Jonathon, Labounty Troy M., Lin Fay Y., Maffei Erica, Raff Gilbert, Villines Todd C., Shaw Leslee J., Berman Daniel S. and Min James K. Differences in Prevalence, Extent, Severity, and Prognosis of Coronary Artery Disease Among Patients With and Without Diabetes Undergoing Coronary Computed Tomography Angiography.Diabetes Care. 35. 1787-1794.
http://care.diabetesjournals.org/content/35/8/1787.abstract
Cardiovascular
2012. Nauta Sjoerd T., Deckers Jaap W., Akkerhuis K. Martijn and van Domburg Ron T. Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes.Diabetes Care. 35. 2043-2047.
http://care.diabetesjournals.org/content/35/10/2043.abstract
Cardiovascular
2013. Hermans Michel P., Ahn Sylvie A., Mahadeb Yovan P. and Rousseau Michel F. Sleep apnoea syndrome and 10-year cardiovascular risk in females with type 2 diabetes: relationship with insulin secretion and insulin resistance.Diabetes/Metabolism Research and Reviews. 29. 227-234.
http://dx.doi.org/10.1002/dmrr.2387
Cardiovascular
2013. Jansson S. P. O., Andersson D. K. G. and Svärdsudd K. Effects of fasting blood glucose, diabetes treatment, blood pressure and anti-hypertension treatment on cardiovascular disease incidence: a 30-year follow-up study of 740 incident patients with Type 2 diabetes.Diabetic Medicine. 30. 349-357.
http://dx.doi.org/10.1111/dme.12106
Cardiovascular
2014. Sjöblom P., Nystrom F. H., Länne T., Engvall J. and Östgren C. J. Microalbuminuria, but not reduced eGFR, is associated with cardiovascular subclinical organ damage in type 2 diabetes.Diabetes & Metabolism. 40. 49-55.
http://www.sciencedirect.com/science/article/pii/S126236361300181X
Cardiovascular
2014. Shore Supriya, Borgerding Joleen A., Gylys-Colwell Ina, McDermott Kelly, Ho P. Michael, Tillquist Maggie N., Lowy Elliott, McGuire Darren K., Stolker Joshua M., Arnold Suzanne V., Kosiborod Mikhail and Maddox Thomas M. Association Between Hyperglycemia at Admission During Hospitalization for Acute Myocardial Infarction and Subsequent Diabetes: Insights From the Veterans Administration Cardiac Care Follow-up Clinical Study.Diabetes Care. 37. 409-418.
http://care.diabetesjournals.org/content/37/2/409.abstract
Cardiovascular
2014. d’Emden MichaelC, Jenkins AliciaJ, Li Liping, Zannino Diana, Mann KristyP, Best JamesD, Stuckey BronwynG A., Park Kris, Saltevo Juha and Keech AnthonyC. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.Diabetologia. 57. 2296-2303.
http://dx.doi.org/10.1007/s00125-014-3344-3
CARDS
2004. Colhoun Helen M., Betteridge D. John, Durrington Paul N., Hitman Graham A., W Neil H. Andrew, Livingstone Shona J., Thomason Margaret J., Mackness Michael I., Charlton-Menys Valentine and Fuller John H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.The Lancet. 364. 685-696.
http://www.sciencedirect.com/science/article/pii/S0140673604168955
Care
2013. Ali Mohammed K., Bullard Kai McKeever, Saaddine Jinan B., Cowie Catherine C., Imperatore Giuseppina and Gregg Edward W. Achievement of Goals in U.S. Diabetes Care, 1999–2010.New England Journal of Medicine. 368. 1613-1624.
http://www.nejm.org/doi/full/10.1056/NEJMsa1213829
CGM
2011. Tansey M., Laffel L., Cheng J., Beck R., Coffey J., Huang E., Kollman C., Lawrence J., Lee J., Ruedy K., Tamborlane W., Wysocki T., Xing D. and on behalf of Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Satisfaction with continuous glucose monitoring in adults and youths with Type 1 diabetes.Diabetic Medicine. 28. 1118-1122.
http://dx.doi.org/10.1111/j.1464-5491.2011.03368.x
CGM
2013. Cordua S., Secher A. L., Ringholm L., Damm P. and Mathiesen E. R. Real-time continuous glucose monitoring during labour and delivery in women with Type 1 diabetes — observations from a randomized controlled trial.Diabetic Medicine. 30. 1374-1381.
http://dx.doi.org/10.1111/dme.12246
CGM
2013. Wojtusciszyn A., Mourad G., Bringer J. and Renard E. Continuous glucose monitoring after kidney transplantation in non-diabetic patients: Early hyperglycaemia is frequent and may herald post-transplantation diabetes mellitus and graft failure.Diabetes & Metabolism. 39. 404-410.
http://www.sciencedirect.com/science/article/pii/S1262363612002145
CKDEPI
2011. Camargo E. G., Soares A. A., Detanico A. B., Weinert L. S., Veronese F. V., Gomes E. C. and Silveiro S. P. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is less accurate in patients with Type 2 diabetes when compared with healthy individuals.Diabetic Medicine. 28. 90-95.
http://dx.doi.org/10.1111/j.1464-5491.2010.03161.x
Colesevelam
2012. Henry R. R., Aroda V. R., Mudaliar S., Garvey W. T., Chou H. S. and Jones M. R. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus.Diabetes, Obesity and Metabolism. 14. 40-46.
http://dx.doi.org/10.1111/j.1463-1326.2011.01486.x
Communication
2011. Guldberg T. L., Vedsted P., Kristensen J. K. and Lauritzen T. Improved quality of Type 2 diabetes care following electronic feedback of treatment status to general practitioners: a cluster randomized controlled trial.Diabetic Medicine. 28. 325-332.
http://dx.doi.org/10.1111/j.1464-5491.2010.03178.x
Communication
2011. Farrell K. and Holmes–Walker D. J. Mobile phone support is associated with reduced ketoacidosis in young adults.Diabetic Medicine. 28. 1001-1004.
http://dx.doi.org/10.1111/j.1464-5491.2011.03302.x
Consensus
2006. Nathan David M., Buse John B., Davidson Mayer B., Heine Robert J., Holman Rury R., Sherwin Robert and Zinman Bernard. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy.Diabetes Care. 29. 1963-1972.
http://care.diabetesjournals.org/content/29/8/1963.short
Consensus
2011. Boulton Andrew J. M., Valensi Paul and Tesfaye Solomon. International Neuropathy Workshop of 2009: Introduction to the final reports.Diabetes/Metabolism Research and Reviews. 27. 617-619.
http://dx.doi.org/10.1002/dmrr.1228
Consensus
2011. O'Connor Patrick J., Bodkin Noni L., Fradkin Judith, Glasgow Russell E., Greenfield Sheldon, Gregg Edward, Kerr Eve A., Pawlson L. Gregory, Selby Joseph V., Sutherland John E., Taylor Michael L. and Wysham Carol H. Consensus Report: Diabetes Performance Measures: Current Status and Future Directions.Clinical Diabetes. 29. 102-112.
http://clinical.diabetesjournals.org/content/29/3/102.short
Consensus
2011. Dyck Peter J., Albers James W., Andersen Henning, Arezzo Joseph C., Biessels Geert-Jan, Bril Vera, Feldman Eva L., Litchy William J., O'Brien Peter C., Russell James W. and on behalf of The Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity.Diabetes/Metabolism Research and Reviews. 27. 620-628.
http://dx.doi.org/10.1002/dmrr.1226
Consensus
2011. Tesfaye S., Vileikyte L., Rayman G., Sindrup S. H., Perkins B. A., Baconja M., Vinik A. I., Boulton A. J. M. and on behalf of The Toronto Expert Panel on Diabetic Neuropathy. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management.Diabetes/Metabolism Research and Reviews. 27. 629-638.
http://dx.doi.org/10.1002/dmrr.1225
Consensus
2011. Spallone Vincenza, Ziegler Dan, Freeman Roy, Bernardi Luciano, Frontoni Simona, Pop-Busui Rodica, Stevens Martin, Kempler Peter, Hilsted Jannik, Tesfaye Solomon, Low Phillip, Valensi Paul and on behalf of The Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management.Diabetes/Metabolism Research and Reviews. 27. 639-653.
http://dx.doi.org/10.1002/dmrr.1239
Consensus
2011. Kempler P., Amarenco G., Freeman R., Frontoni S., Horowitz M., Stevens M., Low P., Pop-Busui R., Tahrani A. A., Tesfaye S., Várkonyi T., Ziegler D., Valensi P. and on behalf of The Toronto Consensus Panel on Diabetic Neuropathy. Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes.Diabetes/Metabolism Research and Reviews. 27. 665-677.
http://dx.doi.org/10.1002/dmrr.1223
Consensus
2012. Umpierrez Guillermo E., Hellman Richard, Korytkowski Mary T., Kosiborod Mikhail, Maynard Gregory A., Montori Victor M., Seley Jane J. and Van den Berghe Greet. Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline.Journal of Clinical Endocrinology & Metabolism. 97. 16-38.
http://jcem.endojournals.org/content/97/1/16.abstract
Consensus
2012. Dhatariya K., Levy N., Kilvert A., Watson B., Cousins D., Flanagan D., Hilton L., Jairam C., Leyden K., Lipp A., Lobo D., Sinclair-Hammersley M., Rayman G. and for the Joint British Diabetes Societies. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes*.Diabetic Medicine. 29. 420-433.
http://dx.doi.org/10.1111/j.1464-5491.2012.03582.x
Consensus
2012. Inzucchi S., Bergenstal R., Buse J., Diamant M., Ferrannini E., Nauck M., Peters A., Tsapas A., Wender R. and Matthews D. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia. 55. 1577-1596.
http://dx.doi.org/10.1007/s00125-012-2534-0
Consensus
2012. John W. G. and on behalf of the U. K. Department of Health Advisory Committee on Diabetes. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011.Diabetic Medicine. 29. 1350-1357.
http://dx.doi.org/10.1111/j.1464-5491.2012.03762.x
Consensus
2012. Benhamou P. Y., Catargi B., Delenne B., Guerci B., Hanaire H., Jeandidier N., Leroy R., Meyer L., Penfornis A., Radermecker R. P., Renard E., Baillot-Rudoni S., Riveline J. P., Schaepelynck P., Sola-Gazagnes A., Sulmont V., Tubiana-Rufi N., Durain D. and Mantovani I. Real-time continuous glucose monitoring (CGM) integrated into the treatment of type 1 diabetes: Consensus of experts from SFD, EVADIAC and SFE.Diabetes & Metabolism. 38. S67-S83.
http://www.sciencedirect.com/science/article/pii/S1262363612715380
Consensus
2012. Vergès B., Avignon A., Bonnet F., Catargi B., Cattan S., Cosson E., Ducrocq G., Elbaz M., Fredenrich A., Gourdy P., Henry P., Lairez O., Leguerrier A. M., Monpère C., Moulin P., Vergès-Patois B., Roussel R., Steg G. and Valensi P. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome.Diabetes & Metabolism. 38. 113-127.
http://www.sciencedirect.com/science/article/pii/S1262363611002230
Consensus
2013. Evert Alison B., Boucher Jackie L., Cypress Marjorie, Dunbar Stephanie A., Franz Marion J., Mayer-Davis Elizabeth J., Neumiller Joshua J., Nwankwo Robin, Verdi Cassandra L., Urbanski Patti and Yancy William S. Nutrition Therapy Recommendations for the Management of Adults With Diabetes.Diabetes Care. 36. 3821-3842.
http://care.diabetesjournals.org/content/36/11/3821.short
Consensus
2014. Association American Diabetes. Standards of Medical Care in Diabetes—2014.Diabetes Care. 37. S14-S80.
http://care.diabetesjournals.org/content/37/Supplement_1/S14.short
2012. Simsek S., Schalkwijk C. G. and Wolffenbuttel B. H. R. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes—the CORALL study.Diabetic Medicine. 29. 628-631.
http://dx.doi.org/10.1111/j.1464-5491.2011.03553.x
Cost Effectiveness
2012. Group The Diabetes Prevention Program Research. The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention.Diabetes Care. 35. 723-730.
http://care.diabetesjournals.org/content/35/4/723.abstract
Cost Effectiveness
2012. Farahani Pendar. A Perspective on Principles of Comparative Cost-Effectiveness Studies for Pharmacotherapy of Chronic Diseases.Clinical Diabetes. 30. 54-60.
http://clinical.diabetesjournals.org/content/30/2/54.abstract
CSII
2011. Sharma D., Morrison G., Joseph F., Purewal T. and Weston P. The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis.Diabetologia. 1-3.
http://dx.doi.org/10.1007/s00125-011-2282-6
CSII
2011. Hermanides J., Nørgaard K., Bruttomesso D., Mathieu C., Frid A., Dayan C. M., Diem P., Fermon C., Wentholt I. M. E., Hoekstra J. B. L. and DeVries J. H. Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type 1 diabetes; a randomized controlled trial.Diabetic Medicine. 28. 1158-1167.
http://dx.doi.org/10.1111/j.1464-5491.2011.03256.x
CSII
2011. Choudhary Pratik, Shin John, Wang Yongyin, Evans Mark L., Hammond Peter J., Kerr David, Shaw James A.M., Pickup John C. and Amiel Stephanie A. Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia.Diabetes Care. 34. 2023-2025.
http://care.diabetesjournals.org/content/34/9/2023.abstract
CSII
2011. Laurenzi Andrea, Bolla Andrea M., Panigoni Gabriella, Doria Valentina, Uccellatore AnnaChiara, Peretti Elena, Saibene Alessandro, Galimberti Gabriella, Bosi Emanuele and Scavini Marina. Effects of Carbohydrate Counting on Glucose Control and Quality of Life Over 24 Weeks in Adult Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion.Diabetes Care. 34. 823-827.
http://care.diabetesjournals.org/content/34/4/823.abstract
CSII
2011. Hovorka Roman, Kumareswaran Kavita, Harris Julie, Allen Janet M, Elleri Daniela, Xing Dongyuan, Kollman Craig, Nodale Marianna, Murphy Helen R, Dunger David B, Amiel Stephanie A, Heller Simon R, Wilinska Malgorzata E and Evans Mark L. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.British Medical Journal. 342.
http://www.bmj.com/content/342/bmj.d1855.abstract
CSII
2011. Bergenstal Richard M., Tamborlane William V., Ahmann Andrew, Buse John B., Dailey George, Davis Stephen N., Joyce Carol, Perkins Bruce A., Welsh John B., Willi Steven M., Wood Michael A. and Group for the STAR 3 Study. Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study.Diabetes Care. 34. 2403-2405.
http://care.diabetesjournals.org/content/34/11/2403.abstract
CSII
2011. Garg Satish K., Voelmle Mary K., Beatson Christie R., Miller Hayley A., Crew Lauren B., Freson Brandon J. and Hazenfield Rachel M. Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion Therapy.Diabetes Care. 34. 574-579.
http://care.diabetesjournals.org/content/34/3/574.abstract
CSII
2012. Chen Ailing, Huang Zhimin, Wan Xuesi, Deng Wanping, Wu Jiyan, Li Licheng, Cai Qiuling, Xiao Haipeng and Li Yanbing. Attitudes Toward Diabetes Affect Maintenance of Drug-Free Remission in Patients With Newly Diagnosed Type 2 Diabetes After Short-Term Continuous Subcutaneous Insulin Infusion Treatment.Diabetes Care. 35. 474-481.
http://care.diabetesjournals.org/content/35/3/474.abstract
CSII
2012. Battelino T., Conget I., Olsen B., Schütz-Fuhrmann I., Hommel E., Hoogma R., Schierloh U., Sulli N., Bolinder J. and Group the Switch Study. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial.Diabetologia. 55. 3155-3162.
http://dx.doi.org/10.1007/s00125-012-2708-9
CSII
2013. Johnson StephanieR, Cooper MatthewN, Jones TimothyW and Davis ElizabethA. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case–control study.Diabetologia. 56. 2392-2400.
http://dx.doi.org/10.1007/s00125-013-3007-9
CSII
2013. Dauber Andrew, Corcia Liat, Safer Jason, Agus Michael S.D., Einis Sara and Steil Garry M. Closed-Loop Insulin Therapy Improves Glycemic Control in Children Aged <7 Years: A randomized controlled trial.Diabetes Care. 36. 222-227.
http://care.diabetesjournals.org/content/36/2/222.abstract
CSII
2013. Radermecker R. P., Fayolle C., Brun J. F., Bringer J. and Renard E. Accuracy assessment of online glucose monitoring by a subcutaneous enzymatic glucose sensor during exercise in patients with type 1 diabetes treated by continuous subcutaneous insulin infusion.Diabetes & Metabolism. 39. 258-262.
http://www.sciencedirect.com/science/article/pii/S1262363613000116
CSII
2014. White H. D., Goenka N., Furlong N. J., Saunders S., Morrison G., Langridge P., Paul P., Ghatak A. and Weston P. J. The UK service level audit of insulin pump therapy in adults.Diabetic Medicine. 31. 412-418.
http://dx.doi.org/10.1111/dme.12325
CVA
2012. Braun Karl F., Otter Wolfgang, Sandor Stefanie M., Standl Eberhard and Schnell Oliver. All-cause in-hospital mortality and comorbidity in diabetic and non-diabetic patients with stroke.Diabetes research and clinical practice. 98. 164-168.
http://linkinghub.elsevier.com/retrieve/pii/S0168822712001507?showall=true
CVD
2013. Roche Madonna M. and Wang Peizhong Peter. Sex Differences in All-Cause and Cardiovascular Mortality, Hospitalization for Individuals With and Without Diabetes, and Patients With Diabetes Diagnosed Early and Late.Diabetes Care. 36. 2582-2590.
http://care.diabetesjournals.org/content/36/9/2582.abstract
Back to Top
Da Qing
2011. Gong Q., Gregg E., Wang J., An Y., Zhang P., Yang W., Li H., Jiang Y., Shuai Y., Zhang B., Zhang J., Gerzoff R., Roglic G., Hu Y., Li G. and Bennett P. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study.Diabetologia. 54. 300-307.
http://dx.doi.org/10.1007/s00125-010-1948-9
DAFNE
2011. Rankin D., Cooke D. D., Clark M., Heller S., Elliott J., Lawton J. and for the U. K. Nihr Dafne Study Group. How and why do patients with Type 1 diabetes sustain their use of flexible intensive insulin therapy? A qualitative longitudinal investigation of patients’ self-management practices following attendance at a Dose Adjustment for Normal Eating (DAFNE) course.Diabetic Medicine. 28. 532-538.
http://dx.doi.org/10.1111/j.1464-5491.2011.03243.x
DAFNE
2012. Hopkins David, Lawrence Ian, Mansell Peter, Thompson Gillian, Amiel Stephanie, Campbell Michael and Heller Simon. Improved Biomedical and Psychological Outcomes 1 Year After Structured Education in Flexible Insulin Therapy for People With Type 1 Diabetes.Diabetes Care. 35. 1638-1642.
http://care.diabetesjournals.org/content/35/8/1638.abstract
DAFNE
2012. Keen A. J. A., Duncan E., McKillop-Smith A., Evans N. D. and Gold A. E. Dose Adjustment for Normal Eating (DAFNE) in routine clinical practice: who benefits?Diabetic Medicine. 29. 670-676.
http://dx.doi.org/10.1111/j.1464-5491.2011.03479.x
DAFNE
2012. Gunn D. and Mansell P. Glycaemic control and weight 7 years after Dose Adjustment For Normal Eating (DAFNE) structured education in Type 1 diabetes.Diabetic Medicine. 29. 807-812.
http://dx.doi.org/10.1111/j.1464-5491.2011.03525.x
Dalcitrapib
2012. Stalenhoef A. F. H., Davidson M. H., Robinson J. G., Burgess T., Duttlinger-Maddux R., Kallend D., Goldberg A. C. and Bays H. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.Diabetes, Obesity and Metabolism. 14. 30-39.
http://dx.doi.org/10.1111/j.1463-1326.2011.01485.x
Davalintide
2011. Mack C. M., Smith P. A., Athanacio J. R., Xu K., Wilson J. K., Reynolds J. M., Jodka C. M., Lu M. G. W. and Parkes D. G. Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide.Diabetes, Obesity and Metabolism. 13. 1105-1113.
http://dx.doi.org/10.1111/j.1463-1326.2011.01465.x
DAWN
2012. Hochberg G., Pucheu S., Kleinebreil L., Halimi S. and Fructuoso-Voisin C. WHO-5, a tool focusing on psychological needs in patients with diabetes: The French contribution to the DAWN study.Diabetes & Metabolism. 38. 515-522.
http://www.sciencedirect.com/science/article/pii/S1262363612001188
DCCT
1993. DCCT. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus.New England Journal of Medicine. 329. 977-986.
http://www.nejm.org/doi/full/10.1056/NEJM199309303291401
DCCT
2010. Molitch Mark E., Steffes Michael, Sun Wanjie, Rutledge Brandy, Cleary Patricia, de Boer Ian H., Zinman Bernard, Lachin John, Interventions for the Epidemiology of Diabetes and Group Complications Study. Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study.Diabetes Care. 33. 1536-1543.
http://care.diabetesjournals.org/content/33/7/1536.abstract
DCCT
2012. Kilpatrick E. S., Rigby A. S., Atkin S. L. and Frier B. M. Does severe hypoglycaemia influence microvascular complications in Type 1 diabetes? An analysis of the Diabetes Control and Complications Trial database.Diabetic Medicine. 29. 1195-1198.
http://dx.doi.org/10.1111/j.1464-5491.2012.03612.x
DCCT
2013. Kramer C. K. and Retnakaran R. Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial.Diabetic Medicine. 30. 1333-1341.
http://dx.doi.org/10.1111/dme.12296
DCCT
2013. Maple-Brown L. J., Ye C. and Retnakaran R. Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes: an analysis of data from the Diabetes Control and Complications Trial.Diabetic Medicine. 30. 95-99.
http://dx.doi.org/10.1111/dme.12004
DCCT
2014. Kim Catherine, Cleary Patricia A., Cowie Catherine C., Braffett Barbara H., Dunn Rodney L., Larkin Mary E., Gatcomb Patricia M., Wessells Hunter B., Nathan David M., Sarma Aruna V. and Group for the DCCT/EDIC Research. Effect of Glycemic Treatment and Microvascular Complications on Menopause in Women With Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.Diabetes Care. 37. 701-708.
http://care.diabetesjournals.org/content/37/3/701.abstract
DCCT/EDIC
2005. Group The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes.New England Journal of Medicine. 353. 2643-2653.
http://www.nejm.org/doi/full/10.1056/NEJMoa052187
DCCT/EDIC
2013. Jacobson Alan M., Braffett Barbara H., Cleary Patricia A., Gubitosi-Klug Rose A., Larkin Mary E. and Group the DCCT/EDIC Research. The Long-Term Effects of Type 1 Diabetes Treatment and Complications on Health-Related Quality of Life: A 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort.Diabetes Care. 36. 3131-3138.
http://care.diabetesjournals.org/content/36/10/3131.abstract
DCCT/EDIC
2014. Nathan David M., McGee Paula, Steffes Michael W., Lachin John M. and Group the DCCT/EDIC Research. Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study.Diabetes. 63. 282-290.
http://diabetes.diabetesjournals.org/content/63/1/282.abstract
DDDSG
2011. Avanzini Fausto, Marelli Giuseppe, Donzelli Walter, Busi Giovanna, Carbone Stefania, Bellato Laura, Colombo Elena Lucia, Foschi Roberto, Riva Emma, Roncaglioni Maria Carla, De Martini Mario and Group on behalf of the Desio Diabetes Diagram Study. Transition From Intravenous to Subcutaneous Insulin.Diabetes Care. 34. 1445-1450.
http://care.diabetesjournals.org/content/34/7/1445.abstract
Decision Support Tool
2012. Rodbard Helena W., Schnell Oliver, Unger Jeffrey, Rees Christen, Amstutz Linda, Parkin Christopher G., Jelsovsky Zhihong, Wegmann Nathan, Axel-Schweitzer Matthias and Wagner Robin S. Use of an Automated Decision Support Tool Optimizes Clinicians’ Ability to Interpret and Appropriately Respond to Structured Self-Monitoring of Blood Glucose Data.Diabetes Care. 35. 693-698.
http://care.diabetesjournals.org/content/35/4/693.abstract
DECODE
1999. Group The DECODE study. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria.The Lancet. 354. 617-621.
http://linkinghub.elsevier.com/retrieve/pii/S0140673698121311
DEPICTED
2012. Robling Mike, McNamara Rachel, Bennert Kristina, Butler Christopher C, Channon Sue, Cohen David, Crowne Elizabeth, Hambly Helen, Hawthorne Kamila, Hood Kerenza, Longo Mirella, Lowes Lesley, Pickles Tim, Playle Rebecca, Rollnick Stephen, Thomas-Jones Emma and Gregory John W. The effect of the Talking Diabetes consulting skills intervention on glycaemic control and quality of life in children with type 1 diabetes: cluster randomised controlled trial (DEPICTED study).British Medical Journal. 344.
http://www.bmj.com/content/344/bmj.e2359
DESMOND
2012. Khunti Kamlesh, Gray Laura J, Skinner Timothy, Carey Marian E, Realf Kathryn, Dallosso Helen, Fisher Harriet, Campbell Michael, Heller Simon and Davies Melanie J. Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care.British Medical Journal. 344.
http://www.bmj.com/content/344/bmj.e2333
DETECT 2
2011. Alssema M., Vistisen D., Heymans M., Nijpels G., Glümer C., Zimmet P., Shaw J., Eliasson M., Stehouwer C., Tabák A., Colagiuri S., Borch-Johnsen K. and Dekker J. The Evaluation of Screening and Early Detection Strategies for Type 2 Diabetes and Impaired Glucose Tolerance (DETECT-2) update of the Finnish diabetes risk score for prediction of incident type 2 diabetes.Diabetologia. 54. 1004-1012.
http://dx.doi.org/10.1007/s00125-010-1990-7
DETECT 2
2011. Colagiuri Stephen, Lee Crystal M.Y., Wong Tien Y., Balkau Beverley, Shaw Jonathan E., Borch-Johnsen Knut and Group the DETECT-2 Collaboration Writing. Glycemic Thresholds for Diabetes-Specific Retinopathy.Diabetes Care. 34. 145-150.
http://care.diabetesjournals.org/content/34/1/145.abstract
DEWL Trial
2012. Krebs J., Elley C., Parry-Strong A., Lunt H., Drury P., Bell D., Robinson E., Moyes S. and Mann J. The Diabetes Excess Weight Loss (DEWL) Trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes.Diabetologia. 55. 905-914.
http://dx.doi.org/10.1007/s00125-012-2461-0
The Diabetes and Aging Study
2013. Lipska Kasia J., Warton E. Margaret, Huang Elbert S., Moffet Howard H., Inzucchi Silvio E., Krumholz Harlan M. and Karter Andrew J. HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes: The Diabetes and Aging Study.Diabetes Care. 36. 3535-3542.
http://care.diabetesjournals.org/content/36/11/3535.abstract
Diabetes Prevention Program
2011. Katula Jeffrey A., Vitolins Mara Z., Rosenberger Erica L., Blackwell Caroline S., Morgan Timothy M., Lawlor Michael S. and Goff David C. One-Year Results of a Community-Based Translation of the Diabetes Prevention Program.Diabetes Care. 34. 1451-1457.
http://care.diabetesjournals.org/content/34/7/1451.abstract
Diabetes Prevention Program
2013. The Diabetes Prevention Program Outcomes Study Research Group, prepared on behalf of the Dppos Research Group, Orchard T. J., Temprosa M., Barrett-Connor E., Fowler S. E., Goldberg R. B., Mather K. J., Marcovina S. M., Montez M., Ratner R. E., Saudek C. D., Sherif H. and Watson K. E. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.Diabetic Medicine. 30. 46-55.
http://dx.doi.org/10.1111/j.1464-5491.2012.03750.x
Diabetic Foot
2012. Holman N., Young R. and Jeffcoate W. Variation in the recorded incidence of amputation of the lower limb in England.Diabetologia. 55. 1919-1925.
http://dx.doi.org/10.1007/s00125-012-2468-6
Diabetic Foot
2012. Monteiro-Soares M., Boyko E. J., Ribeiro J., Ribeiro I. and Dinis-Ribeiro M. Predictive factors for diabetic foot ulceration: a systematic review.Diabetes/Metabolism Research and Reviews. 28. 574-600.
http://dx.doi.org/10.1002/dmrr.2319
Diabetic Foot
2012. Armstrong David G., Bharara Manish, White Matthew, Lepow Brian, Bhatnagar Sugam, Fisher Timothy, Kimbriel Heather R., Walters Jodi, Goshima Kaoru R., Hughes John and Mills Joseph L. The impact and outcomes of establishing an integrated interdisciplinary surgical team to care for the diabetic foot.Diabetes/Metabolism Research and Reviews. 28. 514-518.
http://dx.doi.org/10.1002/dmrr.2299
Diabetic Foot
2012. Nyazee Humaa A., Finney Kristina M., Sarikonda Molly, Towler Dwight A., Johnson Jeffrey E. and Babcock Hilary M. Diabetic foot osteomyelitis: Bone markers and treatment outcomes.Diabetes research and clinical practice. 97. 411-417.
http://linkinghub.elsevier.com/retrieve/pii/S0168822712001349?showall=true
DIAD
2011. Bansal Shanti, Wackers Frans J.Th., Inzucchi Silvio E., Chyun Deborah A., Davey Janice A., Staib Lawrence H., Young Lawrence H. and Investigators for the DIAD Study. Five-Year Outcomes in High-Risk Participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study.Diabetes Care. 34. 204-209.
http://care.diabetesjournals.org/content/34/1/204.abstract
Diet
2011. Lim E., Hollingsworth K., Aribisala B., Chen M., Mathers J. and Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.Diabetologia. 54. 2506-2514.
http://dx.doi.org/10.1007/s00125-011-2204-7
Diet
2011. Cene Crystal Wiley and Pignone Michael. The Effect of Fruit and Vegetable Intake on the Incidence of Diabetes.Clinical Diabetes. 29. 113-115.
http://clinical.diabetesjournals.org/content/29/3/113.short
Diet
2011. Larsen R., Mann N., Maclean E. and Shaw J. The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: a 12 month randomised controlled trial.Diabetologia. 54. 731-740.
http://dx.doi.org/10.1007/s00125-010-2027-y
Diet
2011. Zamora Daisy, Gordon-Larsen Penny, He Ka, Jacobs David R., Shikany James M. and Popkin Barry M. Are the 2005 Dietary Guidelines for Americans Associated With Reduced Risk of Type 2 Diabetes and Cardiometabolic Risk Factors?Diabetes Care. 34. 1183-1185.
http://care.diabetesjournals.org/content/34/5/1183.abstract
Diet
2011. Pignone Michael. High-Protein and Low-Glycemic Diets Improve Weight Maintenance Among Overweight Adults.Clinical Diabetes. 29. 73-74.
http://clinical.diabetesjournals.org/content/29/2/73.short
Diet
2012. Day Caroline and Bailey Clifford J. The hypocaloric diet in type 2 diabetes - déjà vu.The British Journal of Diabetes & Vascular Disease. 12. 48-51.
http://dvd.sagepub.com/cgi/content/abstract/12/1/48
Diet
2012. Wallin Alice, Di Giuseppe Daniela, Orsini Nicola, Patel Pinal S., Forouhi Nita G. and Wolk Alicja. Fish Consumption, Dietary Long-Chain n-3 Fatty Acids, and Risk of Type 2 Diabetes.Diabetes Care. 35. 918-929.
http://care.diabetesjournals.org/content/35/4/918.abstract
Diet
2012. Xun Pengcheng and He Ka. Fish Consumption and Incidence of Diabetes.Diabetes Care. 35. 930-938.
http://care.diabetesjournals.org/content/35/4/930.abstract
DIGAMI
1995. Malmberg Klas, Rydén Lars, Efendic Suad, Herlitz Johan, Nicol Peter, Waldenstrom Anders, Wedel Hans and Welin Lennart. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year.Journal of the American College of Cardiology. 26. 57-65.
http://www.sciencedirect.com/science/article/pii/073510979500126K
DIGAMI
1996. Malmberg K., Ryden L., Hamstent A., Herlitz J., Waldenstram A. and Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction.European Heart Journal. 17. 1337-1344.
http://eurheartj.oxfordjournals.org/content/17/9/1337.abstract
DIGAMI
1999. Malmberg Klas, Norhammar Anna, Wedel Hans and Ryden Lars. Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study.Circulation. 99. 2626-2632.
http://circ.ahajournals.org/content/99/20/2626.abstract
DIGAMI 2
2011. Mellbin L., Malmberg K., Norhammar A., Wedel H. and Rydén L. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.Diabetologia. 54. 1308-1317.
http://dx.doi.org/10.1007/s00125-011-2084-x
DIRECT
2011. Sjølie A. K., Klein R., Porta M., Orchard T., Fuller J., Parving H. H., Bilous R., Aldington S. and Chaturvedi N. Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.Diabetic Medicine. 28. 345-351.
http://dx.doi.org/10.1111/j.1464-5491.2010.03210.x
DPP4
2011. Rosenstock J., Lewin A. J., Norwood P., Somayaji V., Nguyen T. T., Teeter J. G., Johnson S. L., Dai H. and Terra S. G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.Diabetic Medicine. 28. 464-469.
http://dx.doi.org/10.1111/j.1464-5491.2010.03181.x
DPP4
2011. Lukashevich V., Schweizer A., Shao Q., Groop P. H. and Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial.Diabetes, Obesity and Metabolism. 13. 947-954.
http://dx.doi.org/10.1111/j.1463-1326.2011.01467.x
DPP4
2011. Bosi E., Ellis G. C., Wilson C. A. and Fleck P. R. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.Diabetes, Obesity and Metabolism. 13. 1088-1096.
http://dx.doi.org/10.1111/j.1463-1326.2011.01463.x
DPP4
2011. Graefe-Mody U., Friedrich C., Port A., Ring A., Retlich S., Heise T., Halabi A. and Woerle H. J. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*.Diabetes, Obesity and Metabolism. 13. 939-946.
http://dx.doi.org/10.1111/j.1463-1326.2011.01458.x
DPP4
2011. Ellis S. L., Moser E. G., Snell-Bergeon J. K., Rodionova A. S., Hazenfield R. M. and Garg S. K. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.Diabetic Medicine. 28. 1176-1181.
http://dx.doi.org/10.1111/j.1464-5491.2011.03331.x
DPP4
2012. Gonçalves A., Leal E., Paiva A., Teixeira Lemos E., Teixeira F., Ribeiro C. F., Reis F., Ambrósio A. F. and Fernandes R. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood–retinal barrier in a type 2 diabetes animal model.Diabetes, Obesity and Metabolism. 14. 454-463.
http://dx.doi.org/10.1111/j.1463-1326.2011.01548.x
DPP4
2012. Eto T., Inoue S. and Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.Diabetes, Obesity and Metabolism. 14. 1040-1046.
http://dx.doi.org/10.1111/j.1463-1326.2012.01662.x
DPP4
2012. Williams-Herman D., Xu L., Teng R., Golm G. T., Johnson J., Davies M. J., Kaufman K. D. and Goldstein B. J. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.Diabetes, Obesity and Metabolism. 14. 67-76.
http://dx.doi.org/10.1111/j.1463-1326.2011.01492.x
DPP4
2012. Schernthaner G., Barnett A. H., Emser A., Patel S., Troost J., Woerle H. J. and von Eynatten M. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Diabetes, Obesity and Metabolism. 14. 470-478.
http://dx.doi.org/10.1111/j.1463-1326.2012.01565.x
DPP4
2012. Eliasson B., Möller-Goede D., Eeg-Olofsson K., Wilson C., Cederholm J., Fleck P., Diamant M., Taskinen M. R. and Smith U. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.Diabetologia. 55. 915-925.
http://dx.doi.org/10.1007/s00125-011-2447-3
DPP4
2012. Haak T., Meinicke T., Jones R., Weber S., Eynatten M. von and Woerle H. J. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.Diabetes, Obesity and Metabolism. 14. 565-574.
http://dx.doi.org/10.1111/j.1463-1326.2012.01590.x
DPP4
2013. Kim Y. G., Hahn S., Oh T. J., Kwak S. H., Park K. S. and Cho Y. M. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.Diabetologia. 56. 696-708.
http://dx.doi.org/10.1007/s00125-012-2827-3
DPP4
2013. Schernthaner Guntram, Gross Jorge L., Rosenstock Julio, Guarisco Michael, Fu Min, Yee Jacqueline, Kawaguchi Masato, Canovatchel William and Meininger Gary. Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial.Diabetes Care. 36. 2508-2515.
http://care.diabetesjournals.org/content/36/9/2508.abstract
DPP4
2013. Barnett Anthony H., Huisman Holger, Jones Russell, von Eynatten Maximilian, Patel Sanjay and Woerle Hans-Juergen. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.The Lancet. 382. 1413-1423.
http://linkinghub.elsevier.com/retrieve/pii/S0140673613615007
DPP4
2013. Yang S. J., Min K. W., Gupta S. K., Park J. Y., Shivane V. K., Pitale S. U., Agarwal P. K., Sosale A., Gandhi P., Dharmalingam M., Mohan V., Mahesh U., Kim D. M., Kim Y. S., Kim J. A., Kim P. K. and Baik S. H. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.Diabetes, Obesity and Metabolism. 15. 410-416.
http://dx.doi.org/10.1111/dom.12042
DPP4
2013. McGill Janet B., Sloan Lance, Newman Jennifer, Patel Sanjay, Sauce Christophe, von Eynatten Maximilian and Woerle Hans-Juergen. Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study.Diabetes Care. 36. 237-244.
http://care.diabetesjournals.org/content/36/2/237.abstract
DPP4
2013. Solis-Herrera Carolina, Triplitt Curtis, Garduno-Garcia Jose de Jesús, Adams John, DeFronzo Ralph A. and Cersosimo Eugenio. Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.Diabetes Care. 36. 2756-2762.
http://care.diabetesjournals.org/content/36/9/2756.abstract
DPP4
2013. Rathmann W., Kostev K., Gruenberger J. B., Dworak M., Bader G. and Giani G. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.Diabetes, Obesity and Metabolism. 15. 55-61.
http://dx.doi.org/10.1111/j.1463-1326.2012.01674.x
DPP4
2013. Monami M., Ahrén B., Dicembrini I. and Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials.Diabetes, Obesity and Metabolism. 15. 112-120.
http://dx.doi.org/10.1111/dom.12000
DPP4
2013. Arjona Ferreira Juan Camilo, Marre Michel, Barzilai Nir, Guo Hua, Golm Gregory T., Sisk Christine McCrary, Kaufman Keith D. and Goldstein Barry J. Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency.Diabetes Care. 36. 1067-1073.
http://care.diabetesjournals.org/content/36/5/1067.abstract
DPP4
2014. Kovacs C. S., Seshiah V., Swallow R., Jones R., Rattunde H., Woerle H. J., Broedl U. C. and on behalf of the Empa- R. E. G. Pio™ trial investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.Diabetes, Obesity and Metabolism. 16. 147-158.
http://dx.doi.org/10.1111/dom.12188
DPP4
2014. Yale J. F., Bakris G., Cariou B., Nieto J., David-Neto E., Yue D., Wajs E., Figueroa K., Jiang J., Law G., Usiskin K., Meininger G. and on behalf of the D. I. A. Study Group. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.Diabetes, Obesity and Metabolism. 16. 1016-1027.
http://dx.doi.org/10.1111/dom.12348
DPPOS
2012. Group The Diabetes Prevention Program Research. Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study.Diabetes Care. 35. 731-737.
http://care.diabetesjournals.org/content/35/4/731.abstract
DREAM
2004. Gerstein HC, Yusuf S., Holman R., Bosch J. and Pogue J. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.Diabetologia. 47. 1519.
http://www.ncbi.nlm.nih.gov/pubmed/15322749
DREAM
2006. Investigator The DREAM Trial. Effect of Ramipril on the Incidence of Diabetes.New England Journal of Medicine. 355. 1551-1562.
http://www.nejm.org/doi/full/10.1056/NEJMoa065061
DREAM
2006. Investigators The DREAM Trial. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.The Lancet. 368. 1096-1105.
http://linkinghub.elsevier.com/retrieve/pii/S0140673606694208
DREAM
2011. Investigators The DREAM Trial. Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal.Diabetes Care. 34. 1265-1269.
http://care.diabetesjournals.org/content/34/6/1265.abstract
DURABLE
2011. Buse John B., Wolffenbuttel Bruce H.R., Herman William H., Hippler Stephen, Martin Sherry A., Jiang Honghua H., Shenouda Sylvia K. and Fahrbach Jessie L. The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial.Diabetes Care. 34. 249-255.
http://care.diabetesjournals.org/content/34/2/249.abstract
DURATION-4
2012. Russell-Jones David, Cuddihy Robert M., Hanefeld Markolf, Kumar Ajay, González Jose G., Chan Melanie, Wolka Anne M., Boardman Marilyn K. and Group on behalf of the DURATION-4 Study. Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4).Diabetes Care. 35. 252-258.
http://care.diabetesjournals.org/content/35/2/252.abstract
DURATION-6
2013. Buse John B., Nauck Michael, Forst Thomas, Sheu Wayne H. H., Shenouda Sylvia K., Heilmann Cory R., Hoogwerf Byron J., Gao Aijun, Boardman Marilyn K., Fineman Mark, Porter Lisa and Schernthaner Guntram. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.The Lancet. 381. 117-124.
http://linkinghub.elsevier.com/retrieve/pii/S0140673612612677
DURATION 2
2011. Wysham C., Bergenstal R., Malloy J., Yan P., Walsh B., Malone J. and Taylor K. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.Diabetic Medicine. 28. 705-714.
http://dx.doi.org/10.1111/j.1464-5491.2011.03301.x
Back to Top
EDITION 1
2014. Riddle Matthew C., Bolli Geremia B., Ziemen Monika, Muehlen-Bartmer Isabel, Bizet Florence and Home Philip D. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1).Diabetes Care. 37. 2755-2762.
http://care.diabetesjournals.org/content/37/10/2755.abstract
Education
2012. Due-Christensen M., Zoffmann V., Hommel E. and Lau M. Can sharing experiences in groups reduce the burden of living with diabetes, regardless of glycaemic control?Diabetic Medicine. 29. 251-256.
http://dx.doi.org/10.1111/j.1464-5491.2011.03521.x
Education
2013. Zhang H., Xu W., Dahl A. K., Xu Z., Wang H. X. and Qi X. Relation of socio-economic status to impaired fasting glucose and Type 2 diabetes: findings based on a large population-based cross-sectional study in Tianjin, China.Diabetic Medicine. 30. e157-e162.
http://dx.doi.org/10.1111/dme.12156
Elderly
2011. Huang Elbert S., Liu Jennifer Y., Moffet Howard H., John Priya M. and Karter Andrew J. Glycemic Control, Complications, and Death in Older Diabetic Patients.Diabetes Care. 34. 1329-1336.
http://care.diabetesjournals.org/content/34/6/1329.abstract
ELEGANT Study
2014. de Wit HelenaM, Vervoort GeraldM M., Jansen HenryJ, de Grauw WimJ C., de Galan BastiaanE and Tack CeesJ. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).Diabetologia. 57. 1812-1819.
http://dx.doi.org/10.1007/s00125-014-3302-0
Ely
2012. Rahman M., Simmons R., Hennings S., Wareham N. and Griffin S. How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort.Diabetologia. 55. 1651-1659.
http://dx.doi.org/10.1007/s00125-011-2441-9
ENTRED
2011. Pornet Carole, Bourdel-Marchasson Isabelle, Lecomte Pierre, Eschwège Eveline, Romon Isabelle, Fosse Sandrine, Assogba Frank, Roudier Candice and Fagot-Campagna Anne. Trends in the quality of care for elderly people with type 2 diabetes: The need for improvements in safety and quality (the 2001 and 2007 ENTRED Surveys).Diabetes & Metabolism. 37. 152-161.
http://www.sciencedirect.com/science/article/pii/S1262363611000371
ENTRED
2012. Assogba G. F. A., Couchoud C., Roudier C., Pornet C., Fosse S., Romon I., Druet C., Stengel B. and Fagot-Campagna A. Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: The ENTRED surveys (2001 and 2007).Diabetes & Metabolism. 38. 558-566.
http://www.sciencedirect.com/science/article/pii/S126236361200122X
Epidemiology
1994. Moss Scot E., Klein Ronald, Klein Barbara E. K. and Meuer Stacy M. The Association of Glycemia and Cause-Specific Mortality in a Diabetic Population.Arch Intern Med. 154. 2473-2479.
http://archinte.ama-assn.org/cgi/content/abstract/154/21/2473
Epidemiology
2000. Olsson J., Lindberg G., Gottsäter M., Lindwall K., Sjöstrand Å, Tisell A. and Melander A. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study.Diabetologia. 43. 558-560.
http://dx.doi.org/10.1007/s001250051343
Epidemiology
2011. Lee Ji Won R., Brancati Frederick L. and Yeh Hsin-Chieh. Trends in the Prevalence of Type 2 Diabetes in Asians Versus Whites.Diabetes Care. 34. 353-357.
http://care.diabetesjournals.org/content/34/2/353.abstract
Epidemiology
2011. Todd J. A., Knip M. and Mathieu C. Strategies for the prevention of autoimmune Type 1 diabetes.Diabetic Medicine. 28. 1141-1143.
http://dx.doi.org/10.1111/j.1464-5491.2011.03400.x
Epidemiology
2011. McEwen Laura N., Karter Andrew J., Curb J. David, Marrero David G., Crosson Jesse C. and Herman William H. Temporal Trends in Recording of Diabetes on Death Certificates.Diabetes Care. 34. 1529-1533.
http://care.diabetesjournals.org/content/34/7/1529.abstract
Epidemiology
2011. Guariguata Leonor, Whiting David, Weil Clara and Unwin Nigel. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults.Diabetes research and clinical practice. 94. 322-332.
http://www.sciencedirect.com/science/article/pii/S0168822711006036
Epidemiology
2012. Imperatore Giuseppina, Boyle James P., Thompson Theodore J., Case Doug, Dabelea Dana, Hamman Richard F., Lawrence Jean M., Liese Angela D., Liu Lenna L., Mayer-Davis Elizabeth J., Rodriguez Beatriz L., Standiford Debra and Group for the SEARCH for Diabetes in Youth Study. Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2050: Dynamic modeling of incidence, mortality, and population growth.Diabetes Care. 35. 2515-2520.
http://care.diabetesjournals.org/content/35/12/2515.abstract
Epidemiology
2012. de Lusignan S., Sadek N., Mulnier H., Tahir A., Russell-Jones D. and Khunti K. Miscoding, misclassification and misdiagnosis of diabetes in primary care.Diabetic Medicine. 29. 181-189.
http://dx.doi.org/10.1111/j.1464-5491.2011.03419.x
Epidemiology
2014. Faglia Ezio, Clerici Giacomo, Scatena Alessia, Caminiti Maurizio, Curci Vincenzo, Morabito Alberto, Prisco Vincenzo, Greco Rosaria and Edmonds Mike. Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: An observational study.Diabetes research and clinical practice. 103. 292-297.
http://linkinghub.elsevier.com/retrieve/pii/S0168822714000217?showall=true
Epidemiology
2014. Guariguata L., Linnenkamp U., Beagley J., Whiting D. R. and Cho N. H. Global estimates of the prevalence of hyperglycaemia in pregnancy.Diabetes research and clinical practice. 103. 176-185.
http://linkinghub.elsevier.com/retrieve/pii/S0168822713003860?showall=true
Epidemiology
2014. Guariguata L., Whiting D. R., Hambleton I., Beagley J., Linnenkamp U. and Shaw J. E. Global estimates of diabetes prevalence for 2013 and projections for 2035.Diabetes research and clinical practice. 103. 137-149.
http://linkinghub.elsevier.com/retrieve/pii/S0168822713003859?showall=true
Epidemiology
2014. Beagley Jessica, Guariguata Leonor, Weil Clara and Motala Ayesha A. Global estimates of undiagnosed diabetes in adults.Diabetes research and clinical practice. 103. 150-160.
http://linkinghub.elsevier.com/retrieve/pii/S0168822713003847?showall=true
Epidemiology
2014. Patterson Chris, Guariguata Leonor, Dahlquist Gisela, Soltész Gyula, Ogle Graham and Silink Martin. Diabetes in the young – a global view and worldwide estimates of numbers of children with type 1 diabetes.Diabetes research and clinical practice. 103. 161-175.
http://linkinghub.elsevier.com/retrieve/pii/S0168822713003884?showall=true
Epidemiology
2014. Linnenkamp U., Guariguata L., Beagley J., Whiting D. R. and Cho N. H. The IDF Diabetes Atlas methodology for estimating global prevalence of hyperglycaemia in pregnancy.Diabetes research and clinical practice. 103. 186-196.
http://linkinghub.elsevier.com/retrieve/pii/S0168822713003872?showall=true
Epidemiology IDF
2011. Whiting David R., Guariguata Leonor, Weil Clara and Shaw Jonathan. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030.Diabetes research and clinical practice. 94. 311-321.
http://www.sciencedirect.com/science/article/pii/S0168822711005912
EPIRCE Study
2011. Gayoso-Diz Pilar, Otero-Gonzalez Alfonso, Rodriguez-Alvarez María Xosé, Gude Francisco, Cadarso-Suarez Carmen, García Fernando and De Francisco Angel. Insulin resistance index (HOMA-IR) levels in a general adult population: Curves percentile by gender and age. The EPIRCE study.Diabetes research and clinical practice. 94. 146-155.
http://linkinghub.elsevier.com/retrieve/pii/S0168822711003652?showall=true
EPR
2011. Cebul Randall D., Love Thomas E., Jain Anil K. and Hebert Christopher J. Electronic Health Records and Quality of Diabetes Care.New England Journal of Medicine. 365. 825-833.
http://www.nejm.org/doi/full/10.1056/NEJMsa1102519
EPR
2012. Gray L., Davies M., Hiles S., Taub N., Webb D., Srinivasan B. and Khunti K. Detection of impaired glucose regulation and/or type 2 diabetes mellitus, using primary care electronic data, in a multiethnic UK community setting.Diabetologia. 55. 959-966.
http://dx.doi.org/10.1007/s00125-011-2432-x
EPR
2012. Sadek A. R., van Vlymen J., Khunti K. and de Lusignan S. Automated identification of miscoded and misclassified cases of diabetes from computer records.Diabetic Medicine. 29. 410-414.
http://dx.doi.org/10.1111/j.1464-5491.2011.03457.x
EURODIAB
2012. Schoenaker D., Toeller M., Chaturvedi N., Fuller J., Soedamah-Muthu S. and Group the Eurodiab Prospective Complications Study. Dietary saturated fat and fibre and risk of cardiovascular disease and all-cause mortality among type 1 diabetic patients: the EURODIAB Prospective Complications Study.Diabetologia. 55. 2132-2141.
http://dx.doi.org/10.1007/s00125-012-2550-0
EURODIAB
2012. Gruden Gabriella, Barutta Federica, Chaturvedi Nish, Schalkwijk Casper, Stehouwer Coen D., Witte Daniel R., Fuller John H., Cavallo Perin Paolo and Bruno Graziella. Severe Hypoglycemia and Cardiovascular Disease Incidence in Type 1 Diabetes.Diabetes Care. 35. 1598-1604.
http://care.diabetesjournals.org/content/35/7/1598.abstract
Exercise
2010. Hassinen Maija, Lakka Timo A., Hakola Leena, Savonen Kai, Komulainen Pirjo, Litmanen Hannu, Kiviniemi Vesa, Kouki Reija, Heikkilá Harri and Rauramaa Rainer. Cardiorespiratory Fitness and Metabolic Syndrome in Older Men and Women.Diabetes Care. 33. 1655-1657.
http://care.diabetesjournals.org/content/33/7/1655.abstract
Exercise
2011. Chudyk Anna and Petrella Robert J. Effects of Exercise on Cardiovascular Risk Factors in Type 2 Diabetes.Diabetes Care. 34. 1228-1237.
http://care.diabetesjournals.org/content/34/5/1228.abstract
Exercise
2012. Berman Laura J., Weigensberg Marc J. and Spruijt-Metz Donna. Physical activity is related to insulin sensitivity in children and adolescents, independent of adiposity: a review of the literature.Diabetes/Metabolism Research and Reviews. 28. 395-408.
http://dx.doi.org/10.1002/dmrr.2292
Exercise
2012. Mynarski W., Psurek A., Borek Z., Rozpara M., Grabara M. and Strojek K. Declared and real physical activity in patients with type 2 diabetes mellitus as assessed by the International Physical Activity Questionnaire and Caltrac accelerometer monitor: A potential tool for physical activity assessment in patients with type 2 diabetes mellitus.Diabetes research and clinical practice. 98. 46-50.
http://linkinghub.elsevier.com/retrieve/pii/S0168822712002124?showall=true
Exercise
2012. Bacchi Elisabetta, Negri Carlo, Zanolin Maria Elisabetta, Milanese Chiara, Faccioli Niccolò, Trombetta Maddalena, Zoppini Giacomo, Cevese Antonio, Bonadonna Riccardo C., Schena Federico, Bonora Enzo, Lanza Massimo and Moghetti Paolo. Metabolic Effects of Aerobic Training and Resistance Training in Type 2 Diabetic Subjects.Diabetes Care. 35. 676-682.
http://care.diabetesjournals.org/content/35/4/676.abstract
Exercise
2012. Chae Jey Sook, Kang Ryungwoo, Kwak Jung Hyun, Paik Jean Kyung, Kim Oh Yoen, Kim Minjoo, Park Ji Won, Jeon Justin Y. and Lee Jong Ho. Supervised Exercise Program, BMI, and Risk of Type 2 Diabetes in Subjects With Normal or Impaired Fasting Glucose.Diabetes Care. 35. 1680-1685.
http://care.diabetesjournals.org/content/35/8/1680.abstract
Exercise
2013. Newsom Sean A., Everett Allison C., Hinko Alexander and Horowitz Jeffrey F. A Single Session of Low-Intensity Exercise Is Sufficient to Enhance Insulin Sensitivity Into the Next Day in Obese Adults.Diabetes Care. 36. 2516-2522.
http://care.diabetesjournals.org/content/36/9/2516.abstract
Exercise
2013. Sone H., Tanaka S., Suzuki S., Seino H., Hanyu O., Sato A., Toyonaga T., Okita K., Ishibashi S., Kodama S., Akanuma Y. and Yamada N. Leisure-time physical activity is a significant predictor of stroke and total mortality in Japanese patients with type 2 diabetes: analysis from the Japan Diabetes Complications Study (JDCS).Diabetologia. 56. 1021-1030.
http://dx.doi.org/10.1007/s00125-012-2810-z
Exercise
2013. Duclos M., Oppert J. M., Verges B., Coliche V., Gautier J. F., Guezennec Y., Reach G. and Strauch G. Physical activity and type 2 diabetes. Recommandations of the SFD (Francophone Diabetes Society) diabetes and physical activity working group.Diabetes & Metabolism. 39. 205-216.
http://www.sciencedirect.com/science/article/pii/S1262363613000530
Back to Top
2014. Gulli Giovanni, Frasson Stefania, Borzì Vito, Fontanella Andrea, Grandi Marco, Marengo Claudio, Nicolucci Antonio, Pastorelli Ruggero, Solerte Bruno, Gatti Adriano, Raimondo FrancescoCristiano, Bonizzoni Erminio, Gussoni Gualberto, Mazzone Antonino and Ceriello Antonio. Effectiveness of an educational intervention on the management of type 2 diabetic patients hospitalized in Internal Medicine: results from the FADOI-DIAMOND study.Acta Diabetol. 51. 765-770.
http://dx.doi.org/10.1007/s00592-014-0585-z
FDPS
2010. Ilanne-Parikka Pirjo, Laaksonen David E., Eriksson Johan G., Lakka Timo A., Lindstr Jaanaom, Peltonen Markku, Aunola Sirkka, Keinánen-Kiukaanniemi Sirkka, Uusitupa Matti and Tuomilehto Jaakko. Leisure-Time Physical Activity and the Metabolic Syndrome in the Finnish Diabetes Prevention Study.Diabetes Care. 33. 1610-1617.
http://care.diabetesjournals.org/content/33/7/1610.abstract
FDPS
2011. Pajunen P., Peltonen M., Eriksson J. G., Ilanne-Parikka P., Aunola S., Keinänen-Kiukaanniemi S., Uusitupa M., Tuomilehto J., Lindström J. and for the Finnish Diabetes Prevention Study. HbA1c in diagnosing and predicting Type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study.Diabetic Medicine. 28. 36-42.
http://dx.doi.org/10.1111/j.1464-5491.2010.03183.x
FDS
2011. Fegan P. G., Davis W. A., Kamber N., Sivakumar S., Beilby J. and Davis T. M. E. Renin–angiotensin–aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: The Fremantle Diabetes Study.Diabetic Medicine. 28. 849-855.
http://dx.doi.org/10.1111/j.1464-5491.2011.03230.x
FDS
2011. Davis W. A., Bruce D. G. and Davis T. M. E. Economic impact of moderate weight loss in patients with Type 2 diabetes: The Fremantle Diabetes Study.Diabetic Medicine. 28. 1131-1135.
http://dx.doi.org/10.1111/j.1464-5491.2011.03314.x
FHS 1
1997. Hammersley M. S., Meyer L. C., Morris R. J., Manley S. E., Turner R. C. and Holman R. R. The fasting hyperglycaemia study: I. Subject identification and recruitment for a non--insulin-dependent diabetes prevention trial.Metabolism. 46. 44-49.
http://www.sciencedirect.com/science/article/pii/S0026049597903176
FHS 2
1997. Dyson P. A., Hammersley M. S., Morris R. J., Holman R. R. and Turner R. C. The fasting hyperglycaemia study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose.Metabolism. 46. 50-55.
http://www.sciencedirect.com/science/article/pii/S0026049597903188
FHS III
1997. Karunakara S., Hammersley M. S., Morris R. J., Turner R. C. and Holman R. R. The fasting hyperglycaemia study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.Metabolism. 46. 56-60.
http://www.sciencedirect.com/science/article/pii/S002604959790319X
FIELD
2011. Davis T., Ting R., Best J., Donoghoe M., Drury P., Sullivan D., Jenkins A., O’Connell R., Whiting M., Glasziou P., Simes R., Kesäniemi Y., Gebski V., Scott R. and Keech A. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.Diabetologia. 54. 280-290.
http://dx.doi.org/10.1007/s00125-010-1951-1
FIELD
2012. Ting Ru-Dee, Keech Anthony C., Drury Paul L., Donoghoe Mark W., Hedley John, Jenkins Alicia J., Davis Timothy M.E., Lehto Seppo, Celermajer David, Simes R. John, Rajamani Kushwin, Stanton Kim and Investigators on behalf of the FIELD Study. Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment.Diabetes Care. 35. 218-225.
http://care.diabetesjournals.org/content/35/2/218.abstract
FIN-D2D Project
2012. Rautio N., Jokelainen J., Oksa H., Saaristo T., Peltonen M., Puolijoki H., Tuomilehto J., Vanhala M., Moilanen L., Uusitupa M. and Keinänen-Kiukaanniemi S. Family history of diabetes and effectiveness of lifestyle counselling on the cardio-metabolic risk profile in individuals at high risk of Type 2 diabetes: 1-year follow-up of the FIN-D2D project.Diabetic Medicine. 29. 207-211.
http://dx.doi.org/10.1111/j.1464-5491.2011.03388.x
2011. Saltevo J. T., Kautiainen H., Niskanen L., Oksa H., Puolijoki H., Sundvall J., Keinänen-Kiukaanniemi S., Peltonen M., Tuomilehto J., Uusitupa M., Mäntyselkä P. and Vanhala M. J. Ageing and associations of fasting plasma glucose and 2h plasma glucose with HbA1C in apparently healthy population. “FIN-D2D” study.Diabetes research and clinical practice. 93. 344-349.
http://linkinghub.elsevier.com/retrieve/pii/S0168822711002336?showall=true
FINDRISC
2011. Makrilakis K., Liatis S., Grammatikou S., Perrea D., Stathi C., Tsiligros P. and Katsilambros N. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece.Diabetes & Metabolism. 37. 144-151.
http://www.sciencedirect.com/science/article/pii/S1262363610002326
FinnDianne Study
2014. Tolonen Nina, Forsblom Carol, Mäkinen Ville-Petteri, Harjutsalo Valma, Gordin Daniel, Feodoroff Maija, Sandholm Niina, Thorn Lena M., Wadén Johan, Taskinen Marja-Riitta and Groop Per-Henrik. Different Lipid Variables Predict Incident Coronary Artery Disease in Patients With Type 1 Diabetes With or Without Diabetic Nephropathy: The FinnDiane Study.Diabetes Care. 37. 2374-2382.
http://care.diabetesjournals.org/content/37/8/2374.abstract
FINNISH
2005. Hu Gang, Jousilahti Pekka, Barengo Noël C., Qiao Qing, Lakka Timo A. and Tuomilehto Jaakko. Physical Activity, Cardiovascular Risk Factors, and Mortality Among Finnish Adults With Diabetes.Diabetes Care. 28. 799-805.
http://care.diabetesjournals.org/content/28/4/799.abstract
Footcare
2014. Sharma S., Kerry C., Atkins H. and Rayman G. The Ipswich Touch Test: a simple and novel method to screen patients with diabetes at home for increased risk of foot ulceration.Diabetic Medicine. 31. 1100-1103.
http://dx.doi.org/10.1111/dme.12450
FRAMINGHAM
1974. Kannel William B., Hjortland Marthana and Castelli William P. Role of diabetes in congestive heart failure: The Framingham study.The American Journal of Cardiology. 34. 29-34.
http://www.sciencedirect.com/science/article/pii/0002914974900897
FRAMINGHAM
1979. Kannel WB and McGee DL. Diabetes and cardiovascular risk factors: the Framingham study.Circulation. 59. 8-13.
http://circ.ahajournals.org/content/59/1/8.abstract
FRAMINGHAM
1985. Kannel William B. Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study.American Heart Journal. 110. 1100-1107.
http://www.sciencedirect.com/science/article/pii/0002870385902248
FRAMINGHAM
1990. Kannel William B., D'Agostino Ralph B., Wilson Peter W. F., Belanger Albert J. and Gagnon David R. Diabetes, fibrinogen, and risk of cardiovascular disease: The Framingham experience.American Heart Journal. 120. 672-676.
http://www.sciencedirect.com/science/article/pii/000287039090026T
Framingham Heart Study
2013. Jasuja Guneet Kaur, Travison Thomas G., Davda Maithili, Rose Adam J., Zhang Anqi, Kushnir Mark M., Rockwood Alan L., Meikle Wayne, Coviello Andrea D., D’Agostino Ralph, Vasan Ramachandran S. and Bhasin Shalender. Circulating Estrone Levels Are Associated Prospectively With Diabetes Risk in Men of the Framingham Heart Study.Diabetes Care. 36. 2591-2596.
http://care.diabetesjournals.org/content/36/9/2591.abstract
Fremantle Study
2012. Magliano Dianna J, Davis Wendy A, Shaw Jonathan E, Bruce David G and Davis Timothy M E. Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study.European Journal of Endocrinology. 167. 589-599.
http://www.eje-online.org/content/167/4/589.abstract
FRENA
2011. Camafort M., Álvarez-Rodríguez L. R., Muñoz-Torrero J. F. S., Sahuquillo J. C., López-Jiménez L., Coll R., Monreal M. and the Frena Investigators. Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA Registry.Diabetic Medicine. 28. 73-80.
http://dx.doi.org/10.1111/j.1464-5491.2010.03153.x
Back to Top
G-Protein
2013. Dobbins R. L., Shearn S. P., Byerly R. L., Gao F. F., Mahar K. M., Napolitano A., Nachbaur G. J. and Le Monnier de Gouville A. C. GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.Diabetes, Obesity and Metabolism. 15. 1013-1021.
http://dx.doi.org/10.1111/dom.12132
GERODIAB
2012. Doucet J., Le Floch J. P., Bauduceau B. and Verny C. GERODIAB: Glycaemic control and 5-year morbidity/mortality of type 2 diabetic patients aged 70 years and older: 1. Description of the population at inclusion.Diabetes & Metabolism. 38. 523-530.
http://www.sciencedirect.com/science/article/pii/S1262363612001243
Gestational
2011. Tobias Deirdre K., Hu Frank B., Forman John P., Chavarro Jorge and Zhang Cuilin. Increased Risk of Hypertension After Gestational Diabetes Mellitus.Diabetes Care. 34. 1582-1584.
http://care.diabetesjournals.org/content/34/7/1582.abstract
Gestational
2011. Goh J. E. L., Sadler L. and Rowan J. Metformin for gestational diabetes in routine clinical practice.Diabetic Medicine. 28. 1082-1087.
http://dx.doi.org/10.1111/j.1464-5491.2011.03361.x
Gestational
2011. Tobias Deirdre K., Zhang Cuilin, van Dam Rob M., Bowers Katherine and Hu Frank B. Physical Activity Before and During Pregnancy and Risk of Gestational Diabetes Mellitus.Diabetes Care. 34. 223-229.
http://care.diabetesjournals.org/content/34/1/223.abstract
Gestational
2012. Ziegler Anette-G., Wallner Maike, Kaiser Imme, Rossbauer Michaela, Harsunen Minna H., Lachmann Lorenz, Maier Jörg, Winkler Christiane and Hummel Sandra. Long-Term Protective Effect of Lactation on the Development of Type 2 Diabetes in Women With Recent Gestational Diabetes Mellitus.Diabetes. 61. 3167-3171.
http://diabetes.diabetesjournals.org/content/61/12/3167.abstract
Gestational
2012. Cundy T. Proposed new diagnostic criteria for gestational diabetes – a pause for thought?Diabetic Medicine. 29. 176-180.
http://dx.doi.org/10.1111/j.1464-5491.2011.03407.x
Gestational
2013. Cyganek Katarzyna, Hebda-Szydlo Alicja, Skupien Jan, Janas Izabela, Walczyk Joanna, Lipowska Anna, Borys Sebastian and Malecki Maciej T. Postpregnancy Glycemic Control and Weight Changes in Type 1 Diabetic Women.Diabetes Care. 36. 1083-1087.
http://care.diabetesjournals.org/content/36/5/1083.abstract
Gestational
2013. Tertti K., Ekblad U., Koskinen P., Vahlberg T. and Rönnemaa T. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin.Diabetes, Obesity and Metabolism. 15. 246-251.
http://dx.doi.org/10.1111/dom.12017
GIANT Study
2012. Reutens Anne T., Hutchinson Richard, Van Binh Ta, Cockram Clive, Deerochanawong Chaicharn, Ho Low-Tone, Ji Linong, Khalid Bin Abdul Kadir, Kong Alice Pik Shan, Lim-Abrahan Mary Ann, Tan Chee-Eng, Tjokroprawiro Askandar, Yoon Kun-Ho, Zimmet Paul Z. and Shaw Jonathan E. The GIANT study, a cluster-randomised controlled trial of efficacy of education of doctors about type 2 diabetes mellitus management guidelines in primary care practice.Diabetes research and clinical practice. 98. 38-45.
http://linkinghub.elsevier.com/retrieve/pii/S0168822712002173?showall=true
Glimin
2012. Pirags V., Lebovitz H. and Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.Diabetes, Obesity and Metabolism. 14. 852-858.
http://dx.doi.org/10.1111/j.1463-1326.2012.01611.x
GLP-1
2005. Kendall David M., Riddle Matthew C., Rosenstock Julio, Zhuang Dongliang, Kim Dennis D., Fineman Mark S. and Baron Alain D. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea.Diabetes Care. 28. 1083-1091.
http://care.diabetesjournals.org/content/28/5/1083.abstract
GLP-1
2005. Heine Robert J., Van Gaal Luc F., Johns Don, Mihm Michael J., Widel Mario H., Brodows Robert G. and Group* for the GWAA Study. Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes.Annals of Internal Medicine. 143. 559-569.
http://www.annals.org/content/143/8/559.abstract
GLP-1
2006. Linnebjerg H., Kothare P. A., Skrivanek Z., de la Peña A., Atkins M., Ernest C. S. and Trautmann M. E. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.Diabetic Medicine. 23. 240-245.
http://dx.doi.org/10.1111/j.1464-5491.2006.01800.x
GLP-1
2008. Moretto Thomas J., Milton Denái R., Ridge Terry D., MacConell Leigh A., Okerson Ted, Wolka Anne M. and Brodows Robert G. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug--naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study.Clinical Therapeutics. 30. 1448-1460.
http://www.sciencedirect.com/science/article/pii/S0149291808002725
GLP-1
2009. Nauck Michael, Frid Anders, Hermansen Kjeld, Shah Nalini S., Tankova Tsvetalina, Mitha Ismail H., Zdravkovic Milan, During Maria and Matthews David R. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes.Diabetes Care. 32. 84-90.
http://care.diabetesjournals.org/content/32/1/84.abstract
GLP-1
2009. Astrup Arne, Rössner Stephan, Van Gaal Luc, Rissanen Aila, Niskanen Leo, Al Hakim Mazin, Madsen Jesper, Rasmussen Mads F. and Lean Michael E. J. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.The Lancet. 374. 1606-1616.
http://www.sciencedirect.com/science/article/pii/S0140673609613751
GLP-1
2009. Montanya Eduard and Sesti Giorgio. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.Clinical Therapeutics. 31. 2472-2488.
http://www.sciencedirect.com/science/article/pii/S0149291809004342
GLP-1
2010. Arnolds Sabine, Dellweg Sibylle, Clair Janina, Dain Marie-Paule, Nauck Michael A., Rave Klaus and Kapitza Christoph. Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin.Diabetes Care. 33. 1509-1515.
http://care.diabetesjournals.org/content/33/7/1509.abstract
GLP-1
2010. Vilsbøll T., Rosenstock J., Yki-Järvinen H., Cefalu W. T., Chen Y., Luo E., Musser B., Andryuk P. J., Ling Y., Kaufman K. D., Amatruda J. M., Engel S. S. and Katz L. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.Diabetes, Obesity and Metabolism. 12. 167-177.
http://dx.doi.org/10.1111/j.1463-1326.2009.01173.x
GLP-1
2010. Arnolds Sabine, Dellweg Sibylle, Clair Janina, Dain Marie-Paule, Nauck Michael A, Rave Klaus and Kapitza Christoph. Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET) – a proof-of-concept study.Diabetes Care.
http://care.diabetesjournals.org/content/early/2010/03/24/dc09-2191.abstract
GLP-1
2010. Pratley Richard E., Nauck Michael, Bailey Timothy, Montanya Eduard, Cuddihy Robert, Filetti Sebastiano, Thomsen Anne Bloch, Søndergaard Rie Elvang and Davies Melanie. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.The Lancet. 375. 1447-1456.
http://www.sciencedirect.com/science/article/pii/S0140673610603078
GLP-1
2011. Gallwitz Baptist, Bohmer Michael, Segiet Thomas, Molle Andrea, Milek Karsten, Becker Bernd, Helsberg Karin, Petto Helmut, Peters Natalie and Bachmann Oliver. Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes.Diabetes Care. 34. 604-606.
http://care.diabetesjournals.org/content/34/3/604.abstract
GLP-1
2011. Wilding John P H and Hardy Kevin. Glucagon-like peptide-1 analogues for type 2 diabetes.British Medical Journal. 342.
http://www.bmj.com/content/342/bmj.d410.short
GLP-1
2011. Schmidt W. E., Christiansen J. S., Hammer M., Zychma M. J. and Buse J. B. Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.Diabetic Medicine. 28. 715-723.
http://dx.doi.org/10.1111/j.1464-5491.2011.03276.x
GLP-1
2011. Best Jennie H., Hoogwerf Byron J., Herman William H., Pelletier Elise M., Smith Daniel B., Wenten Made and Hussein Mohamed A. Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies.Diabetes Care. 34. 90-95.
http://care.diabetesjournals.org/content/34/1/90.abstract
GLP-1
2011. Thong K. Y., Jose B., Sukumar N., Cull M. L., Mills A. P., Sathyapalan T., Shafiq W., Rigby A. S., Walton C., Ryder R. E. J. and on behalf of the Abcd nationwide exenatide audit contributors. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.Diabetes, Obesity and Metabolism. 13. 703-710.
http://dx.doi.org/10.1111/j.1463-1326.2011.01393.x
GLP-1
2011. Kielgast Urd, Holst Jens J. and Madsbad Sten. Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function.Diabetes. 60. 1599-1607.
http://diabetes.diabetesjournals.org/content/60/5/1599.abstract
GLP-1
2011. Best Jennie H., Rubin Richard R., Peyrot Mark, Li Yan, Yan Ping, Malloy Jaret and Garrison Louis P. Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment.Diabetes Care. 34. 314-319.
http://care.diabetesjournals.org/content/34/2/314.abstract
GLP-1
2011. Davies M., Pratley R., Hammer M., Thomsen A. B. and Cuddihy R. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.Diabetic Medicine. 28. 333-337.
http://dx.doi.org/10.1111/j.1464-5491.2010.03074.x
GLP-1
2011. Marre Michel and Penfornis Alfred. GLP-1 receptor agonists today.Diabetes research and clinical practice. 93. 317-327.
http://linkinghub.elsevier.com/retrieve/pii/S0168822711000052?showall=true
GLP-1
2012. Fineman M. S., Mace K. F., Diamant M., Darsow T., Cirincione B. B., Booker Porter T. K., Kinninger L. A. and Trautmann M. E. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.Diabetes, Obesity and Metabolism. 14. 546-554.
http://dx.doi.org/10.1111/j.1463-1326.2012.01561.x
GLP-1
2012. Jelsing J., Vrang N., Hansen G., Raun K., Tang-Christensen M. and Bjerre Knudsen L. Liraglutide: short-lived effect on gastric emptying—long lasting effects on body weight.Diabetes, Obesity and Metabolism. 14. 531-538.
http://dx.doi.org/10.1111/j.1463-1326.2012.01557.x
GLP-1
2012. Barnett A. H. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.Diabetes, Obesity and Metabolism. 14. 304-314.
http://dx.doi.org/10.1111/j.1463-1326.2011.01523.x
GLP-1
2012. Rhee N. A., Vilsbøll T. and Knop F. K. Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes.Diabetes, Obesity and Metabolism. 14. 291-298.
http://dx.doi.org/10.1111/j.1463-1326.2011.01505.x
GLP-1
2012. Davies M. J., Chubb B. D., Smith I. C. and Valentine W. J. Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.Diabetic Medicine. 29. 313-320.
http://dx.doi.org/10.1111/j.1464-5491.2011.03429.x
GLP-1
2012. Salehi Marzieh, Aulinger Benedict and D’Alessio David A. Effect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test.Diabetes. 61. 2728-2733.
http://diabetes.diabetesjournals.org/content/61/11/2728.abstract
GLP-1
2012. Cariou B. Harnessing the incretin system beyond glucose control: Potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.Diabetes & Metabolism. 38. 298-308.
http://www.sciencedirect.com/science/article/pii/S126236361200078X
GLP-1
2012. Grunberger G., Chang A., Garcia Soria G., Botros F. T., Bsharat R. and Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.Diabetic Medicine. 29. 1260-1267.
http://dx.doi.org/10.1111/j.1464-5491.2012.03745.x
GLP-1
2012. Rosenstock Julio, Shenouda Sylvia K., Bergenstal Richard M., Buse John B., Glass Leonard C., Heilmann Cory R., Kwan Anita Y.M., MacConell Leigh A. and Hoogwerf Byron James. Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes.Diabetes Care. 35. 955-958.
http://care.diabetesjournals.org/content/35/5/955.abstract
GLP-1
2012. Pratley Richard E., Nauck Michael A., Bailey Timothy, Montanya Eduard, Filetti Sebastiano, Garber Alan J., Thomsen Anne B., Furber Sabina, Davies Melanie and Group for the -LIRA-DPP-4 Study. Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes.Diabetes Care. 35. 1986-1993.
http://care.diabetesjournals.org/content/35/10/1986.abstract
GLP-1
2012. Woerle Hans Juergen, Carneiro Lucianno, Derani Ayman, Göke Burkhard and Schirra Jörg. The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes.Diabetes. 61. 2349-2358.
http://diabetes.diabetesjournals.org/content/61/9/2349.abstract
GLP-1
2012. Diamant Michaela, Van Gaal Luc, Stranks Stephen, Guerci Bruno, MacConell Leigh, Haber Harry, Scism-Bacon Jamie and Trautmann Michael. Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks.Diabetes Care. 35. 683-689.
http://care.diabetesjournals.org/content/35/4/683.abstract
GLP-1
2012. Deacon C. F., Mannucci E. and Ahrén B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis.Diabetes, Obesity and Metabolism. 14. 762-767.
http://dx.doi.org/10.1111/j.1463-1326.2012.01603.x
GLP-1
2012. Pendergrass M., Fenton C., Haffner S. M. and Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.Diabetes, Obesity and Metabolism. 14. 596-600.
http://dx.doi.org/10.1111/j.1463-1326.2012.01567.x
GLP-1
2012. Nathanson D., Ullman B., Löfström U., Hedman A., Frick M., Sjöholm Å and Nyström T. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.Diabetologia. 55. 926-935.
http://dx.doi.org/10.1007/s00125-011-2440-x
GLP-1
2013. Ryder REJ, Thong KY, Blann AD, Phillips SM, Barwell ND, Kelly CJG, Semple C, Cull ML, Gupta P Sen and contributors for the ABCD nationwide liraglutide audit. Liraglutide pancreatitis: The ABCD nationwide liraglutide audit.The British Journal of Diabetes & Vascular Disease. 13. 253-259.
http://dvd.sagepub.com/cgi/content/abstract/13/5-6/253
GLP-1
2013. Rosenstock Julio, Balas Bogdan, Charbonnel Bernard, Bolli Geremia B., Boldrin Mark, Ratner Robert, Balena Raffaella and Group for the T-emerge 2 Study. The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial.Diabetes Care. 36. 498-504.
http://care.diabetesjournals.org/content/36/3/498.abstract
GLP-1
2013. Ahrén B. Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives.Diabetes & Metabolism. 39. 195-201.
http://www.sciencedirect.com/science/article/pii/S1262363613000438
GLP-1
2013. Bergenstal R. M., Li Y., Porter T. K. Booker, Weaver C. and Han J. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.Diabetes, Obesity and Metabolism. 15. 264-271.
http://dx.doi.org/10.1111/dom.12026
GLP-1
2013. Hollander Priscilla, Lasko Ben, Barnett Anthony H., Bengus Monica, Kanitra Linda, Pi-Sunyer F. Xavier and Balena Raffaella. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).Obesity. 21. 238-247.
http://dx.doi.org/10.1002/oby.20042
GLP-1
2013. Nauck Michael A. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks.Diabetes Care. 36. 2126-2132.
http://care.diabetesjournals.org/content/36/7/2126.abstract
GLP-1
2013. Riddle Matthew C., Forst Thomas, Aronson Ronnie, Sauque-Reyna Leobardo, Souhami Elisabeth, Silvestre Louise, Ping Lin and Rosenstock Julio. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).Diabetes Care. 36. 2497-2503.
http://care.diabetesjournals.org/content/36/9/2497.abstract
GLP-1
2013. Henry Robert R., Rosenstock Julio, Logan Douglas K., Alessi Thomas R., Luskey Kenneth and Baron Michelle A. Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes.Diabetes Care. 36. 2559-2565.
http://care.diabetesjournals.org/content/36/9/2559.abstract
GLP-1
2013. Ahrén Bo, Leguizamo Dimas Aniceto, Miossec Patrick, Saubadu Stéphane and Aronson Ronnie. Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M).Diabetes Care. 36. 2543-2550.
http://care.diabetesjournals.org/content/36/9/2543.abstract
GLP-1
2013. Hall G. C., McMahon A. D., Dain M. P., Wang E. and Home P. D. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK.Diabetic Medicine. 30. 681-686.
http://dx.doi.org/10.1111/dme.12137
GLP-1
2013. Rosenstock Julio, Raccah Denis, Korányi László, Maffei Laura, Boka Gabor, Miossec Patrick and Gerich John E. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X).Diabetes Care. 36. 2945-2951.
http://care.diabetesjournals.org/content/36/10/2945.abstract
GLP-1
2013. Kim Sun H., Abbasi Fahim, Lamendola Cindy, Liu Alice, Ariel Danit, Schaaf Patricia, Grove Kaylene, Tomasso Vanessa, Ochoa Hector, Liu Yeheng V., Chen Yii-Der Ida and Reaven Gerald. Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes.Diabetes Care. 36. 3276-3282.
http://care.diabetesjournals.org/content/36/10/3276.abstract
GLP-1
2013. Niswender K., Pi-Sunyer X., Buse J., Jensen K. H., Toft A. D., Russell-Jones D. and Zinman B. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.Diabetes, Obesity and Metabolism. 15. 42-54.
http://dx.doi.org/10.1111/j.1463-1326.2012.01673.x
GLP-1
2013. Davies Melanie, Heller Simon, Sreenan Seamus, Sapin Hélène, Adetunji Omolara, Tahbaz Arash and Vora Jiten. Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.Diabetes Care. 36. 1368-1376.
http://care.diabetesjournals.org/content/36/5/1368.abstract
GLP-1
2013. Nauck M., Horton E., Andjelkovic M., Ampudia-Blasco F. J., Parusel C. T., Boldrin M., Balena R. and for the T. emerge Study Group. Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial.Diabetic Medicine. 30. 109-113.
http://dx.doi.org/10.1111/dme.12003
GLP-1
2013. Nauck M., Frid A., Hermansen K., Thomsen A. B., During M., Shah N., Tankova T., Mitha I. and Matthews D. R. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.Diabetes, Obesity and Metabolism. 15. 204-212.
http://dx.doi.org/10.1111/dom.12012
GLP-1
2013. Scott D. A., Boye K. S., Timlin L., Clark J. F. and Best J. H. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.Diabetes, Obesity and Metabolism. 15. 213-223.
http://dx.doi.org/10.1111/dom.12007
GLP-1
2013. Riddle Matthew C., Aronson Ronnie, Home Philip, Marre Michel, Niemoeller Elisabeth, Miossec Patrick, Ping Lin, Ye Jenny and Rosenstock Julio. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L).Diabetes Care. 36. 2489-2496.
http://care.diabetesjournals.org/content/36/9/2489.abstract
GLP-1
2014. Gastaldelli A., Balas B., Ratner R., Rosenstock J., Charbonnel B., Bolli G. B., Boldrin M. and Balena R. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.Diabetes, Obesity and Metabolism. 16. 170-178.
http://dx.doi.org/10.1111/dom.12192
GLP-1
2014. Diamant Michaela, Nauck Michael A., Shaginian Rimma, Malone James K., Cleall Simon, Reaney Matthew, de Vries Danielle, Hoogwerf Byron J., MacConell Leigh and Wolffenbuttel Bruce H.R. Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes.Diabetes Care. 37. 2763-2773.
http://care.diabetesjournals.org/content/37/10/2763.abstract
GLP-1
2014. Shao Ning, Kuang Hong Yu, Hao Ming, Gao Xin Yuan, Lin Wen Jian and Zou Wei. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.Diabetes/Metabolism Research and Reviews. 30. 521-529.
http://dx.doi.org/10.1002/dmrr.2561
Glucose Tolerance
2011. Lorenzo Carlos, Wagenknecht Lynne E., Karter Andrew J., Hanley Anthony J.G., Rewers Marian J. and Haffner Steven M. Cross-Sectional and Longitudinal Changes of Glucose Effectiveness in Relation to Glucose Tolerance.Diabetes Care. 34. 1959-1964.
http://care.diabetesjournals.org/content/34/9/1959.abstract
Glycaemic variability
2014. Suh S., Joung J. Y., Jin S. M., Kim M. Y., Bae J. C., Park H. D., Lee M. S., Lee M. K. and Kim J. H. Strong correlation between glycaemic variability and total glucose exposure in type 2 diabetes is limited to subjects with satisfactory glycaemic control.Diabetes & Metabolism. 40. 272-277.
http://www.sciencedirect.com/science/article/pii/S1262363614000330
GUSTO
1997. Mak Mbbs Koon-Hou, Moliterno M. D. Facc David J., Granger M. D. Facc Christopher B., Miller M. S. Dave P., White M. B. DSc Facc Harvey D., Wilcox M. D. Facc Robert G., Califf M. D. Facc Robert M. and Topol M. D. Facc Eric J. Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction.Journal of the American College of Cardiology. 30. 171-179.
http://www.sciencedirect.com/science/article/pii/S0735109797001186
GUSTO-IIb
2000. McGuire D.K, Emanuelsson H, Granger C.B, Magnus Ohman E, Moliterno D.J, White H.D, Ardissino D, Box J.W, Califf R.M and Topol E.J. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study.European Heart Journal. 21. 1750-1758.
http://eurheartj.oxfordjournals.org/content/21/21/1750.abstract
GUSTO-IIb angioplasty
2000. Hasdai David, Granger Christopher B., Srivatsa S. Sanjay, Criger Douglas A., Ellis Stephen G., Califf Robert M., Topol Eric J. and Holmes Jr David R. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb angioplasty substudy.Journal of the American College of Cardiology. 35. 1502-1512.
http://www.sciencedirect.com/science/article/pii/S073510970000591X
GUSTO 1
1996. Woodfield Scott L., Lundergan Conor F., Reiner Jonathan S., Greenhouse Samuel W., Thompson Mark A., Rohrbeck Steven C., Deychak Yuri, Simoons Maarten L., Califf Robert M., Topol Eric J. and Ross Allan M. Angiographic Findings and Outcome in Diabetic Patients Treated With Thrombolytic Therapy for Acute Myocardial Infarction: The GUSTO-I Experience.Journal of the American College of Cardiology. 28. 1661-1669.
http://www.sciencedirect.com/science/article/pii/S073510979600397X
GUSTO IV
2006. James Stefan K., Lindahl Bertil, Timmer Jorik R., Ottervanger Jan Paul, Siegbahn Agneta, Stridsberg Mats, Armstrong Paul, Califf Robert, Wallentin Lars and Simoons Maarten L. Usefulness of Biomarkers for Predicting Long-Term Mortality in Patients With Diabetes Mellitus and Non-ST-Elevation Acute Coronary Syndromes (A GUSTO IV Substudy).The American Journal of Cardiology. 97. 167-172.
http://www.sciencedirect.com/science/article/pii/S0002914905017959
Back to Top
Haemodialysis
2006. Oomichi Takeshi, Emoto Masanori, Tabata Tsutomu, Morioka Tomoaki, Tsujimoto Yoshihiro, Tahara Hideki, Shoji Tetsuo and Nishizawa Yoshiki. Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis.Diabetes Care. 29. 1496-1500.
http://care.diabetesjournals.org/content/29/7/1496.abstract
HAPO Study
2012. Lowe Lynn P., Metzger Boyd E., Dyer Alan R., Lowe Julia, McCance David R., Lappin Terence R.J., Trimble Elisabeth R., Coustan Donald R., Hadden David R., Hod Moshe, Oats Jeremy J.N., Persson Bengt and Group for the HAPO Study Cooperative Research. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study.Diabetes Care. 35. 574-580.
http://care.diabetesjournals.org/content/35/3/574.abstract
Harmony 2
2014. Ahrén Bo, Johnson Susan L., Stewart Murray, Cirkel Deborah T., Yang Fred, Perry Caroline and Feinglos Mark N. HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin.Diabetes Care. 37. 2141-2148.
http://care.diabetesjournals.org/content/37/8/2141.abstract
HbA1c
2011. Group Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study. Hemoglobin A1c and Mean Glucose in Patients With Type 1 Diabetes.Diabetes Care. 34. 540-544.
http://care.diabetesjournals.org/content/34/3/540.abstract
HbA1c
2011. Cheng Peiyao, Neugaard Britta, Foulis Philip and Conlin Paul R. Hemoglobin A1c as a Predictor of Incident Diabetes.Diabetes Care. 34. 610-615.
http://care.diabetesjournals.org/content/34/3/610.abstract
HbA1c
2011. Giugliano Dario, Maiorino Maria Ida, Bellastella Giuseppe, Chiodini Paolo, Ceriello Antonio and Esposito Katherine. Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes.Diabetes Care. 34. 510-517.
http://care.diabetesjournals.org/content/34/2/510.abstract
HbA1c
2011. Wang Wenyu, Lee Elisa T., Howard Barbara V., Fabsitz Richard R., Devereux Richard B. and Welty Thomas K. Fasting Plasma Glucose and Hemoglobin A1c in Identifying and Predicting Diabetes.Diabetes Care. 34. 363-368.
http://care.diabetesjournals.org/content/34/2/363.abstract
HbA1c
2011. Chubb S. A. Paul, Van Minnen Kylie, Davis Wendy A., Bruce David G. and Davis Timothy M. E. The relationship between self-monitoring of blood glucose results and glycated haemoglobin in type 2 diabetes: The Fremantle Diabetes Study.Diabetes research and clinical practice. 94. 371-376.
http://www.sciencedirect.com/science/article/pii/S0168822711004141
HbA1c
2011. Selvin Elizabeth, Steffes Michael W., Gregg Edward, Brancati Frederick L. and Coresh Josef. Performance of A1C for the Classification and Prediction of Diabetes.Diabetes Care. 34. 84-89.
http://care.diabetesjournals.org/content/34/1/84.abstract
HbA1c
2011. Colayco Danielle C., Niu Fang, McCombs Jeffrey S. and Cheetham T. Craig. A1C and Cardiovascular Outcomes in Type 2 Diabetes.Diabetes Care. 34. 77-83.
http://care.diabetesjournals.org/content/34/1/77.abstract
HbA1c
2011. Selvin Elizabeth, Ning Yang, Steffes Michael W., Bash Lori D., Klein Ronald, Wong Tien Y., Astor Brad C., Sharrett A. Richey, Brancati Frederick L. and Coresh Josef. Glycated Hemoglobin and the Risk of Kidney Disease and Retinopathy in Adults With and Without Diabetes.Diabetes. 60. 298-305.
http://diabetes.diabetesjournals.org/content/60/1/298.abstract
HbA1c
2011. Kowall B., Rathmann W. and Landgraf R. Is HbA1c a valid and feasible tool for the diagnosis of diabetes?Diabetes research and clinical practice. 93. 314-316.
http://linkinghub.elsevier.com/retrieve/pii/S0168822711003469?showall=true
HbA1c
2011. Colagiuri Stephen. Glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus—Practical implications.Diabetes research and clinical practice. 93. 312-313.
http://linkinghub.elsevier.com/retrieve/pii/S0168822711003470?showall=true
HbA1c
2011. WHO. Presidents’ statement on WHO recommendation on HbA1c for diabetes diagnosis.Diabetes research and clinical practice. 93. 310-311.
http://linkinghub.elsevier.com/retrieve/pii/S0168822711003482?showall=true
HbA1c
2011. Wang Hong, Shara Nawar M., Lee Elisa T., Devereux Richard, Calhoun Darren, de Simone Giovanni, Umans Jason G. and Howard Barbara V. Hemoglobin A1c, Fasting Glucose, and Cardiovascular Risk in a Population With High Prevalence of Diabetes.Diabetes Care. 34. 1952-1958.
http://care.diabetesjournals.org/content/34/9/1952.abstract
HbA1c
2011. WHO. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus.Diabetes research and clinical practice. 93. 299-309.
http://linkinghub.elsevier.com/retrieve/pii/S0168822711001318?showall=true
HbA1c
2011. Bae Ji Cheol, Rhee Eun Jung, Lee Won Young, Park Se Eun, Park Cheol Young, Oh Ki Won, Park Sung Woo and Kim Sun Woo. Optimal range of HbA1c for the prediction of future diabetes: A 4-year longitudinal study.Diabetes research and clinical practice. 93. 255-259.
http://www.sciencedirect.com/science/article/pii/S0168822711002841
HbA1c
2011. Cavagnolli G., Comerlato J., Comerlato C., Renz P. B., Gross J. L. and Camargo J. L. HbA1c measurement for the diagnosis of diabetes: is it enough?Diabetic Medicine. 28. 31-35.
http://dx.doi.org/10.1111/j.1464-5491.2010.03159.x
HbA1c
2011. Bonora Enzo, Kiechl Stefan, Mayr Agnes, Zoppini Giacomo, Targher Giovanni, Bonadonna Riccardo C. and Willeit Johann. High-Normal HbA1c Is a Strong Predictor of Type 2 Diabetes in the General Population.Diabetes Care. 34. 1038-1040.
http://care.diabetesjournals.org/content/34/4/1038.abstract
HbA1c
2011. Marcovecchio M. Loredana, Dalton R. Neil, Chiarelli Francesco and Dunger David B. A1C Variability as an Independent Risk Factor for Microalbuminuria in Young People With Type 1 Diabetes.Diabetes Care. 34. 1011-1013.
http://care.diabetesjournals.org/content/34/4/1011.abstract
HbA1c
2012. Ramirez Sylvia Paz B., McCullough Keith P., Thumma Jyothi R., Nelson Robert G., Morgenstern Hal, Gillespie Brenda W., Inaba Masaaki, Jacobson Stefan H., Vanholder Raymond, Pisoni Ronald L., Port Fritz K. and Robinson Bruce M. Hemoglobin A1c Levels and Mortality in the Diabetic Hemodialysis Population: Findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS).Diabetes Care. 35. 2527-2532.
http://care.diabetesjournals.org/content/35/12/2527.abstract
HbA1c
2012. Ramachandran Ambady, Riddle Matthew C., Kabali Conrad, Gerstein Hertzel C. and Investigators on behalf of the ORIGIN. Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes.Diabetes Care. 35. 749-753.
http://care.diabetesjournals.org/content/35/4/749.abstract
HbA1c
2012. Tsugawa Yusuke, Takahashi Osamu, Meigs James B., Davis Roger B., Imamura Fumiaki, Fukui Tsuguya, Taylor William C. and Wee Christina C. New Diabetes Diagnostic Threshold of Hemoglobin A1c and the 3-Year Incidence of Retinopathy.Diabetes. 61. 3280-3284.
http://diabetes.diabetesjournals.org/content/61/12/3280.abstract
HbA1c
2012. Kato M., Noda M., Suga H., Nakamura T., Matsumoto M., Kanazawa Y. and for the Omiya M. A. Cohort Study Group. Haemoglobin A1c cut-off point to identify a high risk group of future diabetes: results from the Omiya MA Cohort Study.Diabetic Medicine. 29. 905-910.
http://dx.doi.org/10.1111/j.1464-5491.2012.03572.x
HbA1c
2012. Rajput Rajesh, YogeshYadav, Rajput Meena and Nanda Smiti. Utility of HbA1c for diagnosis of gestational diabetes mellitus.Diabetes research and clinical practice. 98. 104-107.
http://linkinghub.elsevier.com/retrieve/pii/S0168822712000861?showall=true
HbA1c
2012. Hsu C., Chang H., Huang M., Hwang S., Yang Y., Lee Y., Shin S. and Tai T. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study.Diabetologia. 55. 3163-3172.
http://dx.doi.org/10.1007/s00125-012-2700-4
HbA1c
2012. Kuntz Susan, Johnson Eric L., Blehm Julie and Hosford Charles C. Use of A1C for Screening and Diagnosis of Type 2 Diabetes in Three Rural Health Care Systems.Clinical Diabetes. 30. 61-66.
http://clinical.diabetesjournals.org/content/30/2/61.short
HbA1c
2012. Bhansali A., Walia R., Ravi Kumar P., Ravi Kiran M. and Shanmugasundar G. Accuracy of glycated haemoglobin in screening for pre-diabetes in Asian Indians—a community survey: the Chandigarh Urban Diabetes Study (CUDS).Diabetic Medicine. 29. 1385-1389.
http://dx.doi.org/10.1111/j.1464-5491.2012.03634.x
HbA1c
2012. Bianchi Cristina, Miccoli Roberto, Bonadonna Riccardo C., Giorgino Francesco, Frontoni Simona, Faloia Emanuela, Marchesini Giulio, Dolci Maria A., Cavalot Franco, Cavallo Gisella M., Leonetti Frida, Del Prato Stefano and Investigators on behalf of the GENFIEV. Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance.Diabetes Care. 35. 2607-2612.
http://care.diabetesjournals.org/content/35/12/2607.abstract
HbA1c
2012. Rodríguez-Segade Santiago, Rodríguez Javier, García Lopez José M., Casanueva Felipe F. and Camiña Félix. Estimation of the Glycation Gap in Diabetic Patients With Stable Glycemic Control.Diabetes Care. 35. 2447-2450.
http://care.diabetesjournals.org/content/35/12/2447.abstract
HbA1c
2012. Vehik Kendra, Cuthbertson David, Boulware David, Beam Craig A., Rodriguez Henry, Legault Laurent, Hyytinen Mila, Rewers Marian J., Schatz Desmond A., Krischer Jeffrey P., the TEDDY TRIGR, Diabetes Prevention Trial–Type 1, and Groups Type 1 Diabetes TrialNet Natural History Study. Performance of HbA1c as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth.Diabetes Care. 35. 1821-1825.
http://care.diabetesjournals.org/content/35/9/1821.abstract
HbA1c
2012. Oke J. L., Stevens R. J., Gaitskell K. and Farmer A. J. Establishing an evidence base for frequency of monitoring glycated haemoglobin levels in patients with Type 2 diabetes: projections of effectiveness from a regression model.Diabetic Medicine. 29. 266-271.
http://dx.doi.org/10.1111/j.1464-5491.2011.03412.x
HbA1c
2012. Heianza Yoriko, Arase Yasuji, Fujihara Kazuya, Hsieh Shiun Dong, Saito Kazumi, Tsuji Hiroshi, Kodama Satoru, Yahagi Naoya, Shimano Hitoshi, Yamada Nobuhiro, Hara Shigeko and Sone Hirohito. Longitudinal Trajectories of HbA1c and Fasting Plasma Glucose Levels During the Development of Type 2 Diabetes.Diabetes Care. 35. 1050-1052.
http://care.diabetesjournals.org/content/35/5/1050.abstract
HbA1c
2012. Nichols Gregory A., Kimes Teresa M., Harp Joyce B., Kou Tzuyung Doug and Brodovicz Kimberly G. Glycemic Response and Attainment of A1C Goals Following Newly Initiated Insulin Therapy for Type 2 Diabetes.Diabetes Care. 35. 495-497.
http://care.diabetesjournals.org/content/35/3/495.abstract
HbA1c
2012. Aggarwal Vikas, Schneider Andrea L.C. and Selvin Elizabeth. Low Hemoglobin A1c in Nondiabetic Adults.Diabetes Care. 35. 2055-2060.
http://care.diabetesjournals.org/content/35/10/2055.abstract
HbA1c
2012. Esposito K., Chiodini P., Bellastella G., Maiorino M. I. and Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.Diabetes, Obesity and Metabolism. 14. 228-233.
http://dx.doi.org/10.1111/j.1463-1326.2011.01512.x
HbA1c
2013. Östgren C. J., Sundström J., Svennblad B., Lohm L., Nilsson P. M. and Johansson G. Associations of HbA1c and educational level with risk of cardiovascular events in 32 871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.Diabetic Medicine. 30. e170-e177.
http://dx.doi.org/10.1111/dme.12145
HbA1c
2013. Stark Casagrande Sarah, Fradkin Judith E., Saydah Sharon H., Rust Keith F. and Cowie Catherine C. The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010.Diabetes Care. 36. 2271-2279.
http://care.diabetesjournals.org/content/36/8/2271.abstract
HbA1c
2013. Shi Lizheng, Ye Xin, Lu Mei, Wu Eric Q., Sharma Hari, Thomason Darren and Fonseca Vivian A. Clinical and Economic Benefits Associated With the Achievement of Both HbA1c and LDL Cholesterol Goals in Veterans With Type 2 Diabetes.Diabetes Care. 36. 3297-3304.
http://care.diabetesjournals.org/content/36/10/3297.abstract
HbA1c
2013. Penno Giuseppe, Solini Anna, Bonora Enzo, Fondelli Cecilia, Orsi Emanuela, Zerbini Gianpaolo, Morano Susanna, Cavalot Franco, Lamacchia Olga, Laviola Luigi, Nicolucci Antonio, Pugliese Giuseppe, Insufficiency for the Renal and Group Cardiovascular Events Study. HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.Diabetes Care. 36. 2301-2310.
http://care.diabetesjournals.org/content/36/8/2301.abstract
HbA1c
2013. Cosson E., Chiheb S., Cussac-Pillegand C., Banu I., Hamo-Tchatchouang E., Nguyen M. T., Aout M., Charnaux N. and Valensi P. Haemoglobin glycation may partly explain the discordance between HbA1c measurement and oral glucose tolerance test to diagnose dysglycaemia in overweight/obese subjects.Diabetes & Metabolism. 39. 118-125.
http://www.sciencedirect.com/science/article/pii/S1262363612001632
HbA1c
2013. Su Gong, Mi Shu-hua, Tao Hong, Li Zhao, Yang Hong-Xia, Zheng Hong, Zhou Yun and Tian Lei. Impact of Admission Glycemic Variability, Glucose, and Glycosylated Hemoglobin on Major Adverse Cardiac Events After Acute Myocardial Infarction.Diabetes Care. 36. 1026-1032.
http://care.diabetesjournals.org/content/36/4/1026.abstract
HbA1c
2014. Simmons D. and Hlaing T. Interpretation of HbA1c : association with mean cell volume and haemoglobin concentration.Diabetic Medicine. 31. 1387-1392.
http://dx.doi.org/10.1111/dme.12518
HbA1c
2014. Driskell Owen J., Holland David, Waldron Jenna L., Ford Clare, Scargill Jonathan J., Heald Adrian, Tran Martin, Hanna Fahmy W., Jones Peter W., Pemberton R. John and Fryer Anthony A. Reduced Testing Frequency for Glycated Hemoglobin, HbA1c, Is Associated With Deteriorating Diabetes Control.Diabetes Care. 37. 2731-2737.
http://care.diabetesjournals.org/content/37/10/2731.abstract
HbA1c
2014. Umpierrez Guillermo E., Reyes David, Smiley Dawn, Hermayer Kathie, Khan Amna, Olson Darin E., Pasquel Francisco, Jacobs Sol, Newton Christopher, Peng Limin and Fonseca Vivian. Hospital Discharge Algorithm Based on Admission HbA1c for the Management of Patients With Type 2 Diabetes.Diabetes Care. 37. 2934-2939.
http://care.diabetesjournals.org/content/37/11/2934.abstract
HbA1c
2014. Chilelli NinoCristiano, Cosma Chiara, Ragazzi Eugenio, Burlina Silvia, Zaninotto Martina, Plebani Mario and Lapolla Annunziata. Screening with HbA1c identifies only one in two individuals with diagnosis of prediabetes at oral glucose tolerance test: findings in a real-world Caucasian population.Acta Diabetol. 51. 875-882.
http://dx.doi.org/10.1007/s00592-014-0639-2
HbA1c
2014. Zhao Wenhui, Katzmarzyk Peter T., Horswell Ronald, Wang Yujie, Johnson Jolene and Hu Gang. HbA1c and Coronary Heart Disease Risk Among Diabetic Patients.Diabetes Care. 37. 428-435.
http://care.diabetesjournals.org/content/37/2/428.abstract
HDS
1996. Stratton I., Manley S., Holman R. and Turner R. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control Hypertension in Diabetes Study Group*.Diabetologia. 39. 1554-1561.
http://dx.doi.org/10.1007/s001250050614
HDS 3
1994. Hypertension in Diabetes Study Group. Hypertension in Diabetes Study III. Prospective Study of Therapy of Hypertension in Type 2 Diabetic Patients: Efficacy of ACE Inhibition and β-Blockade.Diabetic Medicine. 11. 773-782.
http://dx.doi.org/10.1111/j.1464-5491.1994.tb00352.x
Health Economics
2012. Hex N., Bartlett C., Wright D., Taylor M. and Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs.Diabetic Medicine. 29. 855-862.
http://dx.doi.org/10.1111/j.1464-5491.2012.03698.x
HEART2D
2009. Raz Itamar, Wilson Peter W.F., Strojek Krzysztof, Kowalska Irina, Bozikov Velimir, Gitt Anselm K., Jermendy Gyorgy, Campaigne Barbara N., Kerr Lisa, Milicevic Zvonko and Jacober Scott J. Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial.Diabetes Care. 32. 381-386.
http://care.diabetesjournals.org/content/32/3/381.abstract
HERO Study
2014. Edelman S., Ng-Mak D. S., Fusco M., Ashton D., Okerson T., Liu Q., Jin J. and Dixon J. B. Control of type 2 diabetes after 1 year of laparoscopic adjustable gastric banding in the helping evaluate reduction in obesity (HERO) study.Diabetes, Obesity and Metabolism. 16. 1009-1015.
http://dx.doi.org/10.1111/dom.12313
HOPE
2000. Investigators The Heart Outcomes Prevention Evaluation Study. Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients.New England Journal of Medicine. 342. 145-153.
http://www.nejm.org/doi/full/10.1056/NEJM200001203420301
HOPE
2001. Svensson Per, de Faire Ulf, Sleight Peter, Yusuf Salim and Östergren Jan. Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures.Hypertension. 38. e28-e32.
http://hyper.ahajournals.org/content/38/6/e28.abstract
HOPE/MICRO-HOPE
2000. Investigators Heart Outcomes Prevention Evaluation (HOPE) Study. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.The Lancet. 355. 253-259.
http://www.sciencedirect.com/science/article/pii/S0140673699123237
HPS
2003. Group Heart Protection Study Collaborative. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.The Lancet. 361. 2005-2016.
http://linkinghub.elsevier.com/retrieve/pii/S0140673603136367
HPS
2011. Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20?536 high-risk individuals: a randomised controlled trial.The Lancet. 378. 2013-2020.
http://linkinghub.elsevier.com/retrieve/pii/S0140673611611252
HYPOCRAS Study
2012. Penfornis A., Bourdel-Marchasson I., Quere S. and Dejager S. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study.Diabetes & Metabolism. 38. 550-557.
http://www.sciencedirect.com/science/article/pii/S1262363612001218
Hypoglycaemia
2012. Farmer A. J., Brockbank K. J., Keech M. L., England E. J. and Deakin C. D. Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England.Diabetic Medicine. 29. 1447-1450.
http://dx.doi.org/10.1111/j.1464-5491.2012.03657.x
Hypoglycaemia
2012. Kristensen P. L., Hansen L. S., Jespersen M. J., Pedersen-Bjergaard U., Beck-Nielsen H., Christiansen J. S., Nørgaard K., Perrild H., Parving H. H., Thorsteinsson B. and Tarnow L. Insulin analogues and severe hypoglycaemia in type 1 diabetes.Diabetes research and clinical practice. 96. 17-23.
http://www.sciencedirect.com/science/article/pii/S0168822711006097
Hypoglycaemia
2012. Barendse S., Singh H., Frier B. M. and Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review.Diabetic Medicine. 29. 293-302.
http://dx.doi.org/10.1111/j.1464-5491.2011.03416.x
Hypoglycaemia
2012. Valentine W. J., Jendle J., Saraheimo M., Thorsteinsson B., Pollock R. F. and Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.Diabetic Medicine. 29. 303-312.
http://dx.doi.org/10.1111/j.1464-5491.2011.03461.x
Hypoglycaemia
2012. Rogers H. A., de Zoysa N. and Amiel S. A. Patient experience of hypoglycaemia unawareness in Type 1 diabetes: are patients appropriately concerned?Diabetic Medicine. 29. 321-327.
http://dx.doi.org/10.1111/j.1464-5491.2011.03444.x
Hypoglycaemia
2012. Aung P. P., Strachan M. W. J., Frier B. M., Butcher I., Deary I. J., Price J. F. and on behalf of the Edinburgh Type 2 Diabetes Study Investigators. Severe hypoglycaemia and late-life cognitive ability in older people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.Diabetic Medicine. 29. 328-336.
http://dx.doi.org/10.1111/j.1464-5491.2011.03505.x
Hypoglycaemia
2012. Punthakee Zubin, Miller Michael E., Launer Lenore J., Williamson Jeff D., Lazar Ronald M., Cukierman-Yaffee Tali, Seaquist Elizabeth R., Ismail-Beigi Faramarz, Sullivan Mark D., Lovato Laura C., Bergenstal Richard M., Gerstein Hertzel C., Investigators for the ACCORD Group of and Investigators the ACCORD-MIND. Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes.Diabetes Care. 35. 787-793.
http://care.diabetesjournals.org/content/35/4/787.abstract
Hypoglycaemia
2012. Holstein Andreas, Patzer Olaf M., Machalke Kathrin, Holstein Judith D., Stumvoll Michael and Kovacs Peter. Substantial Increase in Incidence of Severe Hypoglycemia Between 1997–2000 and 2007–2010.Diabetes Care. 35. 972-975.
http://care.diabetesjournals.org/content/35/5/972.abstract
Hypoglycaemia
2012. Pontiroli A. E., Miele L. and Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis.Diabetes, Obesity and Metabolism. 14. 433-446.
http://dx.doi.org/10.1111/j.1463-1326.2011.01543.x
Hypoglycaemia
2012. Ringholm L., Pedersen-Bjergaard U., Thorsteinsson B., Damm P. and Mathiesen E. R. Hypoglycaemia during pregnancy in women with Type 1 diabetes.Diabetic Medicine. 29. 558-566.
http://dx.doi.org/10.1111/j.1464-5491.2012.03604.x
Hypoglycaemia
2013. Tan H. K. and Flanagan D. The impact of hypoglycaemia on patients admitted to hospital with medical emergencies.Diabetic Medicine. 30. 574-580.
http://dx.doi.org/10.1111/dme.12123
Hypoglycaemia
2013. Garg Rajesh, Hurwitz Shelley, Turchin Alexander and Trivedi Apoorva. Hypoglycemia, With or Without Insulin Therapy, Is Associated With Increased Mortality Among Hospitalized Patients.Diabetes Care. 36. 1107-1110.
http://care.diabetesjournals.org/content/36/5/1107.abstract
Hypoglycaemia
2013. Brod M., Wolden M., Christensen T. and Bushnell D. M. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function.Diabetes, Obesity and Metabolism. 15. 546-557.
http://dx.doi.org/10.1111/dom.12070
Hypoglycaemia
2013. Hsu Pai-Feng, Sung Shih-Hsien, Cheng Hao-Min, Yeh Jong-Shiuan, Liu Wen-Ling, Chan Wan-Leong, Chen Chen-Huan, Chou Pesus and Chuang Shao-Yuan. Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes: A nationwide population-based study.Diabetes Care. 36. 894-900.
http://care.diabetesjournals.org/content/36/4/894.abstract
Hypoglycaemia
2014. Östenson C. G., Geelhoed-Duijvestijn P., Lahtela J., Weitgasser R., Markert Jensen M. and Pedersen-Bjergaard U. Self-reported non-severe hypoglycaemic events in Europe.Diabetic Medicine. 31. 92-101.
http://dx.doi.org/10.1111/dme.12261
Hypoglycaemia
2014. Little Stuart A., Leelarathna Lalantha, Walkinshaw Emma, Tan Horng Kai, Chapple Olivia, Lubina-Solomon Alexandra, Chadwick Thomas J., Barendse Shalleen, Stocken Deborah D., Brennand Catherine, Marshall Sally M., Wood Ruth, Speight Jane, Kerr David, Flanagan Daniel, Heller Simon R., Evans Mark L. and Shaw James A.M. Recovery of Hypoglycemia Awareness in Long-standing Type 1 Diabetes: A Multicenter 2 × 2 Factorial Randomized Controlled Trial Comparing Insulin Pump With Multiple Daily Injections and Continuous With Conventional Glucose Self-monitoring (HypoCOMPaSS).Diabetes Care. 37. 2114-2122.
http://care.diabetesjournals.org/content/37/8/2114.abstract
Hypoglycaemia
2014. Rajendran R. and Rayman G. Serious harm from inpatient hypoglycaemia: a survey of hospitals in the UK.Diabetic Medicine. 31. 1218-1221.
http://dx.doi.org/10.1111/dme.12457
Hypoglycaemia
2014. Stahn Annett, Pistrosch Frank, Ganz Xenia, Teige Madlen, Koehler Carsta, Bornstein Stefan and Hanefeld Markolf. Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias.Diabetes Care. 37. 516-520.
http://care.diabetesjournals.org/content/37/2/516.abstract
Back to Top
IADPSG
2012. Kalter-Leibovici Ofra, Freedman Laurence S., Olmer Liraz, Liebermann Nicky, Heymann Anthony, Tal Orna, Lerner-Geva Liat, Melamed Nir and Hod Moshe. Screening and Diagnosis of Gestational Diabetes Mellitus.Diabetes Care. 35. 1894-1896.
http://care.diabetesjournals.org/content/35/9/1894.abstract
IADPSG
2014. Liao S., Mei J., Song W., Liu Y., Tan Y. D., Chi S., Li P., Chen X. and Deng S. The impact of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) fasting glucose diagnostic criterion on the prevalence and outcomes of gestational diabetes mellitus in Han Chinese women.Diabetic Medicine. 31. 341-351.
http://dx.doi.org/10.1111/dme.12349
IDES
2012. Nicolucci A., Balducci S., Cardelli P., Cavallo S., Fallucca S., Bazuro A., Simonelli P., Iacobini C., Zanuso S., Pugliese G. and Investigators for the Italian Diabetes Exercise Study. Relationship of exercise volume to improvements of quality of life with supervised exercise training in patients with type 2 diabetes in a randomised controlled trial: the Italian Diabetes and Exercise Study (IDES).Diabetologia. 55. 579-588.
http://dx.doi.org/10.1007/s00125-011-2425-9
IDMPS
2012. Gagliardino J. J., Aschner P., Baik S. H., Chan J., Chantelot J. M., Ilkova H. and Ramachandran A. Patients’ education, and its impact on care outcomes, resource consumption and working conditions: Data from the International Diabetes Management Practices Study (IDMPS).Diabetes & Metabolism. 38. 128-134.
http://www.sciencedirect.com/science/article/pii/S1262363611001625
IGR
2014. McAuley Paul A., Artero Enrique G., Sui Xuemei, Lavie Carl J., Almeida M. Joao and Blair Steven N. Fitness, Fatness, and Survival in Adults With Prediabetes.Diabetes Care. 37. 529-536.
http://care.diabetesjournals.org/content/37/2/529.abstract
Inpatient
2011. Richard J. L., Lavigne J. P., Got I., Hartemann A., Malgrange D., Tsirtsikolou D., Baleydier A. and Senneville E. Management of patients hospitalized for diabetic foot infection: Results of the French OPIDIA study.Diabetes & Metabolism. 37. 208-215.
http://www.sciencedirect.com/science/article/pii/S1262363610002429
Inpatient
2013. Healy Sara J., Black Dawn, Harris Cara, Lorenz Andrew and Dungan Kathleen M. Inpatient Diabetes Education Is Associated With Less Frequent Hospital Readmission Among Patients With Poor Glycemic Control.Diabetes Care. 36. 2960-2967.
http://care.diabetesjournals.org/content/36/10/2960.abstract
Inpatient
2013. Yu D. and Simmons D. Relationship between HbA1c and risk of all-cause hospital admissions among people with Type 2 diabetes.Diabetic Medicine. 30. 1407-1411.
http://dx.doi.org/10.1111/dme.12235
Inpatient
2013. Holman N., Hillson R. and Young R. J. Excess mortality during hospital stays among patients with recorded diabetes compared with those without diabetes.Diabetic Medicine. 30. 1393-1402.
http://dx.doi.org/10.1111/dme.12282
Inpatient
2013. Mendez Carlos E., Mok Ki-Tae, Ata Ashar, Tanenberg Robert J., Calles-Escandon Jorge and Umpierrez Guillermo E. Increased Glycemic Variability Is Independently Associated With Length of Stay and Mortality in Noncritically Ill Hospitalized Patients.Diabetes Care. 36. 4091-4097.
http://care.diabetesjournals.org/content/36/12/4091.abstract
Insulin
1993. Reichard Per, Nilsson Bengt-Yngve and Rosenqvist Urban. The Effect of Long-Term Intensified Insulin Treatment on the Development of Microvascular Complications of Diabetes Mellitus.New England Journal of Medicine. 329. 304-309.
http://www.nejm.org/doi/full/10.1056/NEJM199307293290502
Insulin
1995. Ohkubo Yasuo, Kishikawa Hideki, Araki Eiichi, Miyata Takao, Isami Satoshi, Motoyoshi Sadatoshi, Kojima Yujiro, Furuyoshi Naohiko and Shichiri Motoaki. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.Diabetes research and clinical practice. 28. 103-117.
http://www.sciencedirect.com/science/article/pii/016882279501064K
Insulin
1999. Mäkimattila S., Nikkilä K. and Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus.Diabetologia. 42. 406-412.
http://dx.doi.org/10.1007/s001250051172
Insulin
2007. Holman Rury R., Thorne Kerensa I., Farmer Andrew J., Davies Melanie J., Keenan Joanne F., Paul Sanjoy and Levy Jonathan C. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes.New England Journal of Medicine. 357. 1716-1730.
http://www.nejm.org/doi/full/10.1056/NEJMoa075392
Insulin
2011. Fonseca V., Gill J., Zhou R. and Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.Diabetes, Obesity and Metabolism. 13. 814-822.
http://dx.doi.org/10.1111/j.1463-1326.2011.01412.x
Insulin
2011. Gram Jeppe, Henriksen Jan Erik, Grodum Ellen, Juhl Henning, Hansen Tony Bill, Christiansen Christian, Yderstræde Knud, Gjessing Hans, Hansen Henrik M., Vestergaard Vibe, Hangaard Jørgen and Beck-Nielsen Henning. Pharmacological Treatment of the Pathogenetic Defects in Type 2 Diabetes.Diabetes Care. 34. 27-33.
http://care.diabetesjournals.org/content/34/1/27.abstract
Insulin
2011. Zachariah Sunil, Sheldon Ben, Shojaee-Moradie Fariba, Jackson Nicola C., Backhouse Katharine, Johnsen Sigurd, Jones Richard H., Umpleby A. Margot and Russell-Jones David L. Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 Diabetes.Diabetes Care. 34. 1487-1491.
http://care.diabetesjournals.org/content/34/7/1487.abstract
Insulin
2011. Evans M., Schumm-Draeger P. M., Vora J. and King A. B. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations.Diabetes, Obesity and Metabolism. 13. 677-684.
http://dx.doi.org/10.1111/j.1463-1326.2011.01395.x
Insulin
2011. Hall G. C., McMahon A. D., Dain M. P. and Home P. D. A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes.Diabetes research and clinical practice. 94. 442-448.
http://www.sciencedirect.com/science/article/pii/S0168822711004918
Insulin
2011. Hansen B., Kurtzhals P., Jensen A., Dejgaard A. and Russell-Jones D. Insulin X10 revisited: a super-mitogenic insulin analogue.Diabetologia. 54. 2226-2231.
http://dx.doi.org/10.1007/s00125-011-2203-8
Insulin
2011. Ratner R., Wynne A., Nakhle S., Brusco O., Vlajnic A. and Rendell M. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096).Diabetes, Obesity and Metabolism. 13. 1142-1148.
http://dx.doi.org/10.1111/j.1463-1326.2011.01478.x
Insulin
2011. Suissa S., Azoulay L., Dell’Aniello S., Evans M., Vora J. and Pollak M. Long-term effects of insulin glargine on the risk of breast cancer.Diabetologia. 54. 2254-2262.
http://dx.doi.org/10.1007/s00125-011-2190-9
Insulin
2011. Koivisto V., Cleall S., Pontiroli A. E. and Giugliano D. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.Diabetes, Obesity and Metabolism. 13. 1149-1157.
http://dx.doi.org/10.1111/j.1463-1326.2011.01484.x
Insulin
2011. Watson L., Wilson B. P., Alsop J. and Kumar S. Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?Diabetes, Obesity and Metabolism. 13. 823-831.
http://dx.doi.org/10.1111/j.1463-1326.2011.01413.x
Insulin
2011. Morden Nancy E., Liu Stephen K., Smith Jeremy, Mackenzie Todd A., Skinner Jonathan and Korc Murray. Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer.Diabetes Care. 34. 1965-1971.
http://care.diabetesjournals.org/content/34/9/1965.abstract
Insulin
2011. Rhoads G. G., Dain M. P., Zhang Q. and Kennedy L. Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes.Diabetes, Obesity and Metabolism. 13. 711-717.
http://dx.doi.org/10.1111/j.1463-1326.2011.01394.x
Insulin
2012. Charbonnel B., Penfornis A., Varroud-Vial M., Kusnik-Joinville O. and Detournay B. Insulin therapy for diabetes mellitus: Treatment regimens and associated costs.Diabetes & Metabolism. 38. 156-163.
http://www.sciencedirect.com/science/article/pii/S1262363611002035
Insulin
2012. Riveline Jean-Pierre, Schaepelynck Pauline, Chaillous Lucy, Renard Eric, Sola-Gazagnes Agnès, Penfornis Alfred, Tubiana-Rufi Nadia, Sulmont Véronique, Catargi Bogdan, Lukas Céline, Radermecker Régis P., Thivolet Charles, Moreau François, Benhamou Pierre-Yves, Guerci Bruno, Leguerrier Anne-Marie, Millot Luc, Sachon Claude, Charpentier Guillaume, Hanaire Hélène and Group for the EVADIAC Sensor Study. Assessment of Patient-Led or Physician-Driven Continuous Glucose Monitoring in Patients With Poorly Controlled Type 1 Diabetes Using Basal-Bolus Insulin Regimens.Diabetes Care. 35. 965-971.
http://care.diabetesjournals.org/content/35/5/965.abstract
Insulin
2012. Heller Simon, Buse John, Fisher Miles, Garg Satish, Marre Michel, Merker Ludwig, Renard Eric, Russell-Jones David, Philotheou Areti, Francisco Ann Marie Ocampo, Pei Huiling and Bode Bruce. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.The Lancet. 379. 1489-1497.
http://linkinghub.elsevier.com/retrieve/pii/S0140673612602049
Insulin
2012. Schofield C. J. and Sutherland C. Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes.Diabetic Medicine. 29. 972-979.
http://dx.doi.org/10.1111/j.1464-5491.2012.03655.x
Insulin
2012. Mäkelä Jyrki K., Schmüser Christine, Askonen Kari and Saukkonen Tero. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: A multicenter, observational, primary care study conducted in Finland.Diabetes research and clinical practice. 95. 10-18.
http://www.sciencedirect.com/science/article/pii/S0168822711003044
Insulin
2012. Home P. D., Meneghini L., Wendisch U., Ratner R. E., Johansen T., Christensen T. E., Jendle J., Roberts A. P. and Birkeland K. I. Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes.Diabetic Medicine. 29. 716-720.
http://dx.doi.org/10.1111/j.1464-5491.2011.03547.x
Insulin
2012. Garber Alan J., King Allen B., Prato Stefano Del, Sreenan Seamus, Balci Mustafa K., Muñoz-Torres Manuel, Rosenstock Julio, Endahl Lars A., Francisco Ann Marie Ocampo and Hollander Priscilla. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.The Lancet. 379. 1498-1507.
http://linkinghub.elsevier.com/retrieve/pii/S0140673612602050
Insulin
2012. Schmidt Signe, Meldgaard Merete, Serifovski Nermin, Storm Camilla, Christensen Tomas Møller, Gade-Rasmussen Birthe and Nørgaard Kirsten. Use of an Automated Bolus Calculator in MDI-Treated Type 1 Diabetes.Diabetes Care. 35. 984-990.
http://care.diabetesjournals.org/content/35/5/984.abstract
Insulin
2012. de Mello Vanessa D.F., Lindström Jaana, Eriksson Johan, Ilanne-Parikka Pirjo, Keinänen-Kiukaanniemi Sirkka, Sundvall Jouko, Laakso Markku, Tuomilehto Jaakko and Uusitupa Matti. Insulin Secretion and Its Determinants in the Progression of Impaired Glucose Tolerance to Type 2 Diabetes in Impaired Glucose-Tolerant Individuals.Diabetes Care. 35. 211-217.
http://care.diabetesjournals.org/content/35/2/211.abstract
Insulin
2012. Ruiter R., Visser L., van Herk-Sukel M., Coebergh J., Haak H., Geelhoed-Duijvestijn P., Straus S., Herings R. and Stricker B. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.Diabetologia. 55. 51-62.
http://dx.doi.org/10.1007/s00125-011-2312-4
Insulin
2012. Zinman Bernard, Philis-Tsimikas Athena, Cariou Bertrand, Handelsman Yehuda, Rodbard Helena W., Johansen Thue, Endahl Lars, Mathieu Chantal and Investigators on behalf of the NN- Trial. Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long).Diabetes Care. 35. 2464-2471.
http://care.diabetesjournals.org/content/35/12/2464.abstract
Insulin
2012. Asche C. V., Bode B., Busk A. K. and Nair S. R. The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus.Diabetes, Obesity and Metabolism. 14. 47-57.
http://dx.doi.org/10.1111/j.1463-1326.2011.01487.x
Insulin
2012. Blin P., Lassalle R., Dureau-Pournin C., Ambrosino B., Bernard M., Abouelfath A., Gin H., Le Jeunne C., Pariente A., Droz C. and Moore N. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.Diabetologia. 55. 644-653.
http://dx.doi.org/10.1007/s00125-011-2429-5
Insulin
2012. Saad Ahmed, Dalla Man Chiara, Nandy Debashis K., Levine James A., Bharucha Adil E., Rizza Robert A., Basu Rita, Carter Rickey E., Cobelli Claudio, Kudva Yogish C. and Basu Ananda. Diurnal Pattern to Insulin Secretion and Insulin Action in Healthy Individuals.Diabetes. 61. 2691-2700.
http://diabetes.diabetesjournals.org/content/61/11/2691.abstract
Insulin
2012. Heise T., Nosek L., Bøttcher S. G., Hastrup H. and Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.Diabetes, Obesity and Metabolism. 14. 944-950.
http://dx.doi.org/10.1111/j.1463-1326.2012.01638.x
Insulin
2012. Heise T., Hermanski L., Nosek L., Feldman A., Rasmussen S. and Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.Diabetes, Obesity and Metabolism. 14. 859-864.
http://dx.doi.org/10.1111/j.1463-1326.2012.01627.x
Insulin
2013. Ratner R. E., Gough S. C. L., Mathieu C., Del Prato S., Bode B., Mersebach H., Endahl L. and Zinman B. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.Diabetes, Obesity and Metabolism. 15. 175-184.
http://dx.doi.org/10.1111/dom.12032
Insulin
2013. Idris I., Pillai A., Fernando D. J., Thomson G. and Tate H. Responders to insulin therapy at 18 months in adults with newly diagnosed diabetes: which insulin regimen?Diabetic Medicine. 30. e95-e100.
http://dx.doi.org/10.1111/dme.12096
Insulin
2013. Beluchin E., Bäz L., Müller N., Lehmann T., Kloos C., Wolf G. and Müller U. A. Frequency of self-adjustment of insulin dose and metabolic control in Type 2 diabetes –is there an association?Diabetic Medicine. 30. e91-e94.
http://dx.doi.org/10.1111/dme.12071
Insulin
2013. Luzio S. D., Dunseath G. J., Atkinson M. D. and Owens D. R. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: A single dose clamp study in people with type 2 diabetes.Diabetes & Metabolism. 39. 537-542.
http://www.sciencedirect.com/science/article/pii/S1262363613001602
Insulin
2013. Bode B. W., Buse J. B., Fisher M., Garg S. K., Marre M., Merker L., Renard E., Russell-Jones D. L., Hansen C. T., Rana A., Heller S. R. and Investigators Begin® Basal–Bolus Type 1 Trial. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial.Diabetic Medicine. 30. 1293-1297.
http://dx.doi.org/10.1111/dme.12243
Insulin
2013. Rodbard H. W., Cariou B., Zinman B., Handelsman Y., Philis-Tsimikas A., Skjøth T. V., Rana A., Mathieu C. and The Begin Once Long Trial Investigators. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.Diabetic Medicine. 30. 1298-1304.
http://dx.doi.org/10.1111/dme.12303
Insulin
2013. Rosenstock Julio, Bergenstal Richard M., Blevins Thomas C., Morrow Linda A., Prince Melvin J., Qu Yongming, Sinha Vikram P., Howey Daniel C. and Jacober Scott J. Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study.Diabetes Care. 36. 522-528.
http://care.diabetesjournals.org/content/36/3/522.abstract
Insulin
2013. Freemantle N., Meneghini L., Christensen T., Wolden M. L., Jendle J. and Ratner R. Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.Diabetic Medicine. 30. 226-232.
http://dx.doi.org/10.1111/dme.12086
Insulin
2013. Gough Stephen C.L., Bhargava Anuj, Jain Rajeev, Mersebach Henriette, Rasmussen Søren and Bergenstal Richard M. Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial.Diabetes Care. 36. 2536-2542.
http://care.diabetesjournals.org/content/36/9/2536.abstract
Insulin
2013. Meneghini Luigi, Atkin Stephen L., Gough Stephen C.L., Raz Itamar, Blonde Lawrence, Shestakova Marina, Bain Stephen, Johansen Thue, Begtrup Kamilla, Birkeland Kåre I. and Investigators on behalf of the NN- Trial. The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.Diabetes Care. 36. 858-864.
http://care.diabetesjournals.org/content/36/4/858.abstract
Insulin
2014. Niswender K., Piletic M., Andersen H., Conradsen Hiort L. and Hollander P. Weight change upon once-daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin-naïve individuals with type 2 diabetes: results from the DIET trial.Diabetes, Obesity and Metabolism. 16. 186-192.
http://dx.doi.org/10.1111/dom.12218
Insulin
2014. Koehler Gerd, Heller Simon, Korsatko Stefan, Roepstorff Carsten, Rasmussen Søren, Haahr Hanne and Pieber ThomasR. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.Diabetologia. 57. 40-49.
http://dx.doi.org/10.1007/s00125-013-3056-0
Insulin
2014. Mader J. K., Neubauer K. M., Schaupp L., Augustin T., Beck P., Spat S., Höll B., Treiber G. M., Fruhwald F. M., Pieber T. R. and Plank J. Efficacy, usability and sequence of operations of a workflow-integrated algorithm for basal–bolus insulin therapy in hospitalized type 2 diabetes patients.Diabetes, Obesity and Metabolism. 16. 137-146.
http://dx.doi.org/10.1111/dom.12186
Insulin
2014. Fulcher Gregory R., Christiansen Jens Sandahl, Bantwal Ganapathi, Polaszewska-Muszynska Miroslawa, Mersebach Henriette, Andersen Thomas H. and Niskanen Leo K. Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial.Diabetes Care. 37. 2084-2090.
http://care.diabetesjournals.org/content/37/8/2084.abstract
Insulin
2014. Harris Stewart B., Yale Jean-François, Berard Lori, Stewart John, Abbaszadeh Babak, Webster-Bogaert Susan and Gerstein Hertzel C. Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: A Randomized Noninferiority Trial.Diabetes Care. 37. 604-610.
http://care.diabetesjournals.org/content/37/3/604.abstract
IpTT
2011. Rayman Gerry, Vas Prashanth R., Baker Neil, Taylor, Charles G., Gooday Catherine, Alder Amanda I. and Donohoe Mollie. The Ipswich Touch Test.Diabetes Care. 34. 1517-1518.
http://care.diabetesjournals.org/content/34/7/1517.abstract
IRAS
1997. Mykkanen Leena, Zaccaro Daniel J., O'Leary Daniel H., Howard George, Robbins David C. and Haffner Steven M. Microalbuminuria and Carotid Artery Intima-Media Thickness in Nondiabetic and NIDDM Subjects : The Insulin Resistance Atherosclerosis Study (IRAS).Stroke. 28. 1710-1716.
http://stroke.ahajournals.org/content/28/9/1710.abstract
IRAS
2000. Festa Andreas, D’Agostino Ralph, Howard George, Mykkanen Leena, Tracy Russell P. and Haffner Steven M. Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome : The Insulin Resistance Atherosclerosis Study (IRAS).Circulation. 102. 42-47.
http://circ.ahajournals.org/content/102/1/42.abstract
IRAS
2000. Festa Andreas, D'Agostino Ralph, Jr., Howard George, Mykkanen Leena, Tracy Russell P. and Haffner Steven M. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study.Kidney Int. 58. 1703-1710.
http://dx.doi.org/10.1046/j.1523-1755.2000.00331.x
IRAS
2011. Hanley Anthony J.G., Wagenknecht Lynne E., Norris Jill M., Bergman Richard, Anderson Andrea, Chen Y. Ida, Lorenzo Carlos and Haffner Steven M. Adiponectin and the Incidence of Type 2 Diabetes in Hispanics and African Americans.Diabetes Care. 34. 2231-2236.
http://care.diabetesjournals.org/content/34/10/2231.abstract
IRAS
2012. Rowe Michael W., Bergman Richard N., Wagenknecht Lynne E. and Kolberg Janice A. Performance of a multi-marker Diabetes Risk Score in the Insulin Resistance Atherosclerosis Study (IRAS), a multi-ethnic US cohort.Diabetes/Metabolism Research and Reviews. 28. 519-526.
http://dx.doi.org/10.1002/dmrr.2305
IRAS
2013. Lee C. Christine, Haffner Steven M., Wagenknecht Lynne E., Lorenzo Carlos, Norris Jill M., Bergman Richard N., Stefanovski Darko, Anderson Andrea M., Rotter Jerome I., Goodarzi Mark O. and Hanley Anthony J. Insulin Clearance and the Incidence of Type 2 Diabetes in Hispanics and African Americans: The IRAS Family Study.Diabetes Care. 36. 901-907.
http://care.diabetesjournals.org/content/36/4/901.abstract
Islet Cell Transplant
2012. Barton Franca B., Rickels Michael R., Alejandro Rodolfo, Hering Bernhard J. and al et. Improvement in Outcomes of Clinical Islet Transplantation: 1999–2010.Diabetes Care. 35. 1436-1445.
http://care.diabetesjournals.org/content/35/7/1436.abstract
Back to Top
JDCS
2011. Kawasaki R., Tanaka S., Yamamoto T., Sone H., Ohashi Y., Akanuma Y., Yamada N., Yamashita H. and Group on behalf of the Japan Diabetes Complications Study. Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS).Diabetologia. 54. 2288-2294.
http://dx.doi.org/10.1007/s00125-011-2199-0
JDCS
2013. Tanaka Shiro, Tanaka Sachiko, Iimuro Satoshi, Yamashita Hidetoshi, Katayama Shigehiro, Akanuma Yasuo, Yamada Nobuhiro, Araki Atsushi, Ito Hideki, Sone Hirohito, Ohashi Yasuo, Group for the Japan Diabetes Complications Study and Group the Japanese Elderly Diabetes Intervention Trial. Predicting Macro- and Microvascular Complications in Type 2 Diabetes: The Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine.Diabetes Care. 36. 1193-1199.
http://care.diabetesjournals.org/content/36/5/1193.abstract
JDDM
2011. Yokoyama H., Matsushima M., Kawai K., Hirao K., Oishi M., Sugimoto H., Takeda H., Minami M., Kobayashi M., Sone H. and on behalf of the Japan Diabetes Clinical Data Management Study Group. Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20).Diabetic Medicine. 28. 1221-1228.
http://dx.doi.org/10.1111/j.1464-5491.2011.03347.x
JDDM
2012. Matsuba Ikuro, Saito Kazumi, Takai Masahiko, Hirao Koichi and Sone Hirohito. Fasting Insulin Levels and Metabolic Risk Factors in Type 2 Diabetic Patients at the First Visit in Japan.Diabetes Care. 35. 1853-1857.
http://care.diabetesjournals.org/content/35/9/1853.abstract
JDDM
2012. Yokoyama H., Araki S., Haneda M., Matsushima M., Kawai K., Hirao K., Oishi M., Sugimoto K., Sone H., Maegawa H., Kashiwagi A. and Group for the Japan Diabetes Clinical Data Management Study. Chronic kidney disease categories and renal–cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25).Diabetologia. 55. 1911-1918.
http://dx.doi.org/10.1007/s00125-012-2536-y
JPAD
2011. Okada Sadanori, Morimoto Takeshi, Ogawa Hisao, Kanauchi Masao, Nakayama Masafumi, Uemura Shiro, Doi Naofumi, Jinnouchi Hideaki, Waki Masako, Soejima Hirofumi, Sakuma Mio, Saito Yoshihiko and Investigators for the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial. Differential Effect of Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Diabetes Management.Diabetes Care. 34. 1277-1283.
http://care.diabetesjournals.org/content/34/6/1277.abstract
JPAD
2011. Saito Yoshihiko, Morimoto Takeshi, Ogawa Hisao, Nakayama Masafumi, Uemura Shiro, Doi Naofumi, Jinnouchi Hideaki, Waki Masako, Soejima Hirofumi, Sugiyama Seigo, Okada Sadanori, Akai Yasuhiro and Investigators on behalf of the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial. Low-Dose Aspirin Therapy in Patients With Type 2 Diabetes and Reduced Glomerular Filtration Rate.Diabetes Care. 34. 280-285.
http://care.diabetesjournals.org/content/34/2/280.abstract
Back to Top
LADA
2011. Olsson Lisa, Ahlbom Anders, Grill Valdemar, Midthjell Kristian and Carlsson Sofia. High Levels of Education Are Associated With an Increased Risk of Latent Autoimmune Diabetes in Adults.Diabetes Care. 34. 102-107.
http://care.diabetesjournals.org/content/34/1/102.abstract
LEAD 1
2009. Marre M., Shaw J., Brändle M., Bebakar W. M. W., Kamaruddin N. A., Strand J., Zdravkovic M., Le Thi T. D., Colagiuri S. and on behalf of the Lead- S. U. study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).Diabetic Medicine. 26. 268-278.
http://dx.doi.org/10.1111/j.1464-5491.2009.02666.x
LEAD 1-5
2009. Blonde L. and Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies.Diabetes, Obesity and Metabolism. 11. 26-34.
http://dx.doi.org/10.1111/j.1463-1326.2009.01075.x
LEAD 3
2009. Garber Alan, Henry Robert, Ratner Robert, Garcia-Hernandez Pedro A., Rodriguez-Pattzi Hiromi, Olvera-Alvarez Israel, Hale Paula M., Zdravkovic Milan and Bode Bruce. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.The Lancet. 373. 473-481.
http://www.sciencedirect.com/science/article/pii/S0140673608612465
LEAD 4
2009. Zinman Bernard, Gerich John, Buse John B., Lewin Andrew, Schwartz Sherwyn, Raskin Philip, Hale Paula M., Zdravkovic Milan, Blonde Lawrence and Investigators the LEAD-4 Study. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD).Diabetes Care. 32. 1224-1230.
http://care.diabetesjournals.org/content/32/7/1224.abstract
LEAD 5
2009. Russell-Jones D., Vaag A., Schmitz O., Sethi B., Lalic N., Antic S., Zdravkovic M., Ravn G. and Simó R. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.Diabetologia. 52. 2046-2055.
http://dx.doi.org/10.1007/s00125-009-1472-y
LEAD 6
2009. Buse John B., Rosenstock Julio, Sesti Giorgio, Schmidt Wolfgang E., Montanya Eduard, Brett Jason H., Zychma Marcin and Blonde Lawrence. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).The Lancet. 374. 39-47.
http://www.sciencedirect.com/science/article/pii/S0140673609606590
LIFE
2002. Lindholm Lars H., Ibsen Hans, Dahlöf Björn, Devereux Richard B., Beevers Gareth, de Faire Ulf, Fyhrquist Frej, Julius Stevo, Kjeldsen Sverre E., Kristiansson Krister, Lederballe-Pedersen Ole, Nieminen Markku S., Omvik Per, Oparil Suzanne, Wedel Hans, Aurup Peter, Edelman Jonathan and Snapinn Steven. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.The Lancet. 359. 1004-1010.
http://www.sciencedirect.com/science/article/pii/S014067360208090X
Liraglutide-Detemir Study
2012. DeVries J. Hans, Bain Stephen C., Rodbard Helena W., Seufert Jochen, D’Alessio David, Thomsen Anne B., Zychma Marcin, Rosenstock Julio and Group on behalf of the Liraglutide-Detemir Study. Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets.Diabetes Care. 35. 1446-1454.
http://care.diabetesjournals.org/content/35/7/1446.abstract
Look AHEAD
2011. Wing Rena R., Lang Wei, Wadden Thomas A., Safford Monika, Knowler William C., Bertoni Alain G., Hill James O., Brancati Frederick L., Peters Anne, Wagenknecht Lynne and Group the Look AHEAD Research. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes.Diabetes Care. 34. 1481-1486.
http://care.diabetesjournals.org/content/34/7/1481.abstract
Look AHEAD Study
2013. Wing Rena R., Bond Dale S., Gendrano Isaias Noel, Wadden Thomas, Bahnson Judy, Lewis Cora E., Brancati Frederick, Schneider Stephen, Kitabchi Abbas E., Van Dorsten Brent, Rosen Raymond C. and Group the Sexual Dysfunction Subgroup of the Look AHEAD Research. Effect of Intensive Lifestyle Intervention on Sexual Dysfunction in Women With Type 2 Diabetes: Results from an ancillary Look AHEAD study.Diabetes Care. 36. 2937-2944.
http://care.diabetesjournals.org/content/36/10/2937.abstract
Look AHEAD Study-Obesity
2011. Unick Jessica L., Beavers Daniel, Jakicic John M., Kitabchi Abbas E., Knowler William C., Wadden Thomas A., Wing Rena R. and Group for the Look AHEAD Research. Effectiveness of Lifestyle Interventions for Individuals With Severe Obesity and Type 2 Diabetes.Diabetes Care. 34. 2152-2157.
http://care.diabetesjournals.org/content/34/10/2152.abstract
Back to Top
MAGIC
2011. Viazzi Francesca, Leoncini Giovanna, Vercelli Marina, Deferrari Giacomo and Pontremoli Roberto. Serum Uric Acid Levels Predict New-Onset Type 2 Diabetes in Hospitalized Patients With Primary Hypertension: The MAGIC Study.Diabetes Care. 34. 126-128.
http://care.diabetesjournals.org/content/34/1/126.abstract
MARVAL
2002. Viberti Giancarlo, Wheeldon Nigel M. and Investigators for the MicroAlbuminuria Reduction With VALsartan Study. Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus.Circulation. 106. 672-678.
http://circ.ahajournals.org/content/106/6/672.abstract
MEMO Study
2011. Crasto W., Jarvis J., Khunti K., Skinner T. C., Gray L. J., Brela J., Troughton J., Daly H., Lawrence I. G., McNally P. G., Carey M. E. and Davies M. J. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: The Microalbuminuria Education and Medication Optimisation (MEMO) study.Diabetes research and clinical practice. 93. 328-336.
http://linkinghub.elsevier.com/retrieve/pii/S016882271100235X?showall=true
Meta-analysis. Xu Na, Wu Hongfang, Li Daiqing and Wang Jianhua. Diagnostic accuracy of glycated hemoglobin compared with oral glucose tolerance test for diagnosing diabetes mellitus in Chinese adults: A meta-analysis.Diabetes research and clinical practice. 106. 11-18.
http://www.diabetesresearchclinicalpractice.com/article/S0168-8227(14)00193-4/abstract
Meta-analysis
2005. Abuissa Hussam, Jones Philip G., Marso Steven P. and O'Keefe Jr James H. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials.Journal of the American College of Cardiology. 46. 821-826.
http://www.sciencedirect.com/science/article/pii/S0735109705012714
Meta-analysis
2006. Stettler Christoph, Allemann Sabin, Juni Peter, Cull Carole A., Holman Rury R., Egger Matthias, Krahenbuhl Stephan and Diem Peter. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.American Heart Journal. 152. 27-38.
http://www.sciencedirect.com/science/article/pii/S0002870305008707
Meta-analysis
2007. Amori Renee E., Lau Joseph and Pittas Anastassios G. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes.JAMA: The Journal of the American Medical Association. 298. 194-206.
http://jama.ama-assn.org/content/298/2/194.abstract
Meta-analysis
2008. Bazzano L. A., Lee L. J., Shi L., Reynolds K., Jackson J. A. and Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.Diabetic Medicine. 25. 924-932.
http://dx.doi.org/10.1111/j.1464-5491.2008.02517.x
Meta-analysis
2011. Johnson J. and Bowker S. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials.Diabetologia. 54. 25-31.
http://dx.doi.org/10.1007/s00125-010-1933-3
Meta-analysis
2011. Liang X., Wang Q., Yang X., Cao J., Chen J., Mo X., Huang J., Wang L. and Gu D. Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis.Diabetic Medicine. 28. 455-463.
http://dx.doi.org/10.1111/j.1464-5491.2010.03180.x
Meta-analysis
2011. Blacklock C. L., Hirst J. A., Taylor K. S., Stevens R. J., Roberts N. W. and Farmer A. J. Evidence for a dose effect of renin–angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.Diabetic Medicine. 28. 1182-1187.
http://dx.doi.org/10.1111/j.1464-5491.2011.03341.x
Meta-analysis
2011. Moxey P. W., Gogalniceanu P., Hinchliffe R. J., Loftus I. M., Jones K. J., Thompson M. M. and Holt P. J. Lower extremity amputations — a review of global variability in incidence.Diabetic Medicine. 28. 1144-1153.
http://dx.doi.org/10.1111/j.1464-5491.2011.03279.x
Meta-analysis
2011. Hemmingsen Bianca, Lund Søren S, Gluud Christian, Vaag Allan, Almdal Thomas, Hemmingsen Christina and Wetterslev Jørn. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.British Medical Journal. 343.
http://www.bmj.com/content/343/bmj.d6898
Meta-analysis
2012. Singh-Franco D., McLaughlin-Middlekauff J., Elrod S. and Harrington C. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Diabetes, Obesity and Metabolism. 14. 694-708.
http://dx.doi.org/10.1111/j.1463-1326.2012.01586.x
Meta-analysis
2012. Dumville J., Soares M., O’Meara S. and Cullum N. Systematic review and mixed treatment comparison: dressings to heal diabetic foot ulcers.Diabetologia. 55. 1902-1910.
http://dx.doi.org/10.1007/s00125-012-2558-5
Meta-analysis
2012. Murad Mohammad Hassan, Coburn John A., Coto-Yglesias Fernando, Dzyubak Svitlana, Hazem Ahmad, Lane Melanie A., Prokop Larry J. and Montori Victor M. Glycemic Control in Non-Critically Ill Hospitalized Patients: A Systematic Review and Meta-Analysis.Journal of Clinical Endocrinology & Metabolism. 97. 49-58.
http://jcem.endojournals.org/content/97/1/49.abstract
Meta-analysis
2012. Dunkley A. J., Charles K., Gray L. J., Camosso-Stefinovic J., Davies M. J. and Khunti K. Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis.Diabetes, Obesity and Metabolism. 14. 616-625.
http://dx.doi.org/10.1111/j.1463-1326.2012.01571.x
Meta-analysis
2012. Musso G., Cassader M., Rosina F. and Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Diabetologia. 55. 885-904.
http://dx.doi.org/10.1007/s00125-011-2446-4
Meta-analysis
2012. Gerrald K. R., Van Scoyoc E., Wines R. C., Runge T. and Jonas D. E. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.Diabetes, Obesity and Metabolism. 14. 481-492.
http://dx.doi.org/10.1111/j.1463-1326.2011.01540.x
Meta-analysis
2012. Colmers I. N., Bowker S. L. and Johnson J. A. Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis.Diabetes & Metabolism. 38. 475-484.
http://www.sciencedirect.com/science/article/pii/S1262363612001231
Meta-analysis
2012. Hemmingsen Bianca, Christensen Louise Lundby, Wetterslev Jørn, Vaag Allan, Gluud Christian, Lund Søren S and Almdal Thomas. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses.British Medical Journal. 344.
Meta-analysis
2012. Colmers I. N., Bowker S. L., Tjosvold L. A. and Johnson J. A. Insulin use and cancer risk in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.Diabetes & Metabolism. 38. 485-506.
http://www.sciencedirect.com/science/article/pii/S1262363612001589
Meta-analysis
2012. Farmer Andrew J, Perera Rafael, Ward Alison, Heneghan Carl, Oke Jason, Barnett Anthony H, Davidson Mayer B, Guerci Bruno, Coates Vivien, Schwedes Ulrich and O’Malley Simon. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes.British Medical Journal. 344.
Meta-analysis
2012. Nakao Yoko M., Teramukai Satoshi, Tanaka Sachiko, Yasuno Shinji, Fujimoto Akira, Kasahara Masato, Ueshima Kenji, Nakao Kazuhiro, Hinotsu Shiro, Nakao Kazuwa and Kawakami Koji. Effects of renin–angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: A systematic review and meta-analysis.Diabetes research and clinical practice. 96. 68-75.
http://www.sciencedirect.com/science/article/pii/S0168822711006656
Meta-analysis
2012. Karagiannis Thomas, Paschos Paschalis, Paletas Konstantinos, Matthews David R and Tsapas Apostolos. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.British Medical Journal. 344.
Meta-analysis
2012. Stevens R., Ali R., Bankhead C., Bethel M., Cairns B., Camisasca R., Crowe F., Farmer A., Harrison S., Hirst J., Home P., Kahn S., McLellan J., Perera R., Plüddemann A., Ramachandran A., Roberts N., Rose P., Schweizer A., Viberti G. and Holman R. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.Diabetologia. 55. 2593-2603.
http://dx.doi.org/10.1007/s00125-012-2653-7
Meta-analysis
2013. Wang Xia, Bao Wei, Liu Jun, OuYang Ying-Ying, Wang Di, Rong Shuang, Xiao Xiao, Shan Zhi-Lei, Zhang Yan, Yao Ping and Liu Lie-Gang. Inflammatory Markers and Risk of Type 2 Diabetes: A systematic review and meta-analysis.Diabetes Care. 36. 166-175.
http://care.diabetesjournals.org/content/36/1/166.abstract
Meta-analysis
2013. Kodama Keiichi, Tojjar Damon, Yamada Satoru, Toda Kyoko, Patel Chirag J. and Butte Atul J. Ethnic Differences in the Relationship Between Insulin Sensitivity and Insulin Response: A systematic review and meta-analysis.Diabetes Care. 36. 1789-1796.
http://care.diabetesjournals.org/content/36/6/1789.abstract
Meta-analysis
2013. Freemantle N., Evans M., Christensen T., Wolden M. L. and Bjorner J. B. A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.Diabetes, Obesity and Metabolism. 15. 564-571.
http://dx.doi.org/10.1111/dom.12086
Meta-analysis
2013. Kunutsor Setor K., Apekey Tanefa A., Walley John and Kain Kirti. Ferritin levels and risk of type 2 diabetes mellitus: an updated systematic review and meta-analysis of prospective evidence.Diabetes/Metabolism Research and Reviews. 29. 308-318.
http://dx.doi.org/10.1002/dmrr.2394
Meta-analysis
2013. Calanna Salvatore, Christensen Mikkel, Holst Jens J., Laferrère Blandine, Gluud Lise L., Vilsbøll Tina and Knop Filip K. Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies.Diabetes Care. 36. 3346-3352.
http://care.diabetesjournals.org/content/36/10/3346.abstract
Meta-analysis
2013. Connelly J., Kirk A., Masthoff J. and MacRury S. The use of technology to promote physical activity in Type 2 diabetes management: a systematic review.Diabetic Medicine. 30. 1420-1432.
http://dx.doi.org/10.1111/dme.12289
Meta-analysis
2013. Hirst J. A., Farmer A. J., Dyar A., Lung T. W. C. and Stevens R. J. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.Diabetologia. 56. 973-984.
http://dx.doi.org/10.1007/s00125-013-2856-6
Meta-analysis
2013. Song Yiqing, Wang Lu, Pittas Anastassios G., Del Gobbo Liana C., Zhang Cuilin, Manson JoAnn E. and Hu Frank B. Blood 25-Hydroxy Vitamin D Levels and Incident Type 2 Diabetes: A meta-analysis of prospective studies.Diabetes Care. 36. 1422-1428.
http://care.diabetesjournals.org/content/36/5/1422.abstract
Meta-analysis
2013. Greenwood Darren C., Threapleton Diane E., Evans Charlotte E.L., Cleghorn Christine L., Nykjaer Camilla, Woodhead Charlotte and Burley Victoria J. Glycemic Index, Glycemic Load, Carbohydrates, and Type 2 Diabetes: Systematic review and dose–response meta-analysis of prospective studies.Diabetes Care. 36. 4166-4171.
http://care.diabetesjournals.org/content/36/12/4166.abstract
Meta-analysis
2013. Monami M., Genovese S. and Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.Diabetes, Obesity and Metabolism. 15. 938-953.
http://dx.doi.org/10.1111/dom.12116
Meta-analysis
2013. Wu Hon-Yen, Huang Jenq-Wen, Lin Hung-Ju, Liao Wei-Chih, Peng Yu-Sen, Hung Kuan-Yu, Wu Kwan-Dun, Tu Yu-Kang and Chien Kuo-Liong. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.BMJ. 347.
Meta-analysis
2013. Jeffery R., Iserman E., Haynes R. B. and the Cdss Systematic Review Team. Can computerized clinical decision support systems improve diabetes management? A systematic review and meta-analysis.Diabetic Medicine. 30. 739-745.
http://dx.doi.org/10.1111/dme.12087
Meta-analysis
2014. Schmieder RolandE, Schutte Rudolph, Schumacher Helmut, Böhm Michael, Mancia Giuseppe, Weber MichaelA, McQueen Matthew, Teo Koon and Yusuf Salim. Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies.Diabetologia. 57. 2019-2029.
http://dx.doi.org/10.1007/s00125-014-3330-9
Meta-analysis
2014. Monami M., Dicembrini I. and Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.Diabetes, Obesity and Metabolism. 16. 48-56.
http://dx.doi.org/10.1111/dom.12176
Meta-analysis
2014. Wu D., Li L. and Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.Diabetes, Obesity and Metabolism. 16. 30-37.
http://dx.doi.org/10.1111/dom.12174
Meta-analysis
2014. Monami M., Dicembrini I., Nardini C., Fiordelli I. and Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.Diabetes, Obesity and Metabolism. 16. 38-47.
http://dx.doi.org/10.1111/dom.12175
Meta-analysis
2014. Liakos A., Karagiannis T., Athanasiadou E., Sarigianni M., Mainou M., Papatheodorou K., Bekiari E. and Tsapas A. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.Diabetes, Obesity and Metabolism. 16. 984-993.
http://dx.doi.org/10.1111/dom.12307
Metaanalysis
2013. He F., Xia X., Wu X. F., Yu X. Q. and Huang F. X. Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis.Diabetologia. 56. 457-466.
http://dx.doi.org/10.1007/s00125-012-2796-6
Metaanalysis
2014. Gao W., Dong J., Liu J., Li Y., Liu F., Yang L., Zhou X. and Liao L. Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials.Diabetes, Obesity and Metabolism. 16. 179-185.
http://dx.doi.org/10.1111/dom.12193
Metaanalysis
2014. Hartling L., Dryden D. M., Guthrie A., Muise M., Vandermeer B. and Donovan L. Diagnostic thresholds for gestational diabetes and their impact on pregnancy outcomes: a systematic review.Diabetic Medicine. 31. 319-331.
http://dx.doi.org/10.1111/dme.12357
Metaanalysis
2014. Zhang Mei, Zhang Lin, Wu Bin, Song Haolan, An Zhenmei and Li Shuangqing. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Diabetes/Metabolism Research and Reviews. 30. 204-221.
http://dx.doi.org/10.1002/dmrr.2479
Metaanalysis
2014. Ding Ming, Bhupathiraju Shilpa N., Chen Mu, van Dam Rob M. and Hu Frank B. Caffeinated and Decaffeinated Coffee Consumption and Risk of Type 2 Diabetes: A Systematic Review and a Dose-Response Meta-analysis.Diabetes Care. 37. 569-586.
http://care.diabetesjournals.org/content/37/2/569.abstract
Metabolic Syndrome
2011. Bhasin Shalender, Jasjua Guneet K., Pencina Michael, D’Agostino Ralph, Coviello Andrea D., Vasan Ramachandran S. and Travison Thomas G. Sex Hormone–Binding Globulin, but Not Testosterone, Is Associated Prospectively and Independently With Incident Metabolic Syndrome in Men.Diabetes Care. 34. 2464-2470.
http://care.diabetesjournals.org/content/34/11/2464.abstract
Metanalysis
2014. Zhang Yifei, Hong Jie, Chi Jie, Gu Weiqiong, Ning Guang and Wang Weiqing. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas – a meta-analysis from randomized clinical trials.Diabetes/Metabolism Research and Reviews. 30. 241-256.
http://dx.doi.org/10.1002/dmrr.2482
Methizolamide
2012. Konstantopoulos Nicky, Molero Juan C., McGee Sean L., Spolding Briana, Connor Tim, de Vries Melissa, Wanyonyi Stephen, Fahey Richard, Morrison Shona, Swinton Courtney, Jones Sharon, Cooper Adrian, Garcia-Guerra Lucia, Foletta Victoria C., Krippner Guy, Andrikopoulos Sofianos and Walder Ken R. Methazolamide Is a New Hepatic Insulin Sensitizer That Lowers Blood Glucose In Vivo.Diabetes. 61. 2146-2154.
http://diabetes.diabetesjournals.org/content/61/8/2146.abstract
MI
1988. Herlitz Johan, Malmberg Klas, Karlson BjÖRn W., RydÉN Lars and Hjalmarson ÅKe. Mortality and Morbidity During a Five-year Follow-up of Diabetics with Myocardial Infarction.Acta Medica Scandinavica. 224. 31-38.
http://dx.doi.org/10.1111/j.0954-6820.1988.tb16735.x
MI
1993. Karlson B. W., Herlitz J. and Hjalmarson Å. Prognosis of Acute Myocardial Infarction in Diabetic and Non-diabetic Patients.Diabetic Medicine. 10. 449-454.
http://dx.doi.org/10.1111/j.1464-5491.1993.tb00097.x
MI
2011. Siegelaar Sarah E., Kerr Lisa, Jacober Scott J. and Devries J. Hans. A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction.Diabetes Care. 34. 855-857.
http://care.diabetesjournals.org/content/34/4/855.abstract
MI
2011. MacDonald Michael R., Petrie Mark C., Home Philip D., Komajda Michel, Jones Nigel P., Beck-Nielsen Henning, Gomis Ramon, Hanefeld Markolf, Pocock Stuart J., Curtis Paula S. and McMurray John J.V. Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes.Diabetes Care. 34. 1394-1396.
http://care.diabetesjournals.org/content/34/6/1394.abstract
MI
2012. Webb D. R., Khunti K., Gray L. J., Srinivasan B. T., Farooqi A., Wareham N., Griffin S. C., Davies M. J. and for the Addition-Leicester study group. Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial.Diabetic Medicine. 29. 531-540.
http://dx.doi.org/10.1111/j.1464-5491.2011.03441.x
MI
2012. Mellbin Linda G., Bjerre Mette, Thiel Steffen and Hansen Troels K. Complement Activation and Prognosis in Patients With Type 2 Diabetes and Myocardial Infarction.Diabetes Care. 35. 911-917.
http://care.diabetesjournals.org/content/35/4/911.abstract
MI
2012. Stolker Joshua M., Spertus John A., McGuire Darren K., Lind Marcus, Tang Fengming, Jones Philip G., Inzucchi Silvio E., Rathore Saif S., Maddox Thomas M., Masoudi Frederick A. and Kosiborod Mikhail. Relationship Between Glycosylated Hemoglobin Assessment and Glucose Therapy Intensification in Patients With Diabetes Hospitalized for Acute Myocardial Infarction.Diabetes Care. 35. 991-993.
http://care.diabetesjournals.org/content/35/5/991.abstract
MIND.IT
2013. Vaccaro Olga, Franzini Laura, Miccoli Roberto, Cavalot Franco, Ardigò Diego, Boemi Massimo, De Feo Pierpaolo, Reboldi Gianpaolo, Rivellese Angela Albarosa, Trovati Mariella, Zavaroni Ivana and Group on behalf of the MIND.IT Study. Feasibility and Effectiveness in Clinical Practice of a Multifactorial Intervention for the Reduction of Cardiovascular Risk in Patients With Type 2 Diabetes: The 2-year interim analysis of the MIND.IT study: a cluster randomized trial.Diabetes Care. 36. 2566-2572.
http://care.diabetesjournals.org/content/36/9/2566.abstract
MODY
2011. Fajans Stefan S. and Bell Graeme I. MODY.Diabetes Care. 34. 1878-1884.
http://care.diabetesjournals.org/content/34/8/1878.short
MODY
2012. Shields B., McDonald T., Ellard S., Campbell M., Hyde C. and Hattersley A. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes.Diabetologia. 55. 1265-1272.
http://dx.doi.org/10.1007/s00125-011-2418-8
MODY
2012. Conway Baqiyyah N., May Michael E., Signorello Lisa B. and Blot William J. Mortality Experience of a Low-Income Population With Young-Onset Diabetes.Diabetes Care. 35. 542-548.
http://care.diabetesjournals.org/content/35/3/542.abstract
MODY
2013. Pruhova Stepanka, Dusatkova Petra, Neumann David, Hollay Erik, Cinek Ondrej, Lebl Jan and Sumnik Zdenek. Two Cases of Diabetic Ketoacidosis in HNF1A-MODY Linked to Severe Dehydration: Is it time to change the diagnostic criteria for MODY?Diabetes Care. 36. 2573-2574.
http://care.diabetesjournals.org/content/36/9/2573.abstract
MONICA Study
2011. Eliasson M., Jansson J. H., Lundblad D. and Näslund U. The disparity between long-term survival in patients with and without diabetes following a first myocardial infarction did not change between 1989 and 2006: an analysis of 6,776 patients in the Northern Sweden MONICA Study.Diabetologia. 54. 2538-2543.
http://dx.doi.org/10.1007/s00125-011-2247-9
MONICA/KORA Study
2011. Thorand Barbara, Zierer Astrid, Huth Cornelia, Linseisen Jakob, Meisinger Christa, Roden Michael, Peters Annette, Koenig Wolfgang and Herder Christian. Effect of Serum 25-Hydroxyvitamin D on Risk for Type 2 Diabetes May Be Partially Mediated by Subclinical Inflammation.Diabetes Care. 34. 2320-2322.
http://care.diabetesjournals.org/content/34/10/2320.abstract
Monitoring
2011. Polonsky William H., Fisher Lawrence, Schikman Charles H., Hinnen Deborah A., Parkin Christopher G., Jelsovsky Zhihong, Petersen Bettina, Schweitzer Matthias and Wagner Robin S. Structured Self-Monitoring of Blood Glucose Significantly Reduces A1C Levels in Poorly Controlled, Noninsulin-Treated Type 2 Diabetes.Diabetes Care. 34. 262-267.
http://care.diabetesjournals.org/content/34/2/262.abstract
Monitoring
2012. Evans J. M. M., Mackison D., Emslie-Smith A. and Lawton J. Self-monitoring of blood glucose in Type 2 diabetes: cross-sectional analyses in 1993, 1999 and 2009.Diabetic Medicine. 29. 792-795.
http://dx.doi.org/10.1111/j.1464-5491.2011.03567.x
Mortality
2011. Hansen M., Jensen M. and Carstensen B. Causes of death among diabetic patients in Denmark.Diabetologia. 1-9.
http://dx.doi.org/10.1007/s00125-011-2383-2
Mortality
2012. Thomas G. Neil, ó Hartaigh Bríain, Bosch Jos A., Pilz Stefan, Loerbroks Adrian, Kleber Marcus E., Fischer Joachim E., Grammer Tanja B., Böhm Bernhard O. and März Winfried. Vitamin D Levels Predict All-Cause and Cardiovascular Disease Mortality in Subjects With the Metabolic Syndrome.Diabetes Care. 35. 1158-1164.
http://care.diabetesjournals.org/content/35/5/1158.abstract
Mortality
2012. Williams Emily D., Rawal Lal, Oldenburg Brian F., Renwick Carla, Shaw Jonathan E. and Tapp Robyn J. Risk of Cardiovascular and All-Cause Mortality: Impact of Impaired Health-Related Functioning and Diabetes.Diabetes Care. 35. 1067-1073.
http://care.diabetesjournals.org/content/35/5/1067.abstract
Mortality
2012. Zekry D., Frangos E., Graf C., Michel J. P., Gold G., Krause K. H., Herrmann F. R. and Vischer U. M. Diabetes, comorbidities and increased long-term mortality in older patients admitted for geriatric inpatient care.Diabetes & Metabolism. 38. 149-155.
http://www.sciencedirect.com/science/article/pii/S1262363611001741
Mortality
2013. Jørgensen MaritE, Almdal ThomasP and Carstensen Bendix. Time trends in mortality rates in type 1 diabetes from 2002 to 2011.Diabetologia. 56. 2401-2404.
http://dx.doi.org/10.1007/s00125-013-3025-7
Mortality
2013. De Cosmo Salvatore, Copetti Massimiliano, Lamacchia Olga, Fontana Andrea, Massa Michela, Morini Eleonora, Pacilli Antonio, Fariello Stefania, Palena Antonio, Rauseo Anna, Viti Rafaella, Di Paola Rosa, Menzaghi Claudia, Cignarelli Mauro, Pellegrini Fabio and Trischitta Vincenzo. Development and Validation of a Predicting Model of All-Cause Mortality in Patients With Type 2 Diabetes.Diabetes Care. 36. 2830-2835.
http://care.diabetesjournals.org/content/36/9/2830.abstract
MRFIT
1993. Stamler J, Vaccaro O, Neaton J D and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.Diabetes Care. 16. 434-444.
http://care.diabetesjournals.org/content/16/2/434.abstract
MRFIT
1996. Stamler Jeremiah, Caggiula Arlene, Grandits Greg A., Kjelsberg Marcus and Cutler Jeffrey A. Relationship to Blood Pressure of Combinations of Dietary Macronutrients: Findings of the Multiple Risk Factor Intervention Trial (MRFIT).Circulation. 94. 2417-2423.
http://circ.ahajournals.org/content/94/10/2417.short
Back to Top
NAVIGATOR
2008. Califf Robert M., Boolell Mitradev, Haffner Steven M., Bethel M. Angelyn, McMurray John, Duggal Anil and Holman Rury R. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.American Heart Journal. 156. 623-632.
http://www.sciencedirect.com/science/article/pii/S000287030800389X
NAVIGATOR
2010. Group The NAVIGATOR Study. Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events.New England Journal of Medicine. 362. 1463-1476.
http://www.nejm.org/doi/full/10.1056/NEJMoa1001122
NAVIGATOR
2010. Group The NAVIGATOR Study. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events.New England Journal of Medicine. 362. 1477-1490.
http://www.nejm.org/doi/full/10.1056/NEJMoa1001121
Nephropathy
2008. Parving Hans-Henrik, Persson Frederik, Lewis Julia B., Lewis Edmund J. and Hollenberg Norman K. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy.New England Journal of Medicine. 358. 2433-2446.
http://www.nejm.org/doi/full/10.1056/NEJMoa0708379
Nephropathy
2011. Nichols Gregory A., Vupputuri Suma and Lau Helen. Medical Care Costs Associated With Progression of Diabetic Nephropathy.Diabetes Care. 34. 2374-2378.
http://care.diabetesjournals.org/content/34/11/2374.abstract
Nephropathy
2012. Schlatzer Daniela, Maahs David M., Chance Mark R., Dazard Jean-Eudes, Li Xiaolin, Hazlett Fred, Rewers Marian and Snell-Bergeon Janet K. Novel Urinary Protein Biomarkers Predicting the Development of Microalbuminuria and Renal Function Decline in Type 1 Diabetes.Diabetes Care. 35. 549-555.
http://care.diabetesjournals.org/content/35/3/549.abstract
Nephropathy
2012. Detournay B., Simon D., Guillausseau P. J., Joly D., Verges B., Attali C., Clement O., Briand Y. and Delaitre O. Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes.Diabetes & Metabolism. 38. 102-112.
http://www.sciencedirect.com/science/article/pii/S1262363611002254
Nephropathy
2012. Halimi J. M. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients.Diabetes & Metabolism. 38. 291-297.
http://www.sciencedirect.com/science/article/pii/S1262363612000742
Nephropathy
2012. Baldwin David, Zander Jennifer, Munoz Christina, Raghu Preeya, DeLange-Hudec Susan, Lee Hong, Emanuele Mary Ann, Glossop Valerie, Smallwood Kimberly and Molitch Mark. A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency.Diabetes Care. 35. 1970-1974.
http://care.diabetesjournals.org/content/35/10/1970.abstract
Nephropathy
2012. Wada Y., Hamamoto Y., Ikeda H., Honjo S., Kawasaki Y., Mori K. and Koshiyama H. Seasonal variations of urinary albumin creatinine ratio in Japanese subjects with Type 2 diabetes and early nephropathy.Diabetic Medicine. 29. 506-508.
http://dx.doi.org/10.1111/j.1464-5491.2011.03472.x
Nephropathy
2012. Ricks Joni, Molnar Miklos Z., Kovesdy Csaba P., Shah Anuja, Nissenson Allen R., Williams Mark and Kalantar-Zadeh Kamyar. Glycemic Control and Cardiovascular Mortality in Hemodialysis Patients With Diabetes.Diabetes. 61. 708-715.
http://diabetes.diabetesjournals.org/content/61/3/708.abstract
Nephropathy
2013. Okada Hiroshi, Fukui Michiaki, Tanaka Muhei, Matsumoto Shinobu, Mineoka Yusuke, Nakanishi Naoko, Asano Mai, Yamazaki Masahiro, Hasegawa Goji and Nakamura Naoto. Visit-to-Visit Blood Pressure Variability Is a Novel Risk Factor for the Development and Progression of Diabetic Nephropathy in Patients With Type 2 Diabetes.Diabetes Care. 36. 1908-1912.
http://care.diabetesjournals.org/content/36/7/1908.abstract
Networks
2011. Simmons David, English Patrick, Robins Peter, Craig Andrew and Addicott Rachael. Should diabetes be commissioned through multidisciplinary networks, rather than Practice Based Commissioning?Primary Care Diabetes. 5. 39-44.
http://www.sciencedirect.com/science/article/pii/S1751991810001282
Neuropathy
2011. Abbott Caroline A., Malik Rayaz A., van Ross Ernest R.E., Kulkarni Jai and Boulton Andrew J.M. Prevalence and Characteristics of Painful Diabetic Neuropathy in a Large Community-Based Diabetic Population in the U.K.Diabetes Care. 34. 2220-2224.
http://care.diabetesjournals.org/content/34/10/2220.abstract
Neuropathy
2012. Dyck Peter J., Clark Vicki M., Overland Carol J., Davies Jenny L., Pach John M., Dyck P. James B., Klein Christopher J., Rizza Robert A., Melton L. Joseph, Carter Rickey E., Klein Ronald and Litchy William J. Impaired Glycemia and Diabetic Polyneuropathy.Diabetes Care. 35. 584-591.
http://care.diabetesjournals.org/content/35/3/584.abstract
Neuropathy
2012. Shehab D., Al-Jarallah K., Mojiminiyi O. A., Al Mohamedy H. and Abdella N. A. Does Vitamin D deficiency play a role in peripheral neuropathy in Type 2 diabetes?Diabetic Medicine. 29. 43-49.
http://dx.doi.org/10.1111/j.1464-5491.2011.03510.x
Neuropathy
2012. Soderstrom L. H., Johnson S. P., Diaz V. A. and Mainous A. G. Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001–2004 NHANES.Diabetic Medicine. 29. 50-55.
http://dx.doi.org/10.1111/j.1464-5491.2011.03379.x
Neuropathy
2013. Shin Andrea S. and Camilleri Michael. Diagnostic Assessment of Diabetic Gastroparesis.Diabetes. 62. 2667-2673.
http://diabetes.diabetesjournals.org/content/62/8/2667.short
Neuropathy: ADDITION-Denmark Study
2011. Charles Morten, Ejskjaer Niels, Witte Daniel R., Borch-Johnsen Knut, Lauritzen Torsten and Sandbaek Annelli. Prevalence of Neuropathy and Peripheral Arterial Disease and the Impact of Treatment in People With Screen-Detected Type 2 Diabetes.Diabetes Care. 34. 2244-2249.
http://care.diabetesjournals.org/content/34/10/2244.abstract
NHANES III
2003. Alexander Charles M., Landsman Pamela B., Teutsch Steven M. and Haffner Steven M. NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older.Diabetes. 52. 1210-1214.
http://diabetes.diabetesjournals.org/content/52/5/1210.abstract
NHS Politics
2011. Lister Sam. The politics of NHS reconfiguration.British Medical Journal. 343.
http://www.bmj.com/content/343/bmj.d5311.short
Niacin
2012. Guyton John R., Fazio Sergio, Adewale Adeniyi J., Jensen Erin, Tomassini Joanne E., Shah Arvind and Tershakovec Andrew M. Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial.Diabetes Care. 35. 857-860.
http://care.diabetesjournals.org/content/35/4/857.abstract
NICECG10
2004. NICECG10. Type 2 diabetes: Foot care.DoH.
http://www.nice.org.uk/nicemedia/live/10934/29242/29242.pdf
NICECG15
2004. NICECG15. Type 1 diabetes: diagnosis and management of type 1diabetes in childrenand young people.DoH.
http://www.nice.org.uk/nicemedia/live/10944/29394/29394.pdf
NICECG15
2004. NICECG15. Type 1 diabetes in adults: Part 1.DoH.
http://www.nice.org.uk/nicemedia/live/10944/29393/29393.pdf
NICECG15
2008. NICECG15. Type 1 diabetes in adults: Part 2.DoH.
http://www.nice.org.uk/nicemedia/live/10944/29396/29396.pdf
NICECG62
2008. NICECG62. Antenatal care.DoH.
http://www.nice.org.uk/nicemedia/live/11947/40145/40145.pdf
NICECG63
2008. NICECG63. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period.DoH.
http://www.nice.org.uk/nicemedia/live/11946/41320/41320.pdf
NICECG66
2008. NICECG66. Type 2 diabetes.DoH.
http://www.nice.org.uk/nicemedia/live/11983/40803/40803.pdf
NICECG87
2009. NICECG87. Type 2 diabetes: newer agents DoH.
http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf
NICECG114
2011. NICECG114. Anaemia management in chronic kidney disease.DoH.
http://www.nice.org.uk/nicemedia/live/13329/52851/52851.pdf
NICECG119
2011. NICECG119. Diabetic foot problems: Inpatient management of diabetic foot problems DoH.
http://www.nice.org.uk/nicemedia/live/13416/53556/53556.pdf
NICECGTA53
2002. NICECGTA53. Guidance on the use oflong-acting insulin analoguesfor thetreatment ofdiabetes – insulin glargine.DoH.
http://guidance.nice.org.uk/TA53/Guidance/pdf/English
NICECGTA60
2003. NICECGTA60. Guidance on the use of patient-education models for diabetes.DoH.
http://www.nice.org.uk/nicemedia/live/11496/32610/32610.pdf
NICECGTA151
2003. NICECGTA151. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus DoH.
http://www.nice.org.uk/nicemedia/live/12014/41300/41300.pdf
NICETA203
2010. NICETA203. Liraglutide for treatment of Diabetes Type 2.DoH.
http://www.nice.org.uk/nicemedia/live/13248/51259/51259.pdf
NIDDA study
2011. Bao Jiansong, Gilbertson Heather R., Gray Robyn, Munns Diane, Howard Gabrielle, Petocz Peter, Colagiuri Stephen and Brand-Miller Jennie C. Improving the Estimation of Mealtime Insulin Dose in Adults With Type 1 Diabetes.Diabetes Care. 34. 2146-2151.
http://care.diabetesjournals.org/content/34/10/2146.abstract
NIPPON DATA90
2013. Sakurai Masaru, Saitoh Shigeyuki, Miura Katsuyuki, Nakagawa Hideaki, Ohnishi Hirofumi, Akasaka Hiroshi, Kadota Aya, Kita Yoshikuni, Hayakawa Takehito, Ohkubo Takayoshi, Okayama Akira, Okamura Tomonori, Ueshima Hirotsugu and Group for the NIPPON DATA90 Research. HbA1c and the Risks for All-Cause and Cardiovascular Mortality in the General Japanese Population: NIPPON DATA90.Diabetes Care. 36. 3759-3765.
http://care.diabetesjournals.org/content/36/11/3759.abstract
Back to Top
Obesity
2004. Klein Samuel, Sheard Nancy F., Pi-Sunyer Xavier, Daly Anne, Wylie-Rosett Judith, Kulkarni Karmeen and Clark Nathaniel G. Weight Management Through Lifestyle Modification for the Prevention and Management of Type 2 Diabetes: Rationale and Strategies.Diabetes Care. 27. 2067-2073.
http://care.diabetesjournals.org/content/27/8/2067.short
Obesity
2007. Christensen Robin, Kristensen Pernelle Kruse, Bartels Else Marie, Bliddal Henning and Astrup Arne. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.The Lancet. 370. 1706-1713.
http://www.sciencedirect.com/science/article/pii/S0140673607617218
Obesity
2011. Power Chris and Thomas Claudia. Changes in BMI, Duration of Overweight and Obesity, and Glucose Metabolism: 45 Years of Follow-up of a Birth Cohort.Diabetes Care. 34. 1986-1991.
http://care.diabetesjournals.org/content/34/9/1986.abstract
Obesity
2012. Straznicky Nora E., Grima Mariee T., Sari Carolina I., Eikelis Nina, Lambert Elisabeth A., Nestel Paul J., Esler Murray D., Dixon John B., Chopra Reena, Tilbrook Alan J., Schlaich Markus P. and Lambert Gavin W. Neuroadrenergic Dysfunction Along the Diabetes Continuum.Diabetes. 61. 2506-2516.
http://diabetes.diabetesjournals.org/content/61/10/2506.abstract
Obesity
2012. Andersson C., van Gaal L., Caterson I., Weeke P., James W., Couthino W., Finer N., Sharma A., Maggioni A. and Torp-Pedersen C. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes.Diabetologia. 55. 2348-2355.
http://dx.doi.org/10.1007/s00125-012-2584-3
Obesity
2012. Kabadi Shaum M., Lee Brian K. and Liu Longjian. Joint Effects of Obesity and Vitamin D Insufficiency on Insulin Resistance and Type 2 Diabetes.Diabetes Care. 35. 2048-2054.
http://care.diabetesjournals.org/content/35/10/2048.abstract
Obesity
2012. Paul S., Best J., Klein K., Han J. and Maggs D. Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.Diabetes, Obesity and Metabolism. 14. 826-834.
http://dx.doi.org/10.1111/j.1463-1326.2012.01609.x
Obesity
2013. Aronne Louis J., Wadden Thomas A., Peterson Craig, Winslow David, Odeh Sarah and Gadde Kishore M. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.Obesity. 21. 2163-2171.
http://dx.doi.org/10.1002/oby.20584
Obesity
2013. Midthjell K., Lee C. M. Y., Langhammer A., Krokstad S., Holmen T. L., Hveem K., Colagiuri S. and Holmen J. Trends in overweight and obesity over 22 years in a large adult population: the HUNT Study, Norway.Clinical Obesity. 3. 12-20.
http://dx.doi.org/10.1111/cob.12009
Obesity
2013. Attard Samantha M., Herring Amy H., Howard Annie Green and Gordon-Larsen Penny. Longitudinal trajectories of BMI and cardiovascular disease risk: The national longitudinal study of adolescent health.Obesity. 21. 2180-2188.
http://dx.doi.org/10.1002/oby.20569
Obesity
2013. Jakubowicz Daniela, Barnea Maayan, Wainstein Julio and Froy Oren. High Caloric intake at breakfast vs. dinner differentially influences weight loss of overweight and obese women.Obesity. 21. 2504-2512.
http://dx.doi.org/10.1002/oby.20460
Obesity
2013. Saad Farid, Haider Ahmad, Doros Gheorghe and Traish Abdulmaged. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss.Obesity. 21. 1975-1981.
http://dx.doi.org/10.1002/oby.20407
Obesity
2013. Nackers Lisa M., Middleton Kathryn R., Dubyak Pamela J., Daniels Michael J., Anton Stephen D. and Perri Michael G. Effects of prescribing 1,000 versus 1,500 kilocalories per day in the behavioral treatment of obesity: A randomized trial.Obesity. 21. 2481-2487.
http://dx.doi.org/10.1002/oby.20439
Obesity
2013. Hollander Priscilla, Gupta Alok K., Plodkowski Raymond, Greenway Frank, Bays Harold, Burns Colleen, Klassen Preston, Fujioka Ken and Group for the COR-Diabetes Study. Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes.Diabetes Care. 36. 4022-4029.
http://care.diabetesjournals.org/content/36/12/4022.abstract
Obesity
2013. Donnelly Joseph E., Goetz Jeannine, Gibson Cheryl, Sullivan Debra K., Lee Robert, Smith Bryan K., Lambourne Kate, Mayo Matthew S., Hunt Suzanne, Lee Jae Hoon, Honas Jeffrey J. and Washburn Richard A. Equivalent weight loss for weight management programs delivered by phone and clinic.Obesity. 21. 1951-1959.
http://dx.doi.org/10.1002/oby.20334
Obesity
2013. Logue Jennifer, Walker Jeremy J., Leese Graham, Lindsay Robert, McKnight John, Morris Andrew, Philip Sam, Wild Sarah, Sattar Naveed and Group on behalf of the Scottish Diabetes Research Network Epidemiology. Association Between BMI Measured Within a Year After Diagnosis of Type 2 Diabetes and Mortality.Diabetes Care. 36. 887-893.
http://care.diabetesjournals.org/content/36/4/887.abstract
Obesity
2013. Rothberg Amy E., McEwen Laura N., Fraser Tom, Burant Charles F. and Herman William H. The impact of a managed care obesity intervention on clinical outcomes and costs: A prospective observational study.Obesity. 21. 2157-2162.
http://dx.doi.org/10.1002/oby.20597
Obesity
2013. Reis Jared P., Hankinson Arlene L., Loria Catherine M., Lewis Cora E., Powell-Wiley Tiffany, Wei Gina S. and Liu Kiang. Duration of Abdominal Obesity Beginning in Young Adulthood and Incident Diabetes Through Middle Age: The CARDIA Study.Diabetes Care. 36. 1241-1247.
http://care.diabetesjournals.org/content/36/5/1241.abstract
Obesity
2014. Smith Steven R., O'Neil Patrick M., Astrup Arne, Finer Nicholas, Sanchez-Kam Matilde, Fraher Kyle, Fain Randi and Shanahan William R. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes.Obesity. 22. 2137-2146.
http://dx.doi.org/10.1002/oby.20841
Obesity
2014. Chilton M., Dunkley A., Carter P., Davies M. J., Khunti K. and Gray L. J. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison.Diabetes, Obesity and Metabolism. 16. 237-247.
http://dx.doi.org/10.1111/dom.12198
OHGA
1999. Fisman E. Z., Tenenbaum A., Benderly M., Goldbourt U., Behar S. and Motro M. Antihyperglycemic Treatment in Diabetics with Coronary Disease: Increased Metformin-Associated Mortality over a 5-Year Follow-Up.Cardiology. 91. 195-202.
http://www.karger.com/DOI/10.1159/000006909
OHGA
2008. Nissen Steven E., Nicholls Stephen J., Wolski Kathy, Nesto Richard, Kupfer Stuart, Perez Alfonso, Jure Horacio, De Larochellière Robert, Staniloae Cezar S., Mavromatis Kreton, Saw Jacqueline, Hu Bo, Lincoff A. Michael and Tuzcu E. Murat. Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes.The Journal of the American Medical Association. 299. 1561-1573.
http://jama.ama-assn.org/content/299/13/1561.abstract
OHGA
2010. Zinman Bernard, Haffner Steven M., Herman William H., Holman Rury R., Lachin John M., Kravitz Barbara G., Paul Gitanjali, Jones Nigel P., Aftring R. Paul, Viberti Giancarlo, Kahn Steven E. and Group the A Diabetes Outcome Progression Trial Study. Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes.Journal of Clinical Endocrinology & Metabolism. 95. 134-142.
http://jcem.endojournals.org/content/95/1/134.abstract
OHGA
2011. Kong A. P. S., Yamasaki A., Ozaki R., Saito H., Asami T., Ohwada S., Ko G. T. C., Wong C. K., Leung G. T. C., Lee K. F., Yeung C. Y. and Chan J. C. N. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose–lipid control in type 2 diabetes.Diabetes, Obesity and Metabolism. 13. 806-813.
http://dx.doi.org/10.1111/j.1463-1326.2011.01411.x
OHGA
2012. Hirst Jennifer A., Farmer Andrew J., Ali Raghib, Roberts Nia W. and Stevens Richard J. Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control.Diabetes Care. 35. 446-454.
http://care.diabetesjournals.org/content/35/2/446.abstract
OHGA
2013. Khunti Kamlesh, Wolden Michael L., Thorsted Brian Larsen, Andersen Marc and Davies Melanie J. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people.Diabetes Care. 36. 3411-3417.
http://care.diabetesjournals.org/content/36/11/3411.abstract
OHGA
2013. Fouqueray Pascale, Pirags Valdis, Inzucchi Silvio E., Bailey Clifford J., Schernthaner Guntram, Diamant Michaela and Lebovitz Harold E. The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.Diabetes Care. 36. 565-568.
http://care.diabetesjournals.org/content/36/3/565.abstract
OHGA
2013. Scheen A. J. and Paquot N. Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes.Diabetes & Metabolism. 39. 179-190.
http://www.sciencedirect.com/science/article/pii/S1262363613000414
OHGA
2013. Foster P. D., Mamdani M. M., Juurlink D. N., Shah B. R., Paterson J. M. and Gomes T. Trends in selection and timing of first-line pharmacotherapy in older patients with Type 2 diabetes diagnosed between 1994 and 2006.Diabetic Medicine. 30. 1209-1213.
http://dx.doi.org/10.1111/dme.12214
OMEGA
2010. Neil H. A. W., Ceglarek U., Thiery J., Paul S., Farmer A. and Holman R. R. Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled factorial trial.Atherosclerosis. 213. 512-517.
http://www.sciencedirect.com/science/article/pii/S0021915010007410
OpT2mise
2014. Reznik Yves, Cohen Ohad, Aronson Ronnie, Conget Ignacio, Runzis Sarah, Castaneda Javier and Lee Scott W. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial.The Lancet. 384. 1265-1272.
http://linkinghub.elsevier.com/retrieve/pii/S0140673614610370
OPTIMA Study
2012. Guerci B., Monnier L., Serusclat P., Petit C., Valensi P., Huet D., Raccah D., Colette C., Quéré S. and Dejager S. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized Optima study.Diabetes & Metabolism. 38. 359-366.
http://www.sciencedirect.com/science/article/pii/S1262363612001152
OPTIMISE
2013. Hermans Michel P., Elisaf Moses, Michel Georges, Muls Erik, Nobels Frank, Vandenberghe Hans, Brotons Carlos and Committee for the OPTIMISE International Steering. Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes: The OPTIMISE randomized, controlled trial.Diabetes Care. 36. 3388-3395.
http://care.diabetesjournals.org/content/36/11/3388.abstract
ORIGIN Study
2013. Investigators The ORIGIN Trial. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial.Diabetes Care. 36. 2915-2922.
http://care.diabetesjournals.org/content/36/10/2915.abstract
OSIRIS Study
2012. Raccah D., Haak T. J., Huet D., Monnier L., Robertson D., Labard P., Soler J. and Penfornis A. Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: Results of the OSIRIS study.Diabetes & Metabolism. 38. 507-514.
http://www.sciencedirect.com/science/article/pii/S1262363612001577
Osteomyelitis
2014. Lázaro-Martínez José Luis, Aragón-Sánchez Javier and García-Morales Esther. Antibiotics Versus Conservative Surgery for Treating Diabetic Foot Osteomyelitis: A Randomized Comparative Trial.Diabetes Care. 37. 789-795.
http://care.diabetesjournals.org/content/37/3/789.abstract
Back to Top
Paediatric
2013. Thompson R. J., Agostini K., Potts L., Luscombe J., Christie D., Viner R., White B. and Hindmarsh P. C. Deprivation and ethnicity impact on diabetes control and use of treatment regimen.Diabetic Medicine. 30. 491-494.
http://dx.doi.org/10.1111/dme.12023
PCOS
2012. Gambineri Alessandra, Patton Laura, Altieri Paola, Pagotto Uberto, Pizzi Carmine, Manzoli Lamberto and Pasquali Renato. Polycystic Ovary Syndrome Is a Risk Factor for Type 2 Diabetes.Diabetes. 61. 2369-2374.
http://diabetes.diabetesjournals.org/content/61/9/2369.abstract
Postprandial
2007. Monnier Louis, Colette Claude, Dunseath Gareth J. and Owens David R. The Loss of Postprandial Glycemic Control Precedes Stepwise Deterioration of Fasting With Worsening Diabetes.Diabetes Care. 30. 263-269.
http://care.diabetesjournals.org/content/30/2/263.abstract
Postprandial
2012. Clark Nathaniel G. Postprandial Blood Glucose, Cardiovascular Events, and All-Cause Mortality: How Do We Use Postprandial Glucose in Clinical Practice?Clinical Diabetes. 30. 67-69.
http://clinical.diabetesjournals.org/content/30/2/67.short
PPAR
2012. Chou H. S., Truitt K. E., Moberly J. B., Merante D., Choi Y., Mun Y. and Pfützner A. A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus.Diabetes, Obesity and Metabolism. 14. 1000-1009.
http://dx.doi.org/10.1111/j.1463-1326.2012.01631.x
PPAR
2012. Wilding J. P. H. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.Diabetes, Obesity and Metabolism. 14. 973-982.
http://dx.doi.org/10.1111/j.1463-1326.2012.01601.x
Pre-Eclampsia Intervention trial
2011. Holmes Valerie A., Young Ian S., Patterson Christopher C., Pearson Donald W.M., Walker James D., Maresh Michael J.A., McCance David R., Diabetes for the and Group Pre-eclampsia Intervention Trial Study. Optimal Glycemic Control, Pre-eclampsia, and Gestational Hypertension in Women With Type 1 Diabetes in the Diabetes and Pre-eclampsia Intervention Trial.Diabetes Care. 34. 1683-1688.
http://care.diabetesjournals.org/content/34/8/1683.abstract
Prediabetes
2013. Chatterjee Ranee, Narayan K.M. Venkat, Lipscomb Joseph, Jackson Sandra L., Long Qi, Zhu Ming and Phillips Lawrence S. Screening for Diabetes and Prediabetes Should Be Cost-Saving in Patients at High Risk.Diabetes Care. 36. 1981-1987.
http://care.diabetesjournals.org/content/36/7/1981.abstract
Predicting Diabetes
2012. Mukai N., Doi Y., Ninomiya T., Hata J., Hirakawa Y., Fukuhara M., Iwase M. and Kiyohara Y. Cut-off values of fasting and post-load plasma glucose and HbA1c for predicting Type 2 diabetes in community-dwelling Japanese subjects: the Hisayama Study.Diabetic Medicine. 29. 99-106.
http://dx.doi.org/10.1111/j.1464-5491.2011.03378.x
Predicting Diabetes
2012. Won H. K., Kim K. J., Lee B. W., Kang E. S., Cha B. S. and Lee H. C. Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments.Diabetic Medicine. 29. 74-79.
http://dx.doi.org/10.1111/j.1464-5491.2011.03386.x
Predicting Diabetes
2012. Sattar N. Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities.Diabetic Medicine. 29. 5-13.
http://dx.doi.org/10.1111/j.1464-5491.2011.03480.x
Predicting Diabetes
2012. Doi Y., Ninomiya T., Hata J., Hirakawa Y., Mukai N., Iwase M. and Kiyohara Y. Two risk score models for predicting incident Type 2 diabetes in Japan.Diabetic Medicine. 29. 107-114.
http://dx.doi.org/10.1111/j.1464-5491.2011.03376.x
PREDIMED
2011. Salas-Salvadó J., Bulló M., Babio N., Martínez-González M.Á., Ibarrola-Jurado N., Basora J., Estruch R., Covas M.I., Corella D. and Arós F. Reduction in the Incidence of Type 2 Diabetes With the Mediterranean Diet. Results of the PREDIMED-Reus nutrition intervention randomized trial.Diabetes Care. 34. 14.
http://care.diabetesjournals.org/content/34/1/14.abstract
Pregabalin
2011. Satoh J., Yagihashi S., Baba M., Suzuki M., Arakawa A., Yoshiyama T. and Shoji S. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial.Diabetic Medicine. 28. 109-116.
http://dx.doi.org/10.1111/j.1464-5491.2010.03152.x
Pregnancy
2013. Secher Anna L., Ringholm Lene, Andersen Henrik U., Damm Peter and Mathiesen Elisabeth R. The Effect of Real-Time Continuous Glucose Monitoring in Pregnant Women With Diabetes: A randomized controlled trial.Diabetes Care. 36. 1877-1883.
http://care.diabetesjournals.org/content/36/7/1877.abstract
Pregnancy
2013. Damm Julie Agner, Ásbjörnsdóttir Björg, Callesen Nicoline Foged, Mathiesen Jonathan M., Ringholm Lene, Pedersen Berit Woetmann and Mathiesen Elisabeth R. Diabetic Nephropathy and Microalbuminuria in Pregnant Women With Type 1 and Type 2 Diabetes: Prevalence, antihypertensive strategy, and pregnancy outcome.Diabetes Care. 36. 3489-3494.
http://care.diabetesjournals.org/content/36/11/3489.abstract
PREPARE Study
2011. Yates T., Davies M. J., Sehmi S., Gorely T. and Khunti K. The Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: are improvements in glucose regulation sustained at 2 years?Diabetic Medicine. 28. 1268-1271.
http://dx.doi.org/10.1111/j.1464-5491.2011.03357.x
Prevention
2011. Phung O. J., Sood N. A., Sill B. E. and Coleman C. I. Oral anti-diabetic drugs for the prevention of Type 2 diabetes.Diabetic Medicine. 28. 948-964.
http://dx.doi.org/10.1111/j.1464-5491.2011.03303.x
PRISMA Study
2013. Bosi Emanuele, Scavini Marina, Ceriello Antonio, Cucinotta Domenico, Tiengo Antonio, Marino Raffaele, Bonizzoni Erminio, Giorgino Francesco and Group on behalf of the PRISMA Study. Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes: The PRISMA randomized trial.Diabetes Care. 36. 2887-2894.
http://care.diabetesjournals.org/content/36/10/2887.abstract
PRISMAS
2013. Hermanns Norbert, Kulzer Bernhard, Ehrmann Dominic, Bergis-Jurgan Nikola and Haak Thomas. The effect of a diabetes education programme (PRIMAS) for people with type 1 diabetes: Results of a randomized trial.Diabetes research and clinical practice. 102. 149-157.
http://linkinghub.elsevier.com/retrieve/pii/S0168822713003513?showall=true
PROactive
2005. Dormandy John A., Charbonnel Bernard, Eckland David J. A., Erdmann Erland, Massi-Benedetti Massimo, Moules Ian K., Skene Allan M., Tan Meng H., Lefèbvre Pierre J., Murray Gordon D., Standl Eberhard, Wilcox Robert G., Wilhelmsen Lars, Betteridge John, Birkeland Kåre, Golay Alain, Heine Robert J., Korányi László, Laakso Markku, Moká Marián, Norkus Antanas, Pirags Valdis, Podar Toomas, Scheen André, Scherbaum Werner, Schernthaner Guntram, Schmitz Ole, krha Jan, Smith Ulf and Tato Jan. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.The Lancet. 366. 1279-1289.
http://linkinghub.elsevier.com/retrieve/pii/S0140673605675289
PROactive
2011. Pfister R., Cairns R., Erdmann E., Schneider C. A. and on behalf of the PROactive investigators. Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study.Diabetic Medicine. 28. 1206-1212.
http://dx.doi.org/10.1111/j.1464-5491.2011.03281.x
PROactive study
2014. Erdmann E., Song E., Spanheimer R., van Troostenburg de Bruyn A. R. and Perez A. Observational follow-up of the PROactive study: a 6-year update.Diabetes, Obesity and Metabolism. 16. 63-74.
http://dx.doi.org/10.1111/dom.12180
Protege Study
2011. Sherry Nicole, Hagopian William, Ludvigsson Johnny, Jain Sunil M., Wahlen Jack, Ferry Robert J., Bode Bruce, Aronoff Stephen, Holland Christopher, Carlin David, King Karen L., Wilder Ronald L., Pillemer Stanley, Bonvini Ezio, Johnson Syd, Stein Kathryn E., Koenig Scott, Herold Kevan C. and Daifotis Anastasia G. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.The Lancet. 378. 487-497.
http://linkinghub.elsevier.com/retrieve/pii/S0140673611609318
Psychology
2013. Fall E., Roche B., Izaute M., Batisse M., Tauveron I. and Chakroun N. A brief psychological intervention to improve adherence in type 2 diabetes.Diabetes & Metabolism. 39. 432-438.
http://www.sciencedirect.com/science/article/pii/S1262363613000931
Pulsatile Insulin
2011. Menge Björn A., Grüber Lena, Jørgensen Signe M., Deacon Carolyn F., Schmidt Wolfgang E., Veldhuis Johannes D., Holst Jens J. and Meier Juris J. Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes.Diabetes. 60. 2160-2168.
http://diabetes.diabetesjournals.org/content/60/8/2160.abstract
Back to Top
QDSCORE
2011. Collins G. S. and Altman D. G. External validation of QDSCORE® for predicting the 10-year risk of developing Type 2 diabetes.Diabetic Medicine. 28. 599-607.
http://dx.doi.org/10.1111/j.1464-5491.2011.03237.x
QoL
2006. Clarke Philip M., Simon Judit, Cull Carole A. and Holman Rury R. Assessing the Impact of Visual Acuity on Quality of Life in Individuals With Type 2 Diabetes Using the Short Form-36.Diabetes Care. 29. 1506-1511.
http://care.diabetesjournals.org/content/29/7/1506.abstract
QoL
2011. Janssen M. F., Lubetkin E. I., Sekhobo J. P. and Pickard A. S. The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus.Diabetic Medicine. 28. 395-413.
http://dx.doi.org/10.1111/j.1464-5491.2010.03136.x
QoL
2011. Hajos T. R. S., Pouwer F., de Grooth R., Holleman F., Twisk J. W. R., Diamant M. and Snoek F. J. Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care.Diabetic Medicine. 28. 1096-1102.
http://dx.doi.org/10.1111/j.1464-5491.2011.03329.x
QoL
2012. Romain A. J., Bernard P., Attalin V., Gernigon C., Ninot G. and Avignon A. Health-related quality of life and stages of behavioural change for exercise in overweight/obese individuals.Diabetes & Metabolism. 38. 352-358.
http://www.sciencedirect.com/science/article/pii/S1262363612000511
QoL
2012. Williams Emily D., Magliano Dianna J., Zimmet Paul Z., Kavanagh Anne M., Stevenson Christopher E., Oldenburg Brian F. and Shaw Jonathan E. Area-Level Socioeconomic Status and Incidence of Abnormal Glucose Metabolism.Diabetes Care. 35. 1455-1461.
http://care.diabetesjournals.org/content/35/7/1455.abstract
QoL
2012. Schunk M., Reitmeir P., Schipf S., Völzke H., Meisinger C., Thorand B., Kluttig A., Greiser K. H., Berger K., Müller G., Ellert U., Neuhauser H., Tamayo T., Rathmann W. and Holle R. Health-related quality of life in subjects with and without Type 2 diabetes: pooled analysis of five population-based surveys in Germany.Diabetic Medicine. 29. 646-653.
http://dx.doi.org/10.1111/j.1464-5491.2011.03465.x
QoL
2013. Cooke Debbie, O’Hara Mary Clare, Beinart Naomi, Heller Simon, La Marca Roberto, Byrne Molly, Mansell Peter, Dinneen Sean F., Clark Marie, Bond Rod, Speight Jane and Group for the U.K. NIHR DAFNE Study. Linguistic and Psychometric Validation of the Diabetes-Specific Quality-of-Life Scale in U.K. English for Adults With Type 1 Diabetes.Diabetes Care. 36. 1117-1125.
http://care.diabetesjournals.org/content/36/5/1117.abstract
QoL
2013. van Son Jenny, Nyklíček Ivan, Pop Victor J., Blonk Marion C., Erdtsieck Ronald J., Spooren Pieter F., Toorians Arno W. and Pouwer François. The Effects of a Mindfulness-Based Intervention on Emotional Distress, Quality of Life, and HbA1c in Outpatients With Diabetes (DiaMind): A randomized controlled trial.Diabetes Care. 36. 823-830.
http://care.diabetesjournals.org/content/36/4/823.abstract
Back to Top
RABBIT 2
2011. Umpierrez Guillermo E., Smiley Dawn, Jacobs Sol, Peng Limin, Temponi Angel, Mulligan Patrick, Umpierrez Denise, Newton Christopher, Olson Darin and Rizzo Monica. Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery).Diabetes Care. 34. 256-261.
http://care.diabetesjournals.org/content/34/2/256.abstract
Ramadan
2012. Ahmedani M. Y., Haque M. S., Basit A., Fawwad A. and Alvi S. F. D. Ramadan Prospective Diabetes Study: the role of drug dosage and timing alteration, active glucose monitoring and patient education.Diabetic Medicine. 29. 709-715.
http://dx.doi.org/10.1111/j.1464-5491.2011.03563.x
Red Blood Cells
2012. Malandrino N., Wu W., Taveira T., Whitlatch H. and Smith R. Association between red blood cell distribution width and macrovascular and microvascular complications in diabetes.Diabetologia. 55. 226-235.
http://dx.doi.org/10.1007/s00125-011-2331-1
RENAAL
2011. Miao Y., Dobre D., Lambers Heerspink H., Brenner B., Cooper M., Parving H. H., Shahinfar S., Grobbee D. and de Zeeuw D. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.Diabetologia. 54. 44-50.
http://dx.doi.org/10.1007/s00125-010-1922-6
RETIDIAB
2011. Beynat J., Ben Mehidi A., Aubert J. P., Bron A. M., Massin P. and Creuzot-Garcher C. RETIDIAB®: Assessment of a continuing medical education website for the improvement of diabetic retinopathy management.Diabetes & Metabolism. 37. 118-123.
http://www.sciencedirect.com/science/article/pii/S1262363610002363
RETINAL
2011. Holfort S., Nørgaard K., Jackson G., Hommel E., Madsbad S., Munch I., Klemp K., Sander B. and Larsen M. Retinal function in relation to improved glycaemic control in type 1 diabetes.Diabetologia. 54. 1853-1861.
http://dx.doi.org/10.1007/s00125-011-2149-x
Retinopathy
2011. Aspelund T., Þórisdóttir Ó, Ólafsdottir E., Gudmundsdottir A., Einarsdóttir A., Mehlsen J., Einarsson S., Pálsson Ó, Einarsson G., Bek T. and Stefánsson E. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy.Diabetologia. 54. 2525-2532.
http://dx.doi.org/10.1007/s00125-011-2257-7
Retinopathy
2011. Agardh Elisabet and Tababat-Khani Poya. Adopting 3-Year Screening Intervals for Sight-Threatening Retinal Vascular Lesions in Type 2 Diabetic Subjects Without Retinopathy.Diabetes Care. 34. 1318-1319.
http://care.diabetesjournals.org/content/34/6/1318.abstract
Retinopathy
2011. Kramer Caroline K., Rodrigues Ticiana C., Canani Luis H., Gross Jorge L. and Azevedo Mirela J. Diabetic Retinopathy Predicts All-Cause Mortality and Cardiovascular Events in Both Type 1 and 2 Diabetes.Diabetes Care. 34. 1238-1244.
http://care.diabetesjournals.org/content/34/5/1238.abstract
Retinopathy
2011. Romero-Aroca Pedro, Baget-Bernaldiz Marc, Fernandez-Ballart Juan, Plana-Gil Nuria, Soler-Lluis Nuria, Mendez-Marin Isabel and Bautista-Perez Angel. Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes.Diabetes research and clinical practice. 94. 126-132.
http://linkinghub.elsevier.com/retrieve/pii/S0168822711003548?showall=true
Retinopathy
2011. Gunnlaugsdottir E., Halldorsdottir S., Klein R., Eiriksdottir G., Klein B., Benediktsson R., Harris T., Launer L., Aspelund T., Gudnason V., Cotch M. and Jonasson F. Retinopathy in old persons with and without diabetes mellitus: the Age, Gene/Environment Susceptibility—Reykjavik Study (AGES-R).Diabetologia. 1-10.
http://dx.doi.org/10.1007/s00125-011-2395-y
Retinopathy
2011. Downie Elizabeth, Craig Maria E., Hing Stephen, Cusumano Janine, Chan Albert K.F. and Donaghue Kim C. Continued Reduction in the Prevalence of Retinopathy in Adolescents With Type 1 Diabetes.Diabetes Care. 34. 2368-2373.
http://care.diabetesjournals.org/content/34/11/2368.abstract
Retinopathy
2012. Goatman K. A., Philip S., Fleming A. D., Harvey R. D., Swa K. K., Styles C., Black M., Sell G., Lee N., Sharp P. F. and Olson J. A. External quality assurance for image grading in the Scottish Diabetic Retinopathy Screening Programme.Diabetic Medicine. 29. 776-783.
http://dx.doi.org/10.1111/j.1464-5491.2011.03504.x
Retinopathy
2012. Thomas R L, Dunstan F, Luzio S D, Chowdury S Roy, Hale S L, North R V, Gibbins R L and Owens D R. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis.British Medical Journal. 344.
Retinopathy
2012. van Eijk K. N. D., Blom J. W., Gussekloo J., Polak B. C. P. and Groeneveld Y. Diabetic retinopathy screening in patients with diabetes mellitus in primary care: Incentives and barriers to screening attendance.Diabetes research and clinical practice. 96. 10-16.
http://www.sciencedirect.com/science/article/pii/S0168822711006267
Retinopathy
2012. Sasongko Muhammad Bayu, Wong Tien Y., Nguyen Thanh T., Kawasaki Ryo, Jenkins Alicia J., Shaw Jonathan, Robinson Carol and Wang Jie Jin. Serum Apolipoproteins Are Associated With Systemic and Retinal Microvascular Function in People With Diabetes.Diabetes. 61. 1785-1792.
http://diabetes.diabetesjournals.org/content/61/7/1785.abstract
Retinopathy
2012. Jones Colin D., Greenwood Richard H., Misra Aseema and Bachmann Max O. Incidence and Progression of Diabetic Retinopathy During 17 Years of a Population-Based Screening Program in England.Diabetes Care. 35. 592-596.
http://care.diabetesjournals.org/content/35/3/592.abstract
Retinopathy
2012. Yau Joanne W.Y., Rogers Sophie L., Kawasaki Ryo, Lamoureux Ecosse L., Kowalski Jonathan W., Bek Toke, Chen Shih-Jen, Dekker Jacqueline M., Fletcher Astrid, Grauslund Jakob, Haffner Steven, Hamman Richard F., Ikram M. Kamran, Kayama Takamasa, Klein Barbara E.K., Klein Ronald, Krishnaiah Sannapaneni, Mayurasakorn Korapat, O’Hare Joseph P., Orchard Trevor J., Porta Massimo, Rema Mohan, Roy Monique S., Sharma Tarun, Shaw Jonathan, Taylor Hugh, Tielsch James M., Varma Rohit, Wang Jie Jin, Wang Ningli, West Sheila, Xu Liang, Yasuda Miho, Zhang Xinzhi, Mitchell Paul, Wong Tien Y. and Group for the Meta-Analysis for Eye Disease Study. Global Prevalence and Major Risk Factors of Diabetic Retinopathy.Diabetes Care. 35. 556-564.
http://care.diabetesjournals.org/content/35/3/556.abstract
Retinopathy
2012. Martín-Merino Elisa, Fortuny Joan, Rivero Elena and García-Rodríguez Luis Alberto. Validation of Diabetic Retinopathy and Maculopathy Diagnoses Recorded in a U.K. Primary Care Database.Diabetes Care. 35. 762-767.
http://care.diabetesjournals.org/content/35/4/762.abstract
Retinopathy
2012. Yeo S. T., Edwards R. T., Luzio S. D., Charles J. M., Thomas R. L., Peters J. M. and Owens D. R. Diabetic retinopathy screening: perspectives of people with diabetes, screening intervals and costs of attending screening.Diabetic Medicine. 29. 878-885.
http://dx.doi.org/10.1111/j.1464-5491.2012.03637.x
Retinopathy
2012. Chalk Daniel, Pitt Martin, Vaidya Bijay and Stein Ken. Can the Retinal Screening Interval Be Safely Increased to 2 Years for Type 2 Diabetic Patients Without Retinopathy?Diabetes Care. 35. 1663-1668.
http://care.diabetesjournals.org/content/35/8/1663.abstract
Retinopathy
2012. Yeo S. T., Edwards R. T., Fargher E. A., Luzio S. D., Thomas R. L. and Owens D. R. Preferences of people with diabetes for diabetic retinopathy screening: a discrete choice experiment.Diabetic Medicine. 29. 869-877.
http://dx.doi.org/10.1111/j.1464-5491.2012.03636.x
Retinopathy
2013. Hall H. N., Chinn D. J., Sinclair A. and Styles C. J. Epidemiology of blindness attributable to diabetes in Scotland: change over 20 years in a defined population.Diabetic Medicine. 30. 1349-1354.
http://dx.doi.org/10.1111/dme.12223
Retinopathy
2013. Echouffo–Tcheugui J. B., Ali M. K., Roglic G., Hayward R. A. and Narayan K. M. Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review.Diabetic Medicine. 30. 1272-1292.
http://dx.doi.org/10.1111/dme.12274
Retinopathy
2013. Heng L. Z., Comyn O., Peto T., Tadros C., Ng E., Sivaprasad S. and Hykin P. G. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments.Diabetic Medicine. 30. 640-650.
http://dx.doi.org/10.1111/dme.12089
Retinopathy
2013. Forster AliceS, Forbes Angus, Dodhia Hiten, Connor Clare, Chemin Alain, Sivaprasad Sobha, Mann Samantha and Gulliford MartinC. Non-attendance at diabetic eye screening and risk of sight-threatening diabetic retinopathy: a population-based cohort study.Diabetologia. 56. 2187-2193.
http://dx.doi.org/10.1007/s00125-013-2975-0
Retinopathy
2013. Cho NamH, Kim TaeHyuk, Woo SeJoon, Park KyuHyung, Lim Soo, Cho YoungMin, Park KyongSoo, Jang HakC and Choi SungHee. Optimal HbA1c cutoff for detecting diabetic retinopathy.Acta Diabetol. 50. 837-842.
http://dx.doi.org/10.1007/s00592-013-0452-3
Retinopathy
2013. Harris Nwanyanwu Kristen, Talwar Nidhi, Gardner Thomas W., Wrobel James S., Herman William H. and Stein Joshua D. Predicting Development of Proliferative Diabetic Retinopathy.Diabetes Care. 36. 1562-1568.
http://care.diabetesjournals.org/content/36/6/1562.abstract
Review
2012. Hellemons M. E., Kerschbaum J., Bakker S. J. L., Neuwirt H., Mayer B., Mayer G., de Zeeuw D., Lambers Heerspink H. J. and Rudnicki M. Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review.Diabetic Medicine. 29. 567-577.
http://dx.doi.org/10.1111/j.1464-5491.2011.03437.x
Review
2012. Colagiuri S. Optimal management of type 2 diabetes: the evidence.Diabetes, Obesity and Metabolism. 14. 3-8.
http://dx.doi.org/10.1111/j.1463-1326.2011.01506.x
Review
2012. Scheen A. J. DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials.Diabetes & Metabolism. 38. 89-101.
http://www.sciencedirect.com/science/article/pii/S1262363611002060
Review
2012. Richard J. L., Almasri M. and Schuldiner S. Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature.Diabetologia. 55. 1258-1264.
http://dx.doi.org/10.1007/s00125-012-2507-3
Review
2012. Best James D., Drury Paul L., Davis Timothy M.E., Taskinen Marja-Riitta, Kesäniemi Y. Antero, Scott Russell, Pardy Christopher, Voysey Merryn, Keech Anthony C., Intervention on behalf of the Fenofibrate and Investigators Event Lowering in Diabetes Study. Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes.Diabetes Care. 35. 1165-1170.
http://care.diabetesjournals.org/content/35/5/1165.abstract
Review
2012. Chimen M., Kennedy A., Nirantharakumar K., Pang T., Andrews R. and Narendran P. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review.Diabetologia. 55. 542-551.
http://dx.doi.org/10.1007/s00125-011-2403-2
Review
2012. Dale J. R., Williams S. M. and Bowyer V. What is the effect of peer support on diabetes outcomes in adults? A systematic review.Diabetic Medicine. 29. 1361-1377.
http://dx.doi.org/10.1111/j.1464-5491.2012.03749.x
Review
2012. Rotenstein Lisa S., Kozak Benjamin M., Shivers Joseph P., Yarchoan Mark, Close John and Close Kelly L. The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?Clinical Diabetes. 30. 44-53.
http://clinical.diabetesjournals.org/content/30/2/44.abstract
Review
2012. Dellasega Cheryl, Añel-Tiangco Raquel M. and Gabbay Robert A. How patients with type 2 diabetes mellitus respond to motivational interviewing.Diabetes research and clinical practice. 95. 37-41.
http://www.sciencedirect.com/science/article/pii/S0168822711004542
Review
2012. Kiran Tara, Victor J. Charles, Kopp Alexander, Shah Baiju R. and Glazier Richard H. The Relationship Between Financial Incentives and Quality of Diabetes Care in Ontario, Canada.Diabetes Care. 35. 1038-1046.
http://care.diabetesjournals.org/content/35/5/1038.abstract
Review
2012. Nirantharakumar K., Chen Y. F., Marshall T., Webber J. and Coleman J. J. Clinical decision support systems in the care of inpatients with diabetes in non-critical care setting: systematic review.Diabetic Medicine. 29. 698-708.
http://dx.doi.org/10.1111/j.1464-5491.2011.03540.x
Review
2012. Buckley B. S., Harreiter J., Damm P., Corcoy R., Chico A., Simmons D., Vellinga A., Dunne F. and on behalf of the Dali Core Investigator Group. Gestational diabetes mellitus in Europe: prevalence, current screening practice and barriers to screening. A review.Diabetic Medicine. 29. 844-854.
http://dx.doi.org/10.1111/j.1464-5491.2011.03541.x
Review
2012. Roy T., Lloyd C. E., Pouwer F., Holt R. I. G. and Sartorius N. Screening tools used for measuring depression among people with Type 1 and Type 2 diabetes: a systematic review.Diabetic Medicine. 29. 164-175.
http://dx.doi.org/10.1111/j.1464-5491.2011.03401.x
RISC
2011. Rebelos Eleni, Muscelli Elza, Natali Andrea, Balkau Beverley, Mingrone Geltrude, Piatti Piermarco, Konrad Thomas, Mari Andrea, Ferrannini Ele and Investigators on behalf of the RISC Study. Body Weight, Not Insulin Sensitivity or Secretion, May Predict Spontaneous Weight Changes in Nondiabetic and Prediabetic Subjects.Diabetes. 60. 1938-1945.
http://diabetes.diabetesjournals.org/content/60/7/1938.abstract
Risk Scores
2011. Lipsky Benjamin A., Weigelt John A., Sun Xiaowu, Johannes Richard S., Derby Karen G. and Tabak Ying P. Developing and Validating a Risk Score for Lower-Extremity Amputation in Patients Hospitalized for a Diabetic Foot Infection.Diabetes Care. 34. 1695-1700.
http://care.diabetesjournals.org/content/34/8/1695.abstract
Risk Scores
2011. Schmid Rémy, Vollenweider Peter, Waeber Gérard and Marques-Vidal Pedro. Estimating the Risk of Developing Type 2 Diabetes: A Comparison of Several Risk Scores.Diabetes Care. 34. 1863-1868.
http://care.diabetesjournals.org/content/34/8/1863.abstract
Risk Scores
2013. Chakkera Harini A., Chang Yu-Hui, Ayub Asad, Gonwa Thomas A., Weil E. Jennifer and Knowler William C. Validation of a Pretransplant Risk Score for New-Onset Diabetes After Kidney Transplantation.Diabetes Care. 36. 2881-2886.
http://care.diabetesjournals.org/content/36/10/2881.abstract
Risk Scores
2013. Kwak SooHeon, Choi SungHee, Kim Kyunga, Jung HyeSeung, Cho YoungMin, Lim Soo, Cho NamH, Kim SeongYeon, Park KyongSoo and Jang HakC. Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score.Diabetologia. 56. 2556-2563.
http://dx.doi.org/10.1007/s00125-013-3059-x
ROSES
2011. Franciosi M., Lucisano G., Pellegrini F., Cantarello A., Consoli A., Cucco L., Ghidelli R., Sartore G., Sciangula L., Nicolucci A. and on behalf of the Roses Study Group. ROSES: role of self-monitoring of blood glucose and intensive education in patients with Type 2 diabetes not receiving insulin. A pilot randomized clinical trial.Diabetic Medicine. 28. 789-796.
http://dx.doi.org/10.1111/j.1464-5491.2011.03268.x
ROSSO
2011. Hoffmann F. and Andersohn F. Immortal time bias and survival in patients who self-monitor blood glucose in the Retrolective Study: Self-monitoring of Blood Glucose and Outcome in Patients with Type 2 Diabetes (ROSSO).Diabetologia. 54. 308-311.
http://dx.doi.org/10.1007/s00125-010-1909-3
Back to Top
SAHS
1998. Wei Ming, Gaskill Sharon P, Haffner Steven M and Stern Michael P. Effects of Diabetes and Level of Glycemia on All-Cause and Cardiovascular Mortality: The San Antonio Heart Study.Diabetes Care. 21. 1167-1172.
http://care.diabetesjournals.org/content/21/7/1167.abstract
San Luigi Gonzaga Diabetes Study
2011. Cavalot Franco, Pagliarino Andrea, Valle Manuela, Di Martino Leonardo, Bonomo Katia, Massucco Paola, Anfossi Giovanni and Trovati Mariella. Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up.Diabetes Care. 34. 2237-2243.
http://care.diabetesjournals.org/content/34/10/2237.abstract
SAVOR-TIMI 53
2014. Raz Itamar, Bhatt Deepak L., Hirshberg Boaz, Mosenzon Ofri, Scirica Benjamin M., Umez-Eronini Amarachi, Im KyungAh, Stahre Christina, Buskila Alona, Iqbal Nayyar, Greenberger Norton and Lerch Markus M. Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin.Diabetes Care. 37. 2435-2441.
http://care.diabetesjournals.org/content/37/9/2435.abstract
SCORE
2003. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., De Bacquer D., Ducimetière P., Jousilahti P., Keil U., Njølstad I., Oganov R.G., Thomsen T., Tunstall-Pedoe H., Tverdal A., Wedel H., Whincup P., Wilhelmsen L. and Graham I.M. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.European Heart Journal. 24. 987-1003.
http://eurheartj.oxfordjournals.org/content/24/11/987.abstract
SCOUT Trial
2012. Caterson I. D., Finer N., Coutinho W., Van Gaal L. F., Maggioni A. P., Torp-Pedersen C., Sharma A. M., Legler U. F., Shepherd G. M., Rode R. A., Perdok R. J., Renz C. L., James W. P. T. and on behalf of the Scout Investigators. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.Diabetes, Obesity and Metabolism. 14. 523-530.
http://dx.doi.org/10.1111/j.1463-1326.2011.01554.x
SDRNEG
2011. Govan Lindsay, Wu Olivia, Briggs Andrew, Colhoun Helen M., Fischbacher Colin M., Leese Graham P., McKnight John A., Philip Sam, Sattar Naveed, Wild Sarah H., Lindsay Robert S. and Group on behalf of the Scottish Diabetes Research Network Epidemiology. Achieved Levels of HbA1c and Likelihood of Hospital Admission in People With Type 1 Diabetes in the Scottish Population.Diabetes Care. 34. 1992-1997.
http://care.diabetesjournals.org/content/34/9/1992.abstract
SGLT2
2009. Wilding John P.H., Norwood Paul, T'joen Caroline, Bastien Arnaud, List James F. and Fiedorek Fred T. A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers.Diabetes Care. 32. 1656-1662.
http://care.diabetesjournals.org/content/32/9/1656.abstract
SGLT2
2011. Nauck Michael A., Del Prato Stefano, Meier Juris J., Durán-García Santiago, Rohwedder Katja, Elze Martina and Parikh Shamik J. Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin.Diabetes Care. 34. 2015-2022.
http://care.diabetesjournals.org/content/34/9/2015.abstract
SGLT2
2011. Strojek K., Yoon K. H., Hruba V., Elze M., Langkilde A. M. and Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.Diabetes, Obesity and Metabolism. 13. 928-938.
http://dx.doi.org/10.1111/j.1463-1326.2011.01434.x
SGLT2
2012. Luippold G., Klein T., Mark M. and Grempler R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.Diabetes, Obesity and Metabolism. 14. 601-607.
http://dx.doi.org/10.1111/j.1463-1326.2012.01569.x
SGLT2
2012. Rosenstock Julio, Vico Marisa, Wei Li, Salsali Afshin and List James F. Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy.Diabetes Care. 35. 1473-1478.
http://care.diabetesjournals.org/content/35/7/1473.abstract
SGLT2
2012. Liu Jiwen, Lee TaeWeon and DeFronzo Ralph A. Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?Diabetes. 61. 2199-2204.
http://diabetes.diabetesjournals.org/content/61/9/2199.abstract
SGLT2
2013. Kaku K., Inoue S., Matsuoka O., Kiyosue A., Azuma H., Hayashi N., Tokudome T., Langkilde A. M. and Parikh S. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.Diabetes, Obesity and Metabolism. 15. 432-440.
http://dx.doi.org/10.1111/dom.12047
SGLT2
2013. Wilding J. P. H., Ferrannini E., Fonseca V. A., Wilpshaar W., Dhanjal P. and Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.Diabetes, Obesity and Metabolism. 15. 403-409.
http://dx.doi.org/10.1111/dom.12038
SGLT2
2013. Ferrannini Ele, Veltkamp Stephan A., Smulders Ronald A. and Kadokura Takeshi. Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.Diabetes Care. 36. 1260-1265.
http://care.diabetesjournals.org/content/36/5/1260.abstract
SGLT2
2013. Yale J. F., Bakris G., Cariou B., Yue D., David-Neto E., Xi L., Figueroa K., Wajs E., Usiskin K. and Meininger G. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.Diabetes, Obesity and Metabolism. 15. 463-473.
http://dx.doi.org/10.1111/dom.12090
SGLT2
2013. Häring Hans-Ulrich, Merker Ludwig, Seewaldt-Becker Elke, Weimer Marc, Meinicke Thomas, Woerle Hans J., Broedl Uli C. and Investigators on behalf of the EMPA-REG METSU Trial. Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial.Diabetes Care. 36. 3396-3404.
http://care.diabetesjournals.org/content/36/11/3396.abstract
SGLT2
2013. Rosenstock J., Seman L. J., Jelaska A., Hantel S., Pinnetti S., Hach T. and Woerle H. J. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.Diabetes, Obesity and Metabolism. 15. 1154-1160.
http://dx.doi.org/10.1111/dom.12185
SGLT2
2013. Inagaki N., Kondo K., Yoshinari T., Maruyama N., Susuta Y. and Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.Diabetes, Obesity and Metabolism. 15. 1136-1145.
http://dx.doi.org/10.1111/dom.12149
SGLT2
2014. Wilding J. P. H., Woo V., Rohwedder K., Sugg J., Parikh S. and for the Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.Diabetes, Obesity and Metabolism. 16. 124-136.
http://dx.doi.org/10.1111/dom.12187
SGLT2
2014. Bolinder J., Ljunggren Ö, Johansson L., Wilding J., Langkilde A. M., Sjöström C. D., Sugg J. and Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.Diabetes, Obesity and Metabolism. 16. 159-169.
http://dx.doi.org/10.1111/dom.12189
SGLT2
2014. Jabbour Serge A., Hardy Elise, Sugg Jennifer, Parikh, Shamik and Group for the Study 10. Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.Diabetes Care. 37. 740-750.
http://care.diabetesjournals.org/content/37/3/740.abstract
SGLT-2
2012. Dobbins R. L., O’Connor-Semmes R., Kapur A., Kapitza C., Golor G., Mikoshiba I., Tao W. and Hussey E. K. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.Diabetes, Obesity and Metabolism. 14. 15-22.
http://dx.doi.org/10.1111/j.1463-1326.2011.01462.x
SGLT-2
2012. Bailey C. J., Iqbal N., T'Joen C. and List J. F. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.Diabetes, Obesity and Metabolism. 14. 951-959.
http://dx.doi.org/10.1111/j.1463-1326.2012.01659.x
SGLT-2
2012. Devineni D., Morrow L., Hompesch M., Skee D., Vandebosch A., Murphy J., Ways K. and Schwartz S. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.Diabetes, Obesity and Metabolism. 14. 539-545.
http://dx.doi.org/10.1111/j.1463-1326.2012.01558.x
SGLT-2
2012. Grempler R., Thomas L., Eckhardt M., Himmelsbach F., Sauer A., Sharp D. E., Bakker R. A., Mark M., Klein T. and Eickelmann P. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.Diabetes, Obesity and Metabolism. 14. 83-90.
http://dx.doi.org/10.1111/j.1463-1326.2011.01517.x
Silent Diabetes Study
2011. Doerr R., Hoffmann U., Otter W., Heinemann L., Hunger-Battefeld W., Kulzer B., Klinge A., Lodwig V., Amann-Zalan I., Sturm D., Tschoepe D., Spitzer S., Stumpf J., Lohmann T. and Schnell O. Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography the Silent Diabetes Study.Diabetologia. 54. 2923-2930.
http://dx.doi.org/10.1007/s00125-011-2253-y
SINERGIA
2011. Musacchio N., Lovagnini Scher A., Giancaterini A., Pessina L., Salis G., Schivalocchi F., Nicolucci A., Pellegrini F. and Rossi M. C. E. Impact of a chronic care model based on patient empowerment on the management of Type 2 diabetes: effects of the SINERGIA programme.Diabetic Medicine. 28. 724-730.
http://dx.doi.org/10.1111/j.1464-5491.2011.03253.x
SMS-DM study
2011. Hussein Wiam I., Hasan Khadija and Jaradat Ahmed A. Effectiveness of mobile phone short message service on diabetes mellitus management; the SMS-DM study.Diabetes research and clinical practice. 94. e24-e26.
http://linkinghub.elsevier.com/retrieve/pii/S0168822711004013?showall=true
SNDR
2010. Eeg-Olofsson Katarina, Cederholm Jan, Nilsson Peter M., Zethelius Bjorn, Svensson Ann-Marie, Gudbjornsdottir Soffia and Eliasson Bjorn. Glycemic Control and Cardiovascular Disease in 7,454 Patients With Type 1 Diabetes.Diabetes Care. 33. 1640-1646.
http://care.diabetesjournals.org/content/33/7/1640.abstract
SNDR
2011. Gudbjörnsdottir S., Eliasson B., Eeg-Olofsson K., Zethelius B., Cederholm J. and Register on behalf of the National Diabetes. Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register.Diabetologia. 54. 2544-2551.
http://dx.doi.org/10.1007/s00125-011-2218-1
SNDR
2011. Zethelius Björn, Eliasson Björn, Eeg-Olofsson Katarina, Svensson Ann-Marie, Gudbjörnsdottir Soffia and Cederholm Jan. A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR).Diabetes research and clinical practice. 93. 276-284.
http://www.sciencedirect.com/science/article/pii/S0168822711002932
SNDR
2011. Cederholm J., Eeg-Olofsson K., Eliasson B., Zethelius B., Gudbjörnsdottir S. and on behalf of the Swedish National Diabetes Register. A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR).Diabetic Medicine. 28. 1213-1220.
http://dx.doi.org/10.1111/j.1464-5491.2011.03342.x
SNDR
2012. Ekström N., Miftaraj M., Svensson A. M., Andersson Sundell K., Cederholm J., Zethelius B., Gudbjörnsdottir S. and Eliasson B. Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register.Diabetes, Obesity and Metabolism. 14. 717-726.
http://dx.doi.org/10.1111/j.1463-1326.2012.01591.x
SNDR
2012. Sparring V., Nyström L., Östman J., Wahlström R., Burström K. and Jonsson P. M. Changing healthcare utilization patterns in diabetes mellitus: case–control studies 1 year and 8 years after diagnosis.Diabetic Medicine. 29. 784-791.
http://dx.doi.org/10.1111/j.1464-5491.2011.03514.x
SNDR
2012. Fhärm E., Cederholm J., Eliasson B., Gudbjörnsdottir S. and Rolandsson O. Time trends in absolute and modifiable coronary heart disease risk in patients with Type 2 diabetes in the Swedish National Diabetes Register (NDR) 2003–2008.Diabetic Medicine. 29. 198-206.
http://dx.doi.org/10.1111/j.1464-5491.2011.03425.x
SNDR
2012. Lind M., Olsson M., Rosengren A., Svensson A. M., Bounias I. and Gudbjörnsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes.Diabetologia. 55. 2946-2953.
http://dx.doi.org/10.1007/s00125-012-2681-3
SNDR
2013. Vestberg Daniel, Rosengren Annika, Olsson Marita, Gudbjörnsdottir Soffia, Svensson Ann-Marie and Lind Marcus. Relationship Between Overweight and Obesity With Hospitalization for Heart Failure in 20,985 Patients With Type 1 Diabetes: A population-based study from the Swedish National Diabetes Registry.Diabetes Care. 36. 2857-2861.
http://care.diabetesjournals.org/content/36/9/2857.abstract
Social
2011. McEwen Laura N., Kim Catherine, Ettner Susan L., Herman William H., Karter Andrew J., Beckles Gloria L. and Brown Arleen F. Competing Demands for Time and Self-Care Behaviors, Processes of Care, and Intermediate Outcomes Among People With Diabetes.Diabetes Care. 34. 1180-1182.
http://care.diabetesjournals.org/content/34/5/1180.abstract
SOLVE
2012. Khunti K., Damci T., Meneghini L., Pan C. Y., Yale J. F. and on behalf of the Solve Study Group. Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice.Diabetes, Obesity and Metabolism. 14. 654-661.
http://dx.doi.org/10.1111/j.1463-1326.2012.01602.x
Statins
2003. Holdaas Hallvard, Fellström Bengt, Jardine Alan G., Holme Ingar, Nyberg Gudrun, Fauchald Per, Grönhagen-Riska Carola, Madsen Søren, Neumayer Hans-Hellmut, Cole Edward, Maes Bart, Ambuhl Patrice, Olsson Anders G., Hartmann Anders, Solbu Dag O. and Pedersen Terje R. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.The Lancet. 361. 2024-2031.
http://linkinghub.elsevier.com/retrieve/pii/S0140673603136380
Statins
2006. Knopp Robert H., D'Emden Michael, Smilde Johan G. and Pocock Stuart J. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes.Diabetes Care. 29. 1478-1485.
http://care.diabetesjournals.org/content/29/7/1478.abstract
Statins
2013. Carter Aleesa A, Gomes Tara, Camacho Ximena, Juurlink David N, Shah Baiju R and Mamdani Muhammad M. Risk of incident diabetes among patients treated with statins: population based study.British Medical Journal. 346.
http://www.bmj.com/content/346/bmj.f2610
STENO 2
2008. Gaede Peter, Lund-Andersen Henrik, Parving Hans-Henrik and Pedersen Oluf. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes.New England Journal of Medicine. 358. 580-591.
http://www.nejm.org/doi/full/10.1056/NEJMoa0706245
STeP Study
2011. Parkin Christopher G., Hinnen Deborah A. and Tetrick David L. Effective Use of Structured Self-Management of Blood Glucose in Type 2 Diabetes: Lessons From the STeP Study.Clinical Diabetes. 29. 131-138.
http://clinical.diabetesjournals.org/content/29/4/131.abstract
STRIP Study
2013. Oranta Olli, Pahkala Katja, Ruottinen Soile, Niinikoski Harri, Lagström Hanna, Viikari Jorma S.A., Jula Antti, Loo Britt-Marie, Simell Olli, Rönnemaa Tapani and Raitakari Olli T. Infancy-Onset Dietary Counseling of Low-Saturated-Fat Diet Improves Insulin Sensitivity in Healthy Adolescents 15–20 Years of Age: The Special Turku Coronary Risk Factor Intervention Project (STRIP) study.Diabetes Care. 36. 2952-2959.
http://care.diabetesjournals.org/content/36/10/2952.abstract
Strong Heart Study
2011. De Marco Marina, de Simone Giovanni, Roman Mary J., Chinali Marcello, Lee Elisa T., Calhoun Darren, Howard Barbara V. and Devereux Richard B. Cardiac Geometry and Function in Diabetic or Prediabetic Adolescents and Young Adults.Diabetes Care. 34. 2300-2305.
http://care.diabetesjournals.org/content/34/10/2300.abstract
Strong Heart Study
2011. Yeh Fawn, Dixon Anne E., Marion Susan, Schaefer Carl, Zhang Ying, Best Lyle G., Calhoun Darren, Rhoades Everett R. and Lee Elisa T. Obesity in Adults Is Associated With Reduced Lung Function in Metabolic Syndrome and Diabetes.Diabetes Care. 34. 2306-2313.
http://care.diabetesjournals.org/content/34/10/2306.abstract
Swedish Childhood Diabetes Study
2011. Berhan Yonas, Waernbaum Ingeborg, Lind Torbjorn, Mollsten Anna, Dahlquist Gisela and Group* for the Swedish Childhood Diabetes Study. Thirty Years of Prospective Nationwide Incidence of Childhood Type 1 Diabetes.Diabetes. 60. 577-581.
http://diabetes.diabetesjournals.org/content/60/2/577.abstract
SWING Study
2012. Reaney Matthew, Cypryk Katarzyna, Tentolouris Nicholas, Jecht Michael, Cleall Simon, Petzinger Ute and Koivisto Veikko. Resource utilisation and clinical data before and after switching between short-acting human insulin and rapid-acting insulin analogues in patients with type 2 diabetes: The SWING study.Diabetes research and clinical practice. 97. 231-241.
http://linkinghub.elsevier.com/retrieve/pii/S0168822712000927?showall=true
SWITCH Study
2014. Hommel E., Olsen B., Battelino T., Conget I., Schütz-Fuhrmann I., Hoogma R., Schierloh U., Sulli N., Gough H., Castañeda J., de Portu S. and Bolinder J. Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: analyses from the SWITCH study.Acta Diabetol. 51. 845-851.
http://dx.doi.org/10.1007/s00592-014-0598-7
Back to Top
TAK-875
2012. Burant Charles F., Viswanathan Prabhakar, Marcinak John, Cao Charlie, Vakilynejad Majid, Xie Benhuai and Leifke Eckhard. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.The Lancet. 379. 1403-1411.
http://linkinghub.elsevier.com/retrieve/pii/S0140673611618795
Taspoglutide
2012. Raz Itamar, Fonseca Vivian, Kipnes Mark, Durrwell Laurence, Hoekstra John, Boldrin Mark and Balena Raffaella. Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment.Diabetes Care. 35. 485-487.
http://care.diabetesjournals.org/content/35/3/485.abstract
Technology
2011. Franc S., Daoudi A., Mounier S., Boucherie B., Dardari D., Laroye H., Neraud B., Requeda E., Canipel L. and Charpentier G. Telemedicine and diabetes: Achievements and prospects.Diabetes & Metabolism. 37. 463-476.
http://www.sciencedirect.com/science/article/pii/S1262363611001273
Technology
2012. Nes Andréa A. G., van Dulmen Sandra, Eide Erlend, Finset Arnstein, Kristjánsdóttir Ólöf Birna, Steen Ida Synnøve and Eide Hilde. The development and feasibility of a web-based intervention with diaries and situational feedback via smartphone to support self-management in patients with diabetes type 2.Diabetes research and clinical practice. 97. 385-393.
http://linkinghub.elsevier.com/retrieve/pii/S0168822712001532?showall=true
TELEMEDICINE
2011. Charpentier Guillaume, Benhamou Pierre-Yves, Dardari Dured, Clergeot Annie, Franc Sylvia, Schaepelynck-Belicar Pauline, Catargi Bogdan, Melki Vincent, Chaillous Lucy, Farret Anne, Bosson Jean-Luc, Penfornis Alfred and Group on behalf of the TeleDiab Study. The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients.Diabetes Care. 34. 533-539.
http://care.diabetesjournals.org/content/34/3/533.abstract
TELEMEDICINE
2012. Cavallerano Jerry D., Silva Paolo S., Tolson Ann M., Francis Taniya, Tolls Dorothy, Patel Bina, Eagan Sharon, Aiello Lloyd M. and Aiello Lloyd P. Imager Evaluation of Diabetic Retinopathy at the Time of Imaging in a Telemedicine Program.Diabetes Care. 35. 482-484.
http://care.diabetesjournals.org/content/35/3/482.abstract
Testosterone
2014. Gianatti Emily J., Dupuis Philippe, Hoermann Rudolf, Strauss Boyd J., Wentworth John M., Zajac Jeffrey D. and Grossmann Mathis. Effect of Testosterone Treatment on Glucose Metabolism in Men With Type 2 Diabetes: A Randomized Controlled Trial.Diabetes Care. 37. 2098-2107.
http://care.diabetesjournals.org/content/37/8/2098.abstract
TIDE Trial
2012. Investigators The Tide Trial. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.Diabetologia. 55. 36-45.
http://dx.doi.org/10.1007/s00125-011-2357-4
Tigerinin-1R
2011. Ojo O. O., Abdel-Wahab Y. H. A., Flatt P. R., Mechkarska M. and Conlon J. M. Tigerinin-1R: a potent, non-toxic insulin-releasing peptide isolated from the skin of the Asian frog, Hoplobatrachus rugulosus.Diabetes, Obesity and Metabolism. 13. 1114-1122.
http://dx.doi.org/10.1111/j.1463-1326.2011.01470.x
TODAY
2013. Group TODAY Study. Treatment Effects on Measures of Body Composition in the TODAY Clinical Trial.Diabetes Care. 36. 1742-1748.
http://care.diabetesjournals.org/content/36/6/1742.abstract
TODAY
2013. Group TODAY Study. Lipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With Type 2 Diabetes: The TODAY clinical trial.Diabetes Care. 36. 1758-1764.
http://care.diabetesjournals.org/content/36/6/1758.abstract
TODAY
2013. Group TODAY Study. Safety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes: The TODAY experience.Diabetes Care. 36. 1765-1771.
http://care.diabetesjournals.org/content/36/6/1765.abstract
TODAY
2013. Group TODAY Study. Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY.Diabetes Care. 36. 1749-1757.
http://care.diabetesjournals.org/content/36/6/1749.abstract
TODAY
2013. Group TODAY Study. Retinopathy in Youth With Type 2 Diabetes Participating in the TODAY Clinical Trial.Diabetes Care. 36. 1772-1774.
http://care.diabetesjournals.org/content/36/6/1772.abstract
TODAY
2013. Group TODAY Study. Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes: The TODAY clinical trial.Diabetes Care. 36. 1735-1741.
http://care.diabetesjournals.org/content/36/6/1735.abstract
TODAY Study
2011. Anderson Barbara J., Edelstein Sharon, Abramson Natalie Walders, Katz Lorraine E. Levitt, Yasuda Patrice M., Lavietes Sylvia J., Trief Paula M., Tollefsen Sherida E., McKay Siripoom Vudhipoom, Kringas Patricia, Casey Terri Lynn and Marcus Marsha D. Depressive Symptoms and Quality of Life in Adolescents With Type 2 Diabetes.Diabetes Care. 34. 2205-2207.
http://care.diabetesjournals.org/content/34/10/2205.abstract
Transitional
2013. Helgeson V. S., Reynolds K. A., Snyder P. R., Palladino D. K., Becker D. J., Siminerio L. and Escobar O. Characterizing the transition from paediatric to adult care among emerging adults with Type 1 diabetes.Diabetic Medicine. 30. 610-615.
http://dx.doi.org/10.1111/dme.12067
Treat-to-Target Trial
2003. Riddle Matthew C., Rosenstock Julio and Gerich John. The Treat-to-Target Trial.Diabetes Care. 26. 3080-3086.
http://care.diabetesjournals.org/content/26/11/3080.abstract
Treatment Intensification
2011. Fu A. Z., Qiu Y., Davies M. J., Radican L. and Engel S. S. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy.Diabetes, Obesity and Metabolism. 13. 765-769.
http://dx.doi.org/10.1111/j.1463-1326.2011.01405.x
Back to Top
UKPDS
1999. Nasr CE, Hoogwerf BJ, Faiman C. and Reddy SS. United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus.Cleveland Clinic journal of medicine. 66. 247.
http://www.ncbi.nlm.nih.gov/pubmed/10199061/
UKPDS
1999. King Paromita, Peacock Ian and Donnelly Richard. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes.British Journal of Clinical Pharmacology. 48. 643-648.
http://dx.doi.org/10.1046/j.1365-2125.1999.00092.x
UKPDS
2003. Manley S. Haemoglobin A1c–a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS).Clinical chemistry and laboratory medicine. 41. 1182-1190.
http://www.reference-global.com/doi/abs/10.1515/CCLM.2003.182
UKPDS
2004. Cull C. A., Neil H. A. W. and Holman R. R. Changing aspirin use in patients with Type 2 diabetes in the UKPDS.Diabetic Medicine. 21. 1368-1371.
http://dx.doi.org/10.1111/j.1464-5491.2004.01328.x
UKPDS
2005. Guzder R. N., Gatling W., Mullee M. A., Mehta R. L. and Byrne C. D. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study.Diabetic Medicine. 22. 554-562.
http://dx.doi.org/10.1111/j.1464-5491.2005.01494.x
UKPDS
2011. van Dieren S., Peelen L., Nöthlings U., van der Schouw Y., Rutten G., Spijkerman A., van der A D., Sluik D., Boeing H., Moons K. and Beulens J. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes.Diabetologia. 54. 264-270.
http://dx.doi.org/10.1007/s00125-010-1960-0
UKPDS
2013. Leal Jose, Hayes Alison J., Gray Alastair M., Holman Rury R. and Clarke Philip M. Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data.Diabetes Care. 36. 1541-1546.
http://care.diabetesjournals.org/content/36/6/1541.abstract
UKPDS 1
1983. Turner R., Mann J., Iceton G., Oakes S., Smith A., Moore J., Hockaday T., Holman R., Stowers J., Stowers M., Murchison L., Borthwick L., Wright D., Fitzgerald M., Gyde S., Pilkington T., Oakley N., Whitehead M., Kohner E., Lawson P., Hayes R., Henry W., Peto R., Moore A., Stark T. and Todd L. UK prospective study of therapies of maturity-onset diabetes.Diabetologia. 24. 404-411.
http://dx.doi.org/10.1007/BF00257337
UKPDS 2
1985. Group UKPDS Study. U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study.Diabetes. 34. 793-798.
http://diabetes.diabetesjournals.org/content/34/8/793.abstract
UKPDS 3
1995. Turner RC, Mann J., Oakes S., Nugent Z., Moore J. and Peto R. United Kingdom prospective diabetes study III. Prevalence of hypertension and of hypotensive therapy in patients with newly diagnosed diabetes. A Multicentre Study.Hypertension. 7. 8-13.
UKPDS 4
1988. Multi-centre Study. UK Prospective Diabetes Study. IV. Characteristics of Newly presenting Type 2 Diabetic Patients: Male Preponderance and Obesity at Different Ages.Diabetic Medicine. 5. 154-159.
http://dx.doi.org/10.1111/j.1464-5491.1988.tb00963.x
UKPDS 5
1988. Multi-centre Study. UK Prospective Diabetes Study V. Characteristics of Newly presenting Type 2 Diabetic Patients: Estimated Insulin Sensitivity and Islet B-cell Function.Diabetic Medicine. 5. 444-448.
http://dx.doi.org/10.1111/j.1464-5491.1988.tb01025.x
UKPDS 6
1990. Manley SM, Meyer LC, Neil HAW, Ross IS, Turner RC and Holman RR. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. UKPDS 6.Diabetes Res. 13. 1-11.
UKPDS 7
1990. Group UKPDS. United Kingdom Prospective diabetes study 7. Response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients.Metab Clin Exp. 39. 905-912.
UKPDS 8
1991. Group UKPDS. UK prospective diabetes study (UKPDS) VIII. Study design, progress and performance.Diabetologia. 34. 877-890.
http://dx.doi.org/10.1007/BF00400195
UKPDS 9
1993. Group UKPDS. UK prospective diabetes study (UKPDS) IX: Relationships of urinary albumin and N-acetylglucosaminidase to glycaemia and hypertension at diagnosis of Type 2 (non-insulin-dependent) diabetes mellitus and after 3 months diet therapy.Diabetologia. 36. 835-842.
http://dx.doi.org/10.1007/BF00400359
UKPDS 10
1993. Group UKPDS. UK Prospective Diabetes Study (UKPDS) X. Urinary albumin excretion over 3 years in diet-treated Type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia.Diabetologia. 36. 1021-1029.
http://dx.doi.org/10.1007/BF02374494
UKPDS 11
1994. Group U. K. Prospective Diabetes Study. UK Prospective Diabetes Study (UKPDS) XI: Biochemical Risk Factors in Type 2 Diabetic Patients at Diagnosis Compared with Age-matched Normal Subjects.Diabetic Medicine. 11. 534-544.
http://dx.doi.org/10.1111/j.1464-5491.1994.tb02032.x
UKPDS 12
1994. Group U. K. Prospective Diabetes Study. UK Prospective Diabetes Study XII: Differences Between Asian, Afro-Caribbean and White Caucasian Type 2 Diabetic Patients at Diagnosis of Diabetes.Diabetic Medicine. 11. 670-677.
http://dx.doi.org/10.1111/j.1464-5491.1994.tb00331.x
UKPDS 13
1995. Holman RR, Cull CA, Fox C. and Turner RC. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.British Medical Journal. 310. 83–88.
http://www.bmj.com/content/310/6972/83.full
UKPDS 14
1995. Keavney B., Dudley C., Stratton I., Holman R., Matthews D., Ratcliffe P. and Turner R. UK Prospective Diabetes Study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM.Diabetologia. 38. 948-952.
http://dx.doi.org/10.1007/BF00400584
UKPDS 15
1995. Dudley Christopher R. K., Keavney Bernard, Stratton Irene M., Turner Robert C. and Ratcliffe Peter J. U.K. Prospective Diabetes Study XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM.Kidney Int. 48. 1907-1911.
http://dx.doi.org/10.1038/ki.1995.490
UKPDS 16
1995. Group UKPDS. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.Diabetes. 44. 1249-1258.
http://diabetes.diabetesjournals.org/content/44/11/1249.abstract
UKPDS 17
1996. Turner Robert, Cull Carole and Holman Rury. United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus.Annals of Internal Medicine. 124. 136-145.
http://www.annals.org/content/124/1_Part_2/136.abstract
UKPDS 18
1996. Eeley E. A., Stratton I. M., Hadden D. R., Turner R. C. and Holman R. R. UKPDS 18: Estimated Dietary Intake in Type 2 Diabetic Patients Randomly Allocated to Diet, Sulphonylurea or Insulin Therapy.Diabetic Medicine. 13. 656-662.
http://dx.doi.org/10.1002/(SICI)1096-9136(199607)13:7<656::AID-DIA131>3.0.CO;2-5
UKPDS 19
1996. Zhang Y., Wat N., Stratton I. M., Warren-Perry M. G., Orho M., Groop L. and Turner R. C. UKPDS 19: Heterogeneity in NIDDM: separate contributions of IRS-1 and b3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations.Diabetologia. 39. 1505-1511.
http://dx.doi.org/10.1007/s001250050605
UKPDS 20
1997. Widjaja A., Stratton I.M., Horn R., Holman R.R., Turner R. and Brabant G. UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects.Journal of Clinical Endocrinology & Metabolism. 82. 654.
http://jcem.endojournals.org/content/82/2/654.full.pdf+html
UKPDS 21
1997. Saker P. J., Hattersley A. T., Barrow B., Hammersley M. S., Horton V., Gillmer M. D. and Turner R. C. UKPDS 21: Low Prevalence of the Mitochondrial Transfer RNA gene (tRNA Leu(UUR)) Mutation at Position 3243bp in UK Caucasian Type 2 Diabetic Patients.Diabetic Medicine. 14. 42-45.
http://dx.doi.org/10.1002/(SICI)1096-9136(199701)14:1<42::AID-DIA295>3.0.CO;2-T
UKPDS 22
1997. Davis Timothy ME, Stratton Irene M, Fox Charles J, Holman Rury R, Turner Robert C and Group U.K. Prospective Diabetes Study. U.K. Prospective Diabetes Study 22: Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM.Diabetes Care. 20. 1435-1441.
http://care.diabetesjournals.org/content/20/9/1435.abstract
UKPDS 23
1998. Turner RC, Millns H., Neil HAW, Stratton IM, Manley SE, Matthews DR and Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23).British Medical Journal. 316. 823.
http://www.bmj.com/content/316/7134/823.abstract
UKPDS 24
1998. Group UKPDS. A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy. UKPDS 24.Annals of Internal Medicine. 128. 165-175.
UKPDS 25
1997. Turner R., Stratton I., Horton V., Manley S., Zimmet P., Mackay I.R., Shattock M., Bottazzo G.F. and Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes.The Lancet. 350. 1288-1293.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2903062-6/fulltext
UKPDS 26
1998. Matthews DR, Cull CA, Stratton IM, Holman RR and Turner RC. UKPDS 26: sulphonylurea failure in non insulin dependent diabetic patients over six years.Diabetic Medicine. 15. 297-303.
http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291096-9136%28199804%2915:4%3C297::AID-DIA572%3E3.0.CO;2-W/abstract
UKPDS 27
1997. Group U.K. Prospective Diabetes Study. U.K. Prospective Diabetes Study 27: Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex.Diabetes Care. 20. 1683-1687.
http://care.diabetesjournals.org/content/20/11/1683.abstract
UKPDS 28
1998. Group U.K. Prospective Diabetes Study. UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes.Diabetes Care. 21. 87-92.
http://care.diabetesjournals.org/content/21/1/87.abstract
UKPDS 29
1999. Davis T.M.E., Millns H., Stratton I.M., Holman R.R. and Turner R.C. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29.Archives of internal medicine. 159. 1097.
http://cat.inist.fr/?aModele=afficheN&cpsidt=1784877
UKPDS 30
1998. Kohner Eva M., Aldington Stephen J., Stratton Irene M., Manley Susan E., Holman Rury R., Matthews David R., Turner Robert C. and for the United Kingdom Prospective Diabetes Study. United Kingdom Prospective Diabetes Study, 30: Diabetic Retinopathy at Diagnosis of Non-Insulin-Dependent Diabetes Mellitus and Associated Risk Factors.Arch Ophthalmol. 116. 297-303.
http://archopht.ama-assn.org/cgi/content/abstract/116/3/297
UKPDS 31
1999. Group UKPDS. UKPDS 31: Hepatocyte nuclear factor-1alpha (the MODY3 gene) mutations in late onset Type II diabetic patients in the United Kingdom.Diabetologia. 42. 120-121.
http://dx.doi.org/10.1007/s001250051127
UKPDS 32
1998. Group U.K. Prospective Diabetes Study. Ethnicity and Cardiovascular Disease: The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32).Diabetes Care. 21. 1271-1277.
http://care.diabetesjournals.org/content/21/8/1271.abstract
UKPDS 33
1998. Group UK Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).The Lancet. 352. 837-853.
http://linkinghub.elsevier.com/retrieve/pii/S0140673698070196
UKPDS 34
1998. Group UK Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).The Lancet. 352. 854-865.
http://linkinghub.elsevier.com/retrieve/pii/S0140673698070378
UKPDS 35
2000. Stratton Irene M, Adler Amanda I, Neil H Andrew W, Matthews David R, Manley Susan E, Cull Carole A, Hadden David, Turner Robert C and Holman Rury R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.British Medical Journal. 321. 405-412.
http://www.bmj.com/content/321/7258/405.abstract
UKPDS 36
2000. Adler A.I., Stratton I.M., Neil H.A.W., Yudkin J.S., Matthews D.R., Cull C.A., Wright A.D., Turner R.C. and Holman R.R. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.British Medical Journal. 321. 412.
http://www.bmj.com/content/321/7258/412.short
UKPDS 37
1999. Group UKPDS. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group.Diabetes Care. 22. 1125-1136.
http://care.diabetesjournals.org/content/22/7/1125.abstract
UKPDS 38
1998. Group UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.British Medical Journal. 317. 703-713.
http://www.bmj.com/content/317/7160/703.abstract
UKPDS 39
1998. Group UKPDS. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.British Medical Journal. 317. 713-720.
http://www.bmj.com/content/317/7160/713.abstract
UKPDS 40
1998. Group U.K.P.D.S. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40.British Medical Journal. 317. 720-726.
http://www.jstor.org/pss/25180362
UKPDS 41
2000. Gray A., Raikou M., McGuire A., Fenn P., Stevens R., Cull C., Stratton I., Adler A., Holman R. and Turner R. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41).British Medical Journal. 320. 1373.
http://www.bmj.com/content/320/7246/1373.full.pdf
UKPDS 42
1999. Kohner E. M., Stratton I. M., Aldington S. J., Turner R. C. and Matthews D. R. Microaneurysms in the development of diabetic retinopathy (UKPDS 42).Diabetologia. 42. 1107-1112.
http://dx.doi.org/10.1007/s001250051278
UKPDS 43
1999. Horton V., Stratton I., Bottazzo G. F., Shattock M., Mackay I., Zimmet P., Manley S., Holman R. and Turner R. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43).Diabetologia. 42. 608-616.
http://dx.doi.org/10.1007/s001250051202
UKPDS 44
1999. Holman R R, Cull C A and Turner R C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).Diabetes Care. 22. 960-964.
http://care.diabetesjournals.org/content/22/6/960.abstract
UKPDS 45
2000. Manley S. E., Stratton I. M., Cull C. A., Frighi V., Eeley E. A., Matthews D. R., Holman R. R., Turner R. C. and Neil H. A. W. Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45).Diabetic Medicine. 17. 518-523.
http://dx.doi.org/10.1046/j.1464-5491.2000.00320.x
UKPDS 46
2000. Stevens R., Adler A., Gray A., Briggs A. and Holman R. Life-expectancy projection by modelling and computer simulation (UKPDS 46).Diabetes research and clinical practice. 50. S5-S13.
http://www.diabetesresearchclinicalpractice.com/article/S0168-8227%2800%2900214-X/abstract
UKPDS 47
1999. Adler Amanda I., Neil H. Andrew W., Manley Susan E., Holman Rury R. and Turner Robert C. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47).American Heart Journal. 138. s353-s359.
http://linkinghub.elsevier.com/retrieve/pii/S0002870399700359?showall=true
UKPDS 48
1999. Varadi A., Lebel L., Hashim Y., Mehta Z., Ashcroft S. J. H. and Turner R. Sequence variants of the sarco(endo)plasmic reticulum Ca2+-transport ATPase 3 gene (SERCA3) in Caucasian Type II diabetic patients (UK Prospective Diabetes Study 48).Diabetologia. 42. 1240-1243.
http://dx.doi.org/10.1007/s001250051298
UKPDS 49
1999. Turner Robert C., Cull Carole A., Frighi Valeria, Holman Rury R. and Group for the UK Prospective Diabetes Study. Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus.The Journal of the American Medical Association. 281. 2005-2012.
http://jama.ama-assn.org/content/281/21/2005.abstract
UKPDS 50
2001. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE and Matthews DR. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.Diabetologia. 44. 156-163.
http://www.springerlink.com/content/bnc8jpfpu6n8983u/
UKPDS 51
2001. Clarke P., Gray A., Adler A., Stevens R., Raikou M., Cull C., Stratton I. and Holman R. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51).Diabetologia. 44. 298-304.
http://dx.doi.org/10.1007/s001250051617
UKPDS 52
2001. Kohner E. M., Stratton I. M., Aldington S. J., Holman R. R. and Matthews D. R. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).Diabetic Medicine. 18. 178-184.
http://dx.doi.org/10.1046/j.1464-5491.2001.00458.x
UKPDS 53
2001. Gloyn A. L., Hashim Y., Ashcroft S. J. H., Ashfield R., Wiltshire S. and Turner R. C. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53).Diabetic Medicine. 18. 206-212.
http://dx.doi.org/10.1046/j.1464-5491.2001.00449.x
UKPDS 54
2001. Gray A., Clarke P., Raikou M., Adler A., Stevens R., Neil A., Cull C., Stratton I., Holman R. and the Ukpds Group. An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).Diabetic Medicine. 18. 438-444.
http://dx.doi.org/10.1046/j.1464-5491.2001.00485.x
UKPDS 55
2001. Davis TM, Cull C.A. and Holman R.R. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55).Diabetes Care. 24. 1167.
http://www.ncbi.nlm.nih.gov/pubmed/11423497
UKPDS 56
2001. Stevens R.J., Kothari V., Adler A.I., Stratton I.M. and Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).Clinical Science. 101. 671-679.
http://www.westhertshospitals.nhs.uk/whc/archive/calculators/UKPDS56%20Risk%20Engine.pdf
UKPDS 57
2002. Wright Alex, Burden A.C. Felix, Paisey Richard B., Cull Carole A. and Holman Rury R. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57) Diabetes Care. 25. 330-336.
http://care.diabetesjournals.org/content/25/2/330.abstract
UKPDS 58
2002. Stevens Richard J., Stratton Irene M. and Holman Rury R. Modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes. UKPDS 58.Journal of Diabetes and its Complications. 16. 371-376.
http://www.sciencedirect.com/science/article/pii/S1056872702001617
UKPDS 59
2002. Adler A.I., Stevens R.J., Neil A., Stratton I.M., Boulton A.J.M. and Holman R.R. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes.Diabetes Care. 25. 894.
http://care.diabetesjournals.org/content/25/5/894.full.pdf+html
UKPDS 60
2002. Kothari V., Stevens R.J., Adler A.I., Stratton I.M., Manley S.E., Neil H.A. and Holman R.R. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.Stroke. 33. 1776.
http://stroke.ahajournals.org/content/33/7/1776.abstract
UKPDS 61
2002. Colagiuri Stephen, Cull Carole A. and Holman Rury R. Are Lower Fasting Plasma Glucose Levels at Diagnosis of Type 2 Diabetes Associated With Improved Outcomes? UKPDS 61.Diabetes Care. 25. 1410-1417.
http://care.diabetesjournals.org/content/25/8/1410.abstract
UKPDS 62
2002. Clarke P., Gray A. and Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).Medical Decision Making. 22. 340.
http://mdm.sagepub.com/content/22/4/340.short
UKPDS 63
2002. Gray Alastair, Clarke Philip, Farmer Andrew and Holman Rury. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63).British Medical Journal. 325. 860.
http://www.bmj.com/content/325/7369/860.1.abstract
UKPDS 64
2003. Adler Amanda I., Stevens Richard J., Manley Sue E., Bilous Rudy W., Cull Carole A. and Holman Rury R. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64).Kidney Int. 63. 225-232.
http://dx.doi.org/10.1046/j.1523-1755.2003.00712.x
UKPDS 65
2003. Clarke P., Gray A., Legood R., Briggs A. and Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).Diabetic Medicine. 20. 442-450.
http://dx.doi.org/10.1046/j.1464-5491.2003.00972.x
UKPDS 66
2004. Stevens Richard J., Coleman Ruth L., Adler Amanda I., Stratton Irene M., Matthews David R. and Holman Rury R. Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes. UKPDS 66.Diabetes Care. 27. 201-207.
http://care.diabetesjournals.org/content/27/1/201.abstract
UKPDS 67
2005. Adler A. I., Levy J. C., Matthews D. R., Stratton I. M., Hines G. and Holman R. R. Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).Diabetic Medicine. 22. 306-311.
http://dx.doi.org/10.1111/j.1464-5491.2004.01418.x
UKPDS 68
2004. Clarke P., Gray A., Briggs A., Farmer A., Fenn P., Stevens R., Matthews D., Stratton I. and Holman R. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).Diabetologia. 47. 1747-1759.
http://dx.doi.org/10.1007/s00125-004-1527-z
UKPDS 69
2004. Matthews DR, Stratton IM, Aldington SJ, Holman RR and Kohner EM. Risks of Progression of Retinopathy and Vision Loss Related to Tight Blood Pressure Control in Type 2 Diabetes Mellitus: UKPDS 69.Arch Ophthalmol. 122. 1631-1640.
http://archopht.ama-assn.org/cgi/content/abstract/122/11/1631
UKPDS 70
2005. Davis T., Wright A., Mehta Z., Cull C., Stratton I., Bottazzo G., Bosi E., Mackay I. and Holman R. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).Diabetologia. 48. 695-702.
http://dx.doi.org/10.1007/s00125-005-1690-x
UKPDS 71
2005. Bottazzo G., Bosi E., Cull C., Bonifacio E., Locatelli M., Zimmet P., Mackay I. and Holman R. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71).Diabetologia. 48. 703-708.
http://dx.doi.org/10.1007/s00125-005-1691-9
UKPDS 72
2005. Clarke P., Gray A., Briggs A., Stevens R., Matthews D. and Holman R. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).Diabetologia. 48. 868-877.
http://dx.doi.org/10.1007/s00125-005-1717-3
UKPDS 73
2006. Wright Alex D., Cull Carole A., Macleod Kenneth M. and Holman Rury R. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.Journal of Diabetes and its Complications. 20. 395-401.
http://www.sciencedirect.com/science/article/pii/S1056872705001194
UKPDS 74
2006. Retnakaran Ravi, Cull Carole A., Thorne Kerensa I., Adler Amanda I. and Holman Rury R. Risk Factors for Renal Dysfunction in Type 2 Diabetes. UKPDS 74.Diabetes. 55. 1832-1839.
http://diabetes.diabetesjournals.org/content/55/6/1832.abstract
UKPDS 75
2006. Stratton I., Cull C., Adler A., Matthews D., Neil H. and Holman R. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).Diabetologia. 49. 1761-1769.
http://dx.doi.org/10.1007/s00125-006-0297-1
UKPDS 76
2006. Calle R., McCarthy M., Banerjee P., Zeggini E., Cull C., Thorne K., Wiltshire S., Terra S., Meyer D., Richmond J., Mancuso J., Milos P., Fryburg D. and Holman R. Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes: UKPDS 76.Diabetologia. 49. 2892-2899.
http://dx.doi.org/10.1007/s00125-006-0436-8
UKPDS 77
2007. Desai M., Cull C., Horton V., Christie M., Bonifacio E., Lampasona V., Bingley P., Levy J., Mackay I., Zimmet P., Holman R. and Clark A. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77.Diabetologia. 50. 2052-2060.
http://dx.doi.org/10.1007/s00125-007-0745-6
UKPDS 78
2007. Cull Carole A., Jensen Christine C., Retnakaran Ravi and Holman Rury R. Impact of the Metabolic Syndrome on Macrovascular and Microvascular Outcomes in Type 2 Diabetes Mellitus. UKPDS 78.Circulation. 116. 2119-2126.
http://circ.ahajournals.org/content/116/19/2119.abstract
UKPDS 80
2008. Holman Rury R., Paul Sanjoy K., Bethel M. Angelyn, Matthews David R. and Neil H. Andrew W. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. UKPDS 80.New England Journal of Medicine. 359. 1577-1589.
http://www.nejm.org/doi/full/10.1056/NEJMoa0806470
UKPDS 81
2008. Holman Rury R., Paul Sanjoy K., Bethel M. Angelyn, Neil H. Andrew W. and Matthews David R. Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. UKPDS 81.New England Journal of Medicine. 359. 1565-1576.
http://www.nejm.org/doi/full/10.1056/NEJMoa0806359
UKPDS 83
2014. Davis T. M. E., Coleman R. L., Holman R. R. and Group Ukpds. Ethnicity and long-term vascular outcomes in Type 2 diabetes: a prospective observational study (UKPDS 83).Diabetic Medicine. 31. 200-207.
http://dx.doi.org/10.1111/dme.12353
Back to Top
VADT
2011. Anderson Robert J., Bahn Gideon D., Moritz Thomas E., Kaufman Derrick, Abraira Carlos, Duckworth William and Group for the VADT Study. Blood Pressure and Cardiovascular Disease Risk in the Veterans Affairs Diabetes Trial.Diabetes Care. 34. 34-38.
http://care.diabetesjournals.org/content/34/1/34.abstract
Vascular
2012. Farkouh Michael E., Domanski Michael, Sleeper Lynn A., Siami Flora S., Dangas George, Mack Michael, Yang May, Cohen David J., Rosenberg Yves, Solomon Scott D., Desai Akshay S., Gersh Bernard J., Magnuson Elizabeth A., Lansky Alexandra, Boineau Robin, Weinberger Jesse, Ramanathan Krishnan, Sousa J. Eduardo, Rankin Jamie, Bhargava Balram, Buse John, Hueb Whady, Smith Craig R., Muratov Victoria, Bansilal Sameer, King Spencer, Bertrand Michel and Fuster Valentin. Strategies for Multivessel Revascularization in Patients with Diabetes.New England Journal of Medicine. 367. 2375-2384.
http://www.nejm.org/doi/full/10.1056/NEJMoa1211585
VETERANS
2009. Duckworth William, Abraira Carlos, Moritz Thomas, Reda Domenic, Emanuele Nicholas, Reaven Peter D., Zieve Franklin J., Marks Jennifer, Davis Stephen N., Hayward Rodney, Warren Stuart R., Goldman Steven, McCarren Madeline, Vitek Mary Ellen, Henderson William G. and Huang Grant D. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes.New England Journal of Medicine. 360. 129-139.
http://www.nejm.org/doi/full/10.1056/NEJMoa0808431
Vitamin D
2013. Salehpour A., Shidfar F., Hosseinpanah F., Vafa M., Razaghi M. and Amiri F. Does vitamin D3 supplementation improve glucose homeostasis in overweight or obese women? A double-blind, randomized, placebo-controlled clinical trial.Diabetic Medicine. 30. 1477-1481.
http://dx.doi.org/10.1111/dme.12273
Back to Top
WESDR
2014. LeCaire Tamara J., Klein Barbara E.K., Howard Kerri P., Lee Kristine E. and Klein Ronald. Risk for End-Stage Renal Disease Over 25 Years in the Population-Based WESDR Cohort.Diabetes Care. 37. 381-388.
http://care.diabetesjournals.org/content/37/2/381.abstract
Whitehall II Study
2014. Virtanen Marianna, Ferrie Jane E., Tabak Adam G., Akbaraly Tasnime N., Vahtera Jussi, Singh-Manoux Archana and Kivimäki Mika. Psychological Distress and Incidence of Type 2 Diabetes in High-Risk and Low-Risk Populations: The Whitehall II Cohort Study.Diabetes Care. 37. 2091-2097.
http://care.diabetesjournals.org/content/37/8/2091.abstract
Wisconsin Epidemiologic Study of Diabetic Retinopathy
1984. Klein Ronald, Klein Barbara E. K., Moss Scot E., Davis Matthew D. and DeMets David L. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: II. Prevalence and Risk of Diabetic Retinopathy When Age at Diagnosis Is Less Than 30 Years.Arch Ophthalmol. 102. 520-526.
http://archopht.ama-assn.org/cgi/content/abstract/102/4/520